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Abstract 
The widely expressed bromodomain and extraterminal motif (BET) proteins bromodomain-containing 
protein 2 (BRD2), BRD3, and BRD4 are multifunctional transcriptional regulators that bind acetylated 
chromatin via their conserved tandem bromodomains. Small molecules that target BET bromodomains 
are being tested for various diseases, but typically do not discern between BET family members. Genomic 
distributions and protein partners of BET proteins have been described, but the basis for differences in 
BET protein function within a given lineage remains unclear. By establishing a gene knockout–rescue 
system in a Brd2-null erythroblast cell line, we compared a series of mutant and chimeric BET proteins for 
their ability to modulate cell growth, differentiation and gene expression. We found that the BET N-
terminal halves bearing the bromodomains convey marked differences in protein stability, but do not 
account for specificity in BET protein function. Instead, when BET proteins were expressed at comparable 
levels, their specificity was largely determined by the C-terminal half. Remarkably, a chimeric BET protein 
comprised of the N-terminal half of the structurally similar short BRD4 isoform (BRD4S) and the C-
terminal half of BRD2 functioned similarly to intact BRD2. We traced part of the BRD2-specific activity to a 
previously uncharacterized short segment predicted to harbor a coiled coil (CC) domain. Deleting the CC 
segment impaired BRD2’s ability to restore growth and differentiation, and the CC region functioned in 
conjunction with the adjacent ET domain (ETCC) to impart BRD2-like activity onto BRD4S. We found that 
despite having different functions, BET proteins share similar genome-wide chromatin binding profiles. 
Neither exchanging the bromodomain-containing N-terminal nor the ETCC-bearing C-terminal regions of 
BET proteins alters their distribution. Rather, BRD2-specific function may in part be mediated by ETCC 
interactions with the RNA polymerase II associated factor and casein kinase II complexes. In summary, 
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ABSTRACT 
STRUCTURE-FUNCTION ANALYSIS OF BET PROTEINS IN TRANSCRIPTION 
Michael T. Werner 
Gerd A. Blobel 
The widely expressed bromodomain and extraterminal motif (BET) proteins 
bromodomain-containing protein 2 (BRD2), BRD3, and BRD4 are multifunctional 
transcriptional regulators that bind acetylated chromatin via their conserved tandem 
bromodomains. Small molecules that target BET bromodomains are being tested for 
various diseases, but typically do not discern between BET family members. Genomic 
distributions and protein partners of BET proteins have been described, but the basis for 
differences in BET protein function within a given lineage remains unclear. By establishing 
a gene knockout–rescue system in a Brd2-null erythroblast cell line, we compared a series 
of mutant and chimeric BET proteins for their ability to modulate cell growth, differentiation 
and gene expression. We found that the BET N-terminal halves bearing the 
bromodomains convey marked differences in protein stability, but do not account for 
specificity in BET protein function. Instead, when BET proteins were expressed at 
comparable levels, their specificity was largely determined by the C-terminal half. 
Remarkably, a chimeric BET protein comprised of the N-terminal half of the structurally 
similar short BRD4 isoform (BRD4S) and the C-terminal half of BRD2 functioned similarly 
to intact BRD2. We traced part of the BRD2-specific activity to a previously 
uncharacterized short segment predicted to harbor a coiled coil (CC) domain. Deleting the 
CC segment impaired BRD2’s ability to restore growth and differentiation, and the CC 




activity onto BRD4S. We found that despite having different functions, BET proteins 
share similar genome-wide chromatin binding profiles. Neither exchanging the 
bromodomain-containing N-terminal nor the ETCC-bearing C-terminal regions of 
BET proteins alters their distribution. Rather, BRD2-specific function may in part 
be mediated by ETCC interactions with the RNA polymerase II associated factor and 
casein kinase II complexes. In summary, our results identify distinct BET protein domains 
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 A large fraction of the work I present in this dissertation is published (Werner 
et al)1. The remainder of this work will form the basis of future studies.  
The first chapter of this dissertation is a broad introduction to serve as 
backdrop for the biological questions that I address about BET proteins. The 
second chapter includes detailed materials and methods used in these studies. 
The third and fourth chapters serve as result sections for my two major lines of 
investigation: 1) isolating the critical element that distinguishes BET proteins from 
each other and 2) characterizing this domain. These chapters contain focused 
introductions, experimental results, and tailored discussions. The final chapter 
draws on these findings to make broader conclusions and to discuss the 




CHAPTER 1: INTRODUCTION 
 
 
Gene transcription is regulated to ensure that cell-appropriate genes are 
expressed at adequate levels. For example, red blood cells must express globin 
genes in order to produce oxygen-carrying hemoglobin. They do this while 
simultaneously preventing the expression of unnecessary genes. Such cell-type 
specific gene expression allows each cell and tissue to take on specialized 
functions – whether carrying oxygen throughout the body or conveying electrical 
impulses across long distances in the nervous system. A breakdown in 
transcriptional regulation can result in disease by interfering with these biological 
processes. Elaborate regulatory mechanisms to control gene expression have 
thus evolved. In ancestral organisms such as bacteria, these mechanisms can be 
thought of as relatively simple transcriptional circuits. A classic example is the lac 
operon, which turns on lactose metabolism genes only when bacteria are in the 
presence of lactose but not glucose. In multicellular eukaryotes, the regulatory 
mechanisms are more complicated but achieve the same goal: finely tuned 
expression of genes in the right cell and at the right time.  
The goal of the work I present here is to describe one layer of eukaryotic 
transcriptional regulation. This layer falls within the realm of epigenetics, a broad 
field of study that describes changes in phenotypes that are unrelated to changes 
in the basic genetic code. Though the term was originally used to describe 
inheritance patterns that could not be explained by typical genetic mechanisms, 
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the term is now applied more broadly to the study of transcriptional regulation and 




Figure 1.1. Electron micrograph of chromatin. Imaged was produced by Olins 
and Olins who first published the finding in 19742. The image depicts the “beads 
on a string” model of chromatin structure. DNA wraps around regularly spaced 
histones. Each DNA-histone core is a nucleosome, the fundamental unit of 
chromatin and a major regulator of gene expression.  
Chromatin is the dense meshwork of DNA and protein found within the 
nucleus. In its most compact form, chromatin is organized into ~30µm width 
structures called chromosomes. Packaging of DNA into chromosomes is critical 
for the physical delivery of the genome to daughter cells during mitosis and 
meiosis. When cells are not dividing (interphase), chromatin is more loosely 
organized into smaller structures. High resolution imaging of interphase chromatin 
reveals a “beads on a string” pattern (Figure 1.1). This corresponds to the periodic 
wrapping of DNA (the string) around core histone proteins (the beads). A 
significant amount of biochemical and functional characterization has revealed that 
the structure and chemical modification of chromatin at this level is critical to the 
regulation of transcription3. Thus, whereas the term genetics can be applied to the 
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study of elements and diseases hard coded into the sequence of DNA itself and 
inherited through cell division, the term epigenetics can be thought of as the study 
of how the structure of chromatin controls the expression of genes and how 
dysregulation manifests as disease.  
In the remainder of this chapter, I will introduce a family of proteins, 
bromodomain and extraterminal motif (BET) proteins, that are broadly considered 
to be “epigenetic reader” proteins. This terminology is based on the finding that 
these proteins possess specialized domains that recognize signatures of 
chemically modified chromatin. BET proteins thus “read” the epigenome by 
translating these chemical signals into transcriptional output. 
BET proteins: linking chromatin acetylation to transcription 
Common post-translational modifications of proteins include 
phosphorylation, acetylation and methylation, which are all well known to affect 
protein function. Histones, in fact, were the first proteins identified to be altered by 
acetylation and methylation, and even in these initial studies the functional 
consequence of acetylation and methylation on RNA synthesis was appreciated4. 
This early work provided the first evidence that post-translational modifications of 
chromatin may influence transcription. 
Chromatin acetylation is associated with active transcription 
Early characterization of histone acetylation revealed that the small 
molecule sodium butyrate could increase histone acetylation and induce cancer 
cell differentiation, providing an additional link between histone acetylation and 
gene expression5. Subsequent studies realized sodium butyrate targeted histone 
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deacetylase activity found in nuclear protein fractions and that in addition to 
increasing histone acetylation levels it also altered chromatin accessibility6,7. A 
direct link between the acetylation of histone tails at lysine residues and 
transcription was not tested until several decades later when antibodies raised 
against acetylated histone isoforms were used to immunoprecipitated chromatin 
containing active but not inactive genes8. Immunofluorescent staining revealed 
non-uniform distribution of acetylated histone isoforms into distinct domains 
associated with different levels of transcriptional activity on polytene chromosomes 
of Drosophila salivary glands9. Together, these studies linked histone acetylation 
and chromatin decondensation (based on imaging of the polytene chromosomes) 
with transcriptional activity. Purification of the first histone acetyltransferases 
(KAT2A/GCN5) and deacetylases (HDAC1/RPD3), known transcriptional 
activators and repressors in yeast respectively, further cemented the notion that 
the directed modification of chromatin by acetylation was directly linked to 
transcription10,11.  
The bromodomain is a specialized domain that binds to acetylated residues 
How does chromatin acetylation activate transcription? It was first proposed 
that acetylation of lysines may neutralize the net positive charge of histones12. It 
was thought that the negative charge of the acetyl group would relax the interaction 
between positively charged histones and negatively charged DNA, leading to local 
decondensation of chromatin and access of the underlying DNA to various 
transcription factors. However, in addition to any biochemical affect acetylation 
may have on the structure of chromatin, a common ~110 amino acid sequence 
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possessed by many chromatin binding proteins was identified as an acetyl-lysine 
recognition domain. This domain was termed the bromodomain. A solution 
structure of the bromodomain from the acetyltransferase PCAF/KAT2B revealed 
the molecular interface of the acetyl-lysine recognition cleft of this domain with 
acetylated lysine13. Despite a considerable amount of diversity in the sequences 
of various bromodomains, this acetyl-lysine recognition pocket is strikingly 
conserved across each bromodomains14. Bromodomains are found in a multitude 
of chromatin-associated proteins, including histone acetyltransferases, 
methyltransferases, chromatin remodeling proteins, nuclear scaffolds and 
helicases15. These transcriptional regulators can be classified as epigenetic writers 
(histone acetyltransferases), erasers (histone deacetylases), or readers (histone 
acetylation binding proteins) based on their ability to add, remove, or bind to these 
chemical modifications on chromatin (Figure 1.2). Thus, the prevailing hypothesis 
as to how acetylation of chromatin affects transcription is that in addition to any 
electrostatic changes that acetyl groups may convey, acetyl groups also recruit a 





Figure 1.2. Schematic depicting the correlation between chromatin 
acetylation and active transcription. Imaged is adapted from Verdin and Ott 
(2015)17. Active gene expression is associated with acetylated nucleosomes. 
Enzymes that acetylate chromatin (histone acetylases) are termed writers, 
whereas those that remove the mark (histone deacetylases) are termed erasers. 
Chromatin remodeling proteins increase the spacing between adjacent histones. 
Proteins that recognize the acetylated but not unacetylated nucleosomes are 
termed readers.  
Discovery of BET proteins and their association with transcription  
 The human genome contains 56 individual bromodomains contained within 
42 distinct proteins15. Sequence homology of the bromodomains can be used to 
study the evolutionary relationships between these bromodomain-containing 
proteins (Figure 1.3). This analysis reveals a lineage of proteins – BRD2, BRD3, 
BRD4 and BRDT – each possessing two bromodomains in the N-terminal halves 
of the proteins in addition to a conserved motif termed the extraterminal domain 
(ET domain) situated C-terminal to the second bromodomain. These proteins are 
thus named bromodomain and extraterminal motif (BET) proteins18.  
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Soon after, Guar nte and colleagues 
elegantly demonstrated that yeast Sir2 and 
mouse SIRT2 proteins are HDACs, the 
activity of which is uniquely dependent 
on NAD+ (REF. 74). During deace ylation, 
NAD+ is cleaved, releasing nicotinamide 
and the ADP–ribose covalently linked to the 
removed acetyl group (acetyl–ADP–ribose) 
(BOX 1). Based on previous work showing 
that a gain-of-functio n mutation of Sir2 was 
associated with an increased lifespan in yeast, 
Guarente further proposed that the depend-
ency of Sir2 on NAD+ for its enzymatic activ-
ity enabled it to sense the energy status of 
the cell. Indeed, NAD+ level  increase when 
cellu lar nutrient levels are restrictively low, 
and this activates Sir2 and other sirtuins, 
thereby transducing a metabolic signal to 
various proteins, including histones, by dea-
cetylating them (BOX 1). At the time f i s pro-
posal, this model that chromatin-modifying 
proteins sense changes in the environment 
through their effect on intermediary metabo-
lites was a bold idea, one which is currently 
gaining much experimental support for 
acetyl ation and other chromati n PTMs 
(reviewed in REF. 75).
Acetylation goes global
With the exception of tubulin, most acetylated 
proteins appeared to be nuclear and associ-
ated with transcription regulation. In 2000, 
Kouzarides wondered in a review whether 
“acetylation was a regulatory modification to 
rival phosphorylation” (REF. 76). Soon after, 
however, the observations that several sirtuins 
were localized in the cytoplasm (for exam-
ple, SIRT2 (REF. 77)) or in mitochondria (for 
example, SIRT3 (REFS 78,79)), suggested that 
acetylation might be more broadly distributed 
than had been anticipated. This prediction 
became partly validated in 2006 by the first 
reported prote ic survey of protein acetyla-
tion. Using a new enrichment approach based 
on acetylatio n-specific antibodies, Zhao and 
colleagues identified 388 acetylation sites in 
195 proteins80. Thus, in one single experi-
ment, more acetylated pr teins had been 
identified than in the preceding 40 years. 
Remarkably and unexpectedly, many of these 
were mitochondrial proteins, and the pre-
diction was made that mitochondria might 
represent a unique environment where acety-
lation is abundant. In the same year, the first 
mitochondrial acetylated protein targeted 
by SIRT3 was identified — acetyl-CoA syn-
thetase81,82 — demonstrating the regulatory 
role of protein acetylation in mitochondrial 
metabolism.
Three years later, Mann and colleagues 
used high-resolution mass spectrometry 
to look deeper into the cellular acetylome. 
They identified 3,600 Lys acetylation sites in 
1,750 proteins83, and observed that acetyla-
tion was particularly prominent in large 
macromolecular complexes involved in a 
range of cellular activities, such as chromatin 
remodelling, the cell cycle, splicing, nuclear 
transport and actin nucleation. With such a 
large number of acetylated proteins involved 
in numerous cellular processes, protein 
acetyl ation was finally established as a 
globall y important PTM.
Targeting acetylation with drugs
The discovery of protein acetylation and of 
the proteins that write, erase or read acetyl 
groups within proteins has led to the identifi-
cation of many novel epigenetic drug targets. 
The first FDA-approved acetylation-modify-
ing agent was the HDAC inhibitor vorinostat 
(also known as suberanilohydroxamic acid 
(SAHA)), initially identified as an agent 
inducing the differentiation of tumour 
cells in vitro and subsequently as an HDAC 
Box 1 | The interface between protein acetylation and metabolism
Metabolism can influence protein acetylation by changes in the cellular concentration of NAD+ and 
acetyl-co nzyme A (acetyl-CoA). For example, during fasting the relative concentration of NAD+ 
increases, leading to an increase in the enzymatic activity of sirtuins and the deacetylation of their 
targets (see the figure). In contrast to kinases, the enzymatic activity of which is largely 
independent of fluctuations in ATP concentrations, the activity of acetyltransferases varies as a 
function of acetyl-CoA concentrations. When nutrient abundance increases, the cellular 
concentration of acetyl-CoA increases, leading to an increase in acetyltransferase activity and 
target protein acetylation.
Figure 4 | Histone acetylation, chromatin condensation and gene expression. Acetylation targets 
Lys residues in the amino-terminal tails of core histone proteins. A string of nucleosomes is shown with 
the tails protruding when acetylated. Acetylation of the tail domains inhibits the folding of nucleo-
some arrays into secondary and tertiary chromatin structures, with acetylation of histones H2B and H4 
having the greatest eff ct on tertiary structure formation103–105. Thus, histone tail acetylation results in 
chromatin decondensation, thereby allowing access to transcription factors and other transcription 
co-activators.
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Figure 1.3. The phylogenetic tree of human BET proteins. Adapted from 
Marmorstein and Zhou15. The dendrogram depicts sequence similarity between 
the 56 human bromodomains. Bromodomains within proteins containing double 
bromodomains are labeled -1 and -2. Circled numbers represent clustering of 
bromodomains into discrete families. Cluster 1 and 2 contain the first and second 
bromodomains of BET proteins, respectively, indicating that the first and second 
bromodomains across BET proteins are more highly related than the first and 
second bromodomains within each protein.  
 
Early work indicated that BET proteins BRD2, BRD3 and BRD4 were 
ubiquitously expressed and provided critical functions in multiple biological 
processes19,20. Mouse embryos depleted of BRD2 or BRD4 are non-viable, indicating 
that BRD2 and BRD4 are both individually essential for embryonic development21–23. 
A BRD3 knockout mouse has not been reported. BRDT expression is restricted to the 
testis where it is required for spermatogenesis in mice19,24. BRD2 was the first 
It has been suggested that the bromodomains in these
nuclear HATs contribute to substrate recruitment and
specificity involving histones and nonhistone proteins,
thereby providing a functional link between lysine acetyla-
tion and acetylation-mediated protein–protein interac-
tions in chromatin-mediated gene transcription (Sanchez
and Zhou 2009). Bromodomains are also found in some
histone lysine methyltransferases such as ASH1L and MLL,
however, a detailed understanding of their function re-
mains elusive.
Bromodomain proteins are involved in chromatin re-
modeling, the topic of Becker and Workman (2013). Bro-
modomain-containing remodelers include SMARC2 (also
known as BRM, SNF2/SWI2) and SMARC4 (BRG1), and
some with ATP-dependent helicase activity include ATAD2
(ATPase family AAA domain-containing prot in 2;
ANCCA) and ATAD2B. Further, double bromodomains
are seen in many proteins including TAF1/TAF1L, the
TFIID 250-kDa subunit of the transcription initiation
complex, as well as the BET proteins of BRD2, BRD3,
BRD4, and the testis-specific protein BRDT. The BET
proteins play an important role in the assembly of the pro-
ductive transcriptional activation complex through the re-
cru tment of the p-TEFb complex (CDK9 and cyclin T1) to
RNA polyermase II, which is required for transcriptional
elongation (Chiang 2009).
3.3 The Association of Bromodomains with Other
Chromatin Modules
Bromodomains are often present with a variety of other
conserved protein modules of different functions with-
in the same proteins (Basu et al. 2008; Basu et al. 2009).
For instance, PCAF, GCN5, p300/CBP are histone lysine
acetyltransferases, whereas HRX/ALL-1 is a h stone lysine
N-methyltransferase and SNF2L2 is an ATP-dependent
helicase. More than 15 different domain types have been































































Figure 7. The phylogenetic tree of human bromodomains. Sequence similarity–based dendrogram of the human
bromodomains was generated using the neighbor-joining method with MEGA (Kumar et al. 2004). Sequences of the
hu an bromodomains were obtained from the SMART database (Letunic t al. 2004) and aligned with SMART
bromodomains’ hidden Markov models using H malign (Sonnhammer et al. 1997). (Modified from Zhang et al.
2010.)
R. Marmorstein and M.-M. Zhou
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mammalian BET protein identified. It was initially characterized as a nuclear kinase 
associated with cell proliferation25. However, it had sequence similarity to the 
Drosophila embryonic development regulator FS(1)H, which when mutated resulted in 
embryonic lethality26,27. It also resembled another mammalian paralog, later identified 
as BRD4, which associated with the Mediator transcriptional complex28. Subsequent 
characterization of BRD2 revealed that like BRD4, it associated with a vast network of 
chromatin regulators and transcriptional cofactors29–31, suggesting that BET proteins 
were integrated into the transcriptional machinery. The molecular nature and 
functional significance of many of these interactions will be detailed in later sections. 
Imaging studies confirmed that BRD2 and BRD4 both localize to chromatin in an 
acetylation- and bromodomain-dependent manner32–34. Their association with 
chromatin is also mediated at least in part by protein dimerization and/or association 
with other protein complexes in a bromodomain-independent manner35,36.  
 The above studies suggest that BET proteins bind chromatin predominantly via 
their bromodomains, associate with transcriptional regulators, and are required for 
proper embryonic development, but what is the evidence that BET proteins directly 
contribute to transcription? An early piece of evidence suggesting their direct role in 
transcription was the observation that yeast strains deficient in the BET paralogue 
BDF137 shared phenotypes strongly reminiscent of strains defective in general 
transcription cofactors38. In addition, a gain-of-function reporter system was used to 
study the Drosophila paralog FS(1)H39. In this assay, overexpression of FS(1)H 
increased reporter activity only when the reporter’s promoter was intact. Gel-shifts 
assays demonstrated direct binding of FS(1)H to the promoter sequence, 
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indicating that FS(1)H activated the reporter through direct binding to this 
promoter. More definitive evidence for a role of BET proteins in transcription was 
obtained using in vitro transcriptional elongation assays. These experiments 
demonstrated that 1) BRD2, BRD3 and BRD4 were each capable of facilitating 
transcriptional elongation through chromatin templates, 2) that this activity only 
occurred on acetylated nucleosome substrates, and 3) intact bromodomains were 
required40,41. In summary, multiple studies provided evidence that BET proteins 
directly facilitate transcription in an acetylation- and bromodomain-dependent 
manner.  
BET protein structure-function 
BET proteins are classified as a family based on the shared and modular 
domain structure for which they are named. These eponymous domains include 
the two tandem N-terminal bromodomains (BD1 and BD2) and a C-terminal 
domain called the extraterminal motif (ET)18. The bromodomains associate with 
acetylated histones on chromatin and other acetylated proteins. The ET domain is 
a protein-protein interaction module. This stereotypical domain structure (Figure 
1.4) thereby allows BET proteins to function as molecular scaffolds onto which 
multiple transcriptional regulators bind acetylated chromatin. Disruption of this 
scaffold is the basis for anti-BET therapeutics, as discussed later. In addition to the 
bromodomains and ET domain, many other conserved features have been 
identified (Figure 1.4, Table 1.1). The remainder of this section will discuss the 




Figure 1.4. Conserved protein domains and other features across the BET 
family. BET proteins share two tandem bromodomains, BD1 and BD2, which bind 
to acetylated proteins, as well as the ET protein interaction domain. Additional 
domains include motif A (uncharacterized) and motif B (a dimerization domain). 
Two protein isoforms of BRD4 are depicted, a short (BRD4S) and long (BRD4L). 
The long isoform contains the CTM domain. Known phosphorylated sites are 
indicated (NPS and CPS). Together, the NPS and BID comprise a phospho-switch. 
Putative atypical kinase domains are highlighted in orange and the kinase catalytic 
site is marked with a purple arrow. The putative acetyl-coA binding sites (depicted 
in teal) and a putative histone acetyl transferase domain (HAT) specific to BRD4L 
are indicated.  
 
 
Table 1.1. Amino acid sequences of mouse BET protein domains and 
features. Sequences are depicted in Figure 1.4.  
Domain Name Abbreviation BRD2 BRD3 BRD4S BRD4L
Bromodomain 1 BD1 73-184 33-144 58-169 58-169
Motif A mA 270-289 233-252 281-300 281-300
Bromodomain 2 BD2 344-456 306-418 350-462 350-462
Motif B mB 509-554 453-498 503-548 503-548
Extraterminal motif ET 630-708 563-641 601-679 601-679
Histone acetyltransferase domain HAT - - - 1157-1197
C-terminal motif CTM - - - 1365-1400
Atypica kinase domain VIA 80-94 40-54 65-79 65-79
Atypica kinase domain VIB 112-122 72-82 97-107 97-107
Atypica kinase domain IX 154-169 114-129 139-154 139-154
Atypica kinase domain VIA (2) 352-363 314-325 358-369 358-369
Atypica kinase domain VIB (2) 385-395 347-357 391-401 391-401
Atypica kinase domain VIII 407-413 369-375 413-419 413-419
Atypica kinase domain IX 427-437 389-399 433-443 433-443
Atypica kinase domain I-II 598-619 547-552 584-590 584-590
Atypica kinase domain III 641-648 574-581 612-619 612-619
N-terminal phosphorylation site NPS 479-510 441-454 485-504 -
Basic domain BID 530-591 474-539 524-580 -
C-terminal phosphorylation site CPS 774-794 705-724 699-717 -
N-terminal acetyl coA binding site - - - 175-180 175-180
C-terminal acetyl coA binding site - - - 1097-1102
Kinase Catalytic Site - 572 521 563 563
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Evolution and conservation of BET proteins 
As noted above, BET proteins share a stereotypical and modular domain 
structure. Clustering based on bromodomain homology suggests that the BRDT 
bromodomains are the most ancestral, followed by BRD4 and then BRD2 and 
BRD3 (Figure 1.3). Clustering of the full-length proteins supports this conclusion 
by showing that BRDT is the most closely related to FS(1)H/FSH in Drosophila. 
BRDT then gave rise to BRD4, followed by BRD2 and BRD3 (Figure 1.5). 
Interestingly, the Brd2 gene is located within the major histocompatibility complex 
(MHC) II locus, which is a cluster of genes associated with immune function. The 
Brd3 gene is located in a region with MHC-like genes, indicating that it likely 
spawned from Brd2 via a gene duplication event42,43.  
 
Figure 1.5. Sequence comparison of full-length BET proteins from human, 
mouse, fish (DANRE), Drosophila (DROME) and yeast. F1QQP6 and Q1LWX7 
are the longest isoforms of BRD3 and BRD2 in DANRE, respectively. The 
dendrogram is the result of sequencing alignment of the indicated proteins in 
UniProt. 
The bromodomains 
The BET bromodomains, as with bromodomains in other proteins, are the 
acetyl-recognition domains13,44.  Deletion of these domains, or point mutations in 
their acetyl-lysine recognition pocket, dramatically reduces the ability of BET 
proteins to associate with chromatin32–36. The BET bromodomains are the targets 
of small molecule inhibitors being tested in various preclinical and clinical 
settings45. The details of these inhibitors are described in more detail below. The 
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amino acid sequences of the BD1 and BD2 bromodomains across the BET family 
are ~75% identical, whereas the sequences of BD1 and BD2 within a given protein 
are only ~44% identical, indicating that BD1 and BD2 are more evolutionarily 
distinct than the proteins (Figure 1.3)46. Nevertheless, the structures of the BET 
bromodomains reveal remarkable similarity overall44,46–52. The bromodomains 
generally consist of four alpha helixes (aZ, aA, aB, aC) and two interconnecting 
loops (ZA and BC)45. The four helices form a left-handed bundle around a 
hydrophobic core with a deep acetyl-recognition cleft formed by juxtaposition of 
the two intervening ZA and BC loops. The structural elements of the helical bundle 
bear strong resemblance across the bromodomains. In contrast, the ZA and BC 
loops comprising the acetyl-lysine binding pocket are more structurally distinct. 
Though the residues in the ZA and BC loops that make contact with the acetyl-
lysine are highly conserved47,53, sequence divergence among the adjacent 
residues is thought to contribute to the specificity of each bromodomain for given 
acetylated substrates.  
BET proteins have been shown in many contexts to bind preferentially to 
multi-acetylated peptides. Because the initial structural characterization of BET 
bromodomains—in particular those of BRD246,49,51,52 and BRD447,53—was 
performed in the context of mono-acetylated peptides (H4K12ac for BRD2 and 
H3K14ac for BRD4), it was hypothesized that preference for multi-acetylated 
substrates was due to the tandem BET bromodomains binding synchronously to 
individual acetylated lysines of a di-acetylated peptide. However, the co-crystal 
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structure of BRDT-BD1 with a di-acetylated H4K5ac/8ac peptide revealed an 
alternative explanation for multi-acetylated substrate binding48. The acetyl-binding 
pocket of BRDT-BD1 can actually accommodate both acetylated lysine residues 
on its own. The first acetyl-lysine engages with BD1 using the canonical binding 
cleft described above. The second acetyl-lysine contacts hydrophobic residues on 
the outside surface of the primary binding pocket. The negative charge imparted 
by the second acetyl group forms a hydrogen bond with a water molecule that 
bridges with the first acetyl group, creating a favorable binding surface. Thus, 
BRDT-BD1 binds preferentially to di-acetylated peptides. Unlike BD1, BD2 only 
engages with one acetylated lysine due to amino acid differences within BC loop 
which prevent BD2 from interacting with the second acetylated lysine. Peptide 
binding assays confirm the distinct binding modalities of BD1 and BD2. BD1 
requires at least two acetylated lysines on histone tail peptides for binding to take 
place, whereas BD2 recognized mono-acetylated peptides with the same affinity 
as multi-acetylated peptides48. Structural homology between BET proteins 
suggests that these BD1 and BD2-specific binding modalities are likely to be 
shared across the BET family. Indeed, subsequent solution structures of the 
BRD3-BD1 in complex with a di-acetylated GATA1 peptide and BRD4-BD1 with 
various di-acetylated histone tail peptide isoforms (H4K5ac/8ac, H4K12ac/16ac, 
and H4K12ac/20ac) confirmed this di-acetyl binding mechanism44,50.  
Interestingly, comparison of BRDT bromodomain binding to in vitro 
reconstituted acetylated nucleosomes versus histone peptides revealed that BD1 
binds 6-fold more strongly to acetylated nucleosomes than to acetylated histone 
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tail peptides54. This enhanced affinity for nucleosomes is due to a positively 
charged patch in close proximity to DNA on the first alpha helix of BD1 (aZ) which 
binds to DNA directly. This additional bivalent binding modality further diversifies 
the in vivo substrate binding preferences of the individual BET bromodomains. For 
example, the DNA binding patch is absent on BRDT-BD2 and though present on 
BRD3-BD1 and BRD4-BD1, does not appear to bind DNA in those cases54.  
Recognition of diacetyl H4K8ac/12ac is a special case both for BRD4-BD1 
and BRD2-BD1. Though BRD4-BD1 binds simultaneously to both of the acetyl 
groups of many diacetylated peptides, for di-acetylated H4K8ac/12ac, it only 
recognizes one acetyl at a time, indicating that the exact context of the diacetylated 
substrate dictates the binding modality used by the bromodomain44. BRD2-BD1 
also behaves differently in terms of H4K8ac/12ac recognition. Like BRD4-BD1, 
BRD2-BD1 does not recognize the di-acetylated surface of this particular substrate 
and instead only associates with one of the acetyl groups. However, unlike BRD4-
BD1, which can interact with either of the acetyl groups, BRD2-BD1 only 
recognizes H4K12ac. In fact, acetylation of H4K8ac interferes with the binding of 
BRD2-BD1 to H4K12ac. The mechanism for this inhibition is that H4K8ac 
interferes with the BRD2-BD1 dimerization, which is important for BRD2-BD1 
recognition of H4K12ac46,51. Dimerization does not appear to occur for any of the 
other BET bromodomains, making this feature unique to BRD2-BD1. Thus, the 
sequence context of an acetylated substrate affects whether the acetyl-lysine is 
recognized by different individual BET bromodomains and the modality by which it 
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is recognized (mono- versus di-acetyl binding). A large-scale study of this 
phenomenon revealed that recognition of acetylated histone peptide substrates is 
influenced not only by the acetyl groups on adjacent residues, but also by methyl- 
and phospho-marks on these flanking residues and by the length and sequence of 
the linker region between any two modifications44.  
How do these structural considerations relate to substrate binding 
preferences of the full-length BET proteins? Histone marks enriched in vivo by 
each full length BET protein include various combinations of di-, tri-, and tetra-
acetylated H4K5/8/12/16 preferentially over monoacetylated H455. Of the di-
acetylated H4 peptides, H4K8ac/16ac and H4K5ac/8ac were the most strongly 
enriched. This was true even in the case of BRD2, which was originally thought to 
prefer mono-acetylated residues – specifically H4K12ac – based on early but 
limited histone interaction studies32 and subsequent structural evaluation of its 
bromodomains46,49,51,52. The direct binding of full-length BET proteins with multi-
acetylated histones is supported biochemically by the bromodomain structures 
described above as well as various histone peptide and nucleosomal binding 
studies, the latter of which suggest that some BET proteins may associate more 
tightly with chromatin in vivo via bivalent DNA-histone nucleosomal interactions54. 
Indeed, genome-wide chromatin distributions of BRD2 in vivo correlate better with 
di-acetylated H4K5ac/8ac, a direct substrate, than with either H3K27ac or 
H3K4me3, which are histone marks associated with transcription but not predicted 
to directly bind to BET proteins56. Nevertheless, it is likely BET proteins affiliate 
with large multi-unit complexes which may influence to some extent where BET 
17 
 
proteins are found on chromatin and the chemical makeup of this chromatin. Thus, 
the specificity and selectivity of BET proteins for substrates in vivo may be 
determined not simply by the structures of the acetyl-recognition pocket in the 
bromodomains, but also by protein-protein complex formation that may anchor 
BET proteins to regions not necessarily enriched for preferred bromodomain 
substrates. An example of this is the observation that H2A.Z-containing 
nucleosomes preferentially enrich BRD2 over BRD3 and BRD457–59 despite no 
preference of the BRD2 bromodomains for binding acetylated H2A peptides44. A 
comprehensive comparison of histone binding preferences and chromatin 
occupancy is needed to better understand to what extent the bromodomains drive 
genome-wide binding of each BET protein. 
BET proteins also interact with acetylated transcription factors. BRD3-BD1 
binds to diacetylated GATA1 using a mechanism strikingly similar  to acetylated 
histone recognition (two acetyl-lysines spaced three residues apart)50. A similar 
binding mechanism also occurs between BRD4-BD2 but not BRD4-BD1 and 
diacetylated TWIST60, which is interesting because the opposite would be 
expected based on recognition of diacetylated histone peptides44,48. Nevertheless, 
this arrangement allows BRD4-BD2 to bind acetylated TWIST and BRD4-BD1 to 
bind acetylated H4, which may be a general mechanism by which BET proteins 
anchor acetylated transcription factors to chromatin. BRD4 also binds to di-
acetylated ERG61, mono-acetylated RELA (a component of the NF-kB transcription 
factor complex)62 and to the acetylated androgen receptor63. The binding 
mechanisms for these interactions have been investigated to varying detail, but 
18 
 
more generally it also remains unclear whether any of the above transcription 
factor interactions are specific for particular BET proteins. Nevertheless, the ability 
of BET proteins to recognize acetylated transcription factors may be as functionally 
significant as their ability to bind to acetylated histones. 
The ET domain 
The bromodomains are largely responsible for acetyl-lysine recognition and 
the association of BET proteins with chromatin. However, the ET domain is also 
critical for BET protein function, and like the bromodomains, is strongly conserved 
across the BET family. The ET domain has been shown to mediate protein 
interactions with several transcriptional co-activators including JMJD6, ATAD5, 
GLTSCR1, CHD4, and NSD3 (WHSC1L1)31,64–66. The interaction between BRD4 
and JMJD6 was shown to promote enhancer-mediated promoter-proximal pause-
release of RNA polymerase II (POL)267, and the interaction with NSD3 was shown 
to promote leukemic gene expression and cell growth through CHD865. The ET 
domain also functions as the binding site for IN (from murine leukemia virus)68 and 
LANA (from Kaposi’s sarcoma-associated herpesvirus)69 to promote viral 
integration and latency, respectively, and it maintains HIV latency through an 
association with endogenous BRG1 in HIV-infected cells70. The ET domain also 
associates with CHD4, a component of the NuRD complex which functions in both 
transcriptional activation and repression71. Structural characterization of the ET 
domain in complex with many of these substrates reveals a common binding motif 
recognized by the ET domain31,64,66,68,71,72. More recently, the association between 
BRD4 and the cohesin-loading factor NIPBL was shown through yeast two-hybrid 
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screening assays to be mediated by the ET domain, though it is unclear if NIPBL 
contains the same ET-binding motif73,74. Interestingly, mutations in BRD4 and 
NIPBL are both associated with Cornelia de Lange syndrome (CdLS), suggesting 
a causal link. It is possible that the BRD4 mutations disrupt a functional interaction 
between BRD4 and NIPBL as several of the BRD4 mutations are located in the 
bromodomains or ET domain74,75. This highlights the role of BET proteins as 
molecular scaffolds onto which additional factors bind to acetylated chromatin. 
Mutations in any of the critical regions of BRD4 may generate hypomorphic BRD4 
alleles unable to effectively recruit transcriptional regulators to chromatin. This 
same biology is the basis for therapeutic BET bromodomain-disrupting drugs that 
inhibit disease-promoting pathways by dislodging transcriptional regulators from 
chromatin. Of note, there is no indication that ET-mediated interactions are specific 
for one particular BET protein. Thus, as with the bromodomains, it is unclear if the 
ET domains contribute to BET protein specific functions. 
The BRD4L-specific C-terminal tail and the short isoform of BRD4 
The Brd4 gene encodes both a short (BRD4S) and long (BRD4L) isoform. 
BRD4L is structurally distinct from BRD2, BRD3, and BRD4S in that it possesses 
an extended tail with a protein-interaction domain located at the C-terminus (Figure 
1.4). This C-terminal motif (CTM) binds to polymerase elongation factor beta 
(PTEFb)76. PTEFb is a dimer composed of CCNT1 and CDK9, the latter of which 
phosphorylates POL2. Recruitment of PTEFb and phosphorylation of POL2 is a 
key molecular switch that transitions POL2 from its paused configuration to its 
elongation mode77. The CTM of BRD4 is thus thought to recruit PTEFb to gene 
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promoters to facilitate transcriptional elongation78. BRD4L also contains a putative 
histone acetyltransferase catalytic (HAT) domain and acetyl-CoA binding sites that 
enable BRD4L to directly acetylate H3K122, which destabilizes nucleosomes and 
de-compacts chromatin (Figure 1.4)79. A screen of mutations that disrupt BRD4 
activity validates that in addition to the bromodomains and the ET domain both the 
CTM and the HAT of BRD4L also contribute to its overall function80.  
BRD4S lacks the extended C-terminal tail of BRD4L due to the presence of 
a stop codon in an alternatively spliced exon. BRD4S therefore lacks the HAT and 
CTM domains and more closely resembles BRD2 and BRD318. The regulation of 
this alternative splicing event has not been studied, and the functional significance 
of the ratio of BRD4S and BRD4L protein isoforms has not been directly tested, 
though it may drive certain phenotypes such as tumor growth and metastasis in 
cancer cells81. BRD4S localizes to the nuclear periphery where it interacts with 
different protein partners in comparison to BRD4L82. Importantly these changes in 
nuclear compartmentalization occur despite BRD4S and BRD4L containing the 
same acetyl-binding bromodomains, indicating that additional protein interaction 
domains can drive BET protein localization. BRD4S also functions to maintain HIV 
latency in infected T cells by recruiting repressive BRG1, a component of a 
chromatin remodeling complex70, and like BRD2 and BRD3, can recruit the viral 
latency protein LANA1 in KSHV-infected cells69. However, its expression and 
function in most cell types remains poorly characterized. 
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Additional conserved features 
In addition to the domains described above, BET proteins also possess a 
conserved regions motif A and motif B (Figure 1.4). Whereas no function has been 
ascribed to motif A, limited analysis of motif B indicates that it facilitates homo- and 
hetero-dimerization of BET proteins and their association with chromatin35. Motif B 
also interacts with LYAR, which contributes to BET occupancy on chromatin and 
promotes transcription, particularly of ribosomal genes83,84.  
BET proteins possess shared serine-rich patches in the N- and C-terminal 
regions termed the NPS and CPS respectively (Figure 1.4). Phosphorylation of the 
NPS induces a conformation change that affects chromatin occupancy85. This 
phospho-switch mechanism was proposed for BRD4, but based on conservation 
of the relevant residues, may also apply to the other BET proteins. In the 
unphosphorylated state, BD2 forms an intra-molecular interaction with NPS that 
prevents BD2 from engaging chromatin. Phosphorylation of the NPS releases BD2 
in favor of a basic region termed the BID, allowing BD2 to bind freely to acetylated 
chromatin. The degree of phosphorylation may thus determine the substrates to 
which BET proteins bind. Interestingly, hyperphosphorylation of BET proteins may 
result in bromodomain-independent occupancy on chromatin through gained 
interactions with the Mediator complex, though it is unclear if this is related to the 
phospho-switch mechanism above86. Thus, the binding of BET proteins to 
acetylated substrates is not only determined by the residues in contact between 
the bromodomains and the acetylated peptide substrates, but also by tertiary 
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folding of the full length BET proteins, which is subject to regulation through post-
translational processes such as phosphorylation. 
Perturbing BET protein function 
 BET proteins have received considerable attention as therapeutic targets. 
This is due in part to their direct involvement in a rare cancer called NUT midline 
carcinoma (NMC) and their indirect role in more common cancers such as acute 
myeloid leukemia (AML) among others87. However, the large majority of data 
implicating BET proteins in disease is based on the exploratory use of BET 
inhibitors in various disease models. It is important to note that BET proteins are 
critical transcriptional regulators. Thus, any therapeutic benefit derived from BET 
inhibition may be limited by unwanted effects on normal transcription. For example, 
it has been shown that global reduction of BRD4 in the adult mouse results in 
multiple deficits including weight loss, epidermal hyperplasia, and stem cell 
depletion within the small intestine88. Depletion of BRD2 can result in bone marrow 
failure89. This section will therefore summarize the initial observations that drove 
the development of BET inhibitors. It will then discuss subsequent studies 
exploring their role in other diseases. And it will conclude with the transcriptional 
effects associated with BET inhibition. The goal is to provide a lens through which 
the mechanism of action of these drugs and their potential side effects can be 
understood. 
Role of BET proteins in disease 
NUT midline carcinoma is a rare but aggressive squamous cell carcinoma 
characterized by chromosomal translocations directly involving BRD3 or BRD490. 
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Translocations involving BRD2 have not been described. The translocations result 
in chimeric proteins comprised of the intact chromatin-binding domains of BRD3/4 
and the transcriptional activation domain of the NUT protein. The BRD3/4-NUT 
fusion protein recruits the histone acetyl transferase EP300 leading to a cycle of 
hyperacetylation that extends across large swaths of DNA91,92. This 
hyperacetylation in turn leads to aberrant expression of the underlying genes and 
ultimately cancer93. It is unclear why this malignancy only occurs at midline 
anatomic structures of the head, neck, and mediastinum but in addition to the onset 
of disease in young adults, this anatomic pattern suggests an embryonic origin. In 
addition to being direct mediators of NMC, BET proteins were also identified in 
global candidate screens that looked for susceptibility genes in AML80,94. 
Mechanistically, the dependency of AML cells on BET proteins for cell growth is 
based on BET proteins driving oncogenic Myc expression.  
Inhibition using small molecules 
Based on this clinical need, a new class of drugs targeting BET proteins 
was developed. Evolution of candidate compounds and chemical screening 
approaches converged on thienodiazepine chemistry to target the BET 
bromodomains95,96. Due to the structural similarity of the BET bromodomains, 
these inhibitors typically do not discriminate between individual BET proteins. The 
first proof-of-principle use of these pre-clinical compounds was in NMC, where the 
inhibitor directly targets the translocated BRD3/4-NUT oncogene product95. 
Treatment with the BET inhibitor JQ1 significantly displaced BRD4 and BRD4-NUT 
from chromatin, induced growth arrest, and differentiated the malignant cells into 
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a more benign, squamous state. Gene expression analysis indicated that sub-
micromolar doses of JQ1 did not simply suppress all genes, but rather selectively 
turned off the oncogenic program driven by BRD4-NUT95. A second 
thienodiazepine-based BET-specific inhibitor, I-BET, was shown to displace BRD4 
from tetra-acetylated H4 peptide, indicating that bromodomains inhibitors 
outcompete the natural ligands of BET proteins96. Strikingly, I-BET prevented LPS-
induced inflammatory gene expression in macrophages, which had previously 
shown to require BRD497, while minimally affecting non-inducible genes.  
 BET inhibitors have been shown to disrupt cell growth in a number of 
hematological and solid malignancies. An incomplete list of these studies include 
diffuse large B cell lymphoma98, multiple myeloma99, triple negative breast 
cancer100, castration-resistance prostate cancer63, melanoma58, Ewing 
sarcoma101, liposarcoma102, and glioblastoma103. BET inhibitors have been used 
in other disease settings as well. In cultured pancreatic islet cells, inhibition of BET 
proteins may protect against the development of insulin resistance104. In hepatic 
cells, targeting BET proteins protects against fibrosis by blocking multiple 
profibrotic transcriptional pathways105. And under cardiac stress conditions, 
targeting BET proteins prevents cardiomyocyte hypertrophy and cardiac 
remodeling106.  Thus, the exploratory use of BET inhibitors has demonstrated that 
in addition to treating many solid and hematological malignancies, these drugs 
may have additional use in inflammatory, metabolic, and cardiac disorders. 
Based on these promising preliminary findings, several generations of BET 
inhibitors have since been developed and are at various stages of preclinical and 
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clinical testing45,107. For example, bivalent BET inhibitors using linkers demonstrate 
stronger anti-leukemic efficacy than molar equivalents of their monovalent 
counterparts. This enhanced avidity may be due to the ability of individual 
bromodomains to interact with multiple acetylated lysine residues simultaneously 
or to the ability of BET proteins to engage two substrates using their tandem 
bromodomains. Inhibitors that discriminate between the first and second 
bromodomains (BD1 and BD2) have also been developed108–110. Comparison of 
BD1- and BD2-specific transcriptional effects largely corroborate structural studies 
indicating that BD1 is the more critical bromodomain for substrate binding. 
However, the less drastic transcriptional impact caused by BD2 inhibition can be 
leveraged therapeutically to target more aggressive cancers with better 
specificity109 or to prevent particular phenotypes, such as inflammatory gene 
expression, without altering baseline genes110. Interestingly, BD1 inhibition largely 
recapitulates BD1+BD2 inhibition in terms of antiproliferative effect, whereas BD2 
inhibition more directly targets inducible gene expression during inflammation110. 
In summary, BET bromodomain inhibitors block BET protein activity by 
competitively occupying their acetyl-lysine binding pocket, which displaces the 
natural acetylated peptide ligands and forces the disassociation of BET proteins 
from chromatin30,95,96. These drugs may have widespread clinical use, but a better 
understanding of BET protein function is required. Therefore, the transcriptional 
consequences of removing BET proteins from chromatin will be discussed below.  
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Transcriptional mechanisms revealed by BET inhibition  
 There is striking consistency across experimental approaches that 
perturbing BET protein function reduces transcriptional elongation41,67,106,111,112. 
This is consistent with several lines of evidence implicating BET proteins in 
promoting POL2 pause-release and/or functioning as histone chaperones to allow 
POL2 processivity through nucleosomes. BET proteins can complex with PTEFb30, 
a known transcriptional elongation factor that releases POL2 from its paused state 
into its elongating state77. BET proteins found at enhancers may contribute to 
POL2 pause-release by recruiting JMJD6 to enhancers which then form enhancer-
promoter contacts that allow JMJD6 to release PTEFb from its inhibitory 
complex67. In support of this model, some studies suggest that degree of BET 
protein enrichment at enhancers correlates with BET inhibitor sensitivity98,99. 
However, these PTEFb-related mechanisms may not be as functional as originally 
thought, given that BET proteins can affect elongation independent of PTEFb 
occupancy111. In addition to pause-release, assays using highly purified 
components have shown that BET proteins can each individually stimulate 
transcriptional elongation independent of the PTEFb-interacting CTM domain 
when added to in vitro transcription reactions and that this activity is sensitive to 
bromodomain inhibition40,41. It was therefore proposed that BET proteins are 
histone chaperones that assemble and disassemble nucleosomes from acetylated 
histones to allow the passage of POL2. Though the biochemical basis for this 
hypothesis remains unexplored, this model is supported by the fact that the amount 
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of BET protein enriched on gene bodies correlates better with transcriptional 
activity than the amount enriched at gene promoters41.  
In addition to pause-release and elongation, BET proteins also function in 
transcriptional initiation through their interactions with acetylated transcription 
factors. Displacement of BET proteins from chromatin via BET bromodomain 
inhibition has been shown to decrease transcription factor binding resulting in 
concomitant changes in gene expression61–63,96,113. Our lab has shown that in the 
case of GATA1, BET proteins may play a role not only in GATA1 recruitment and 
thus transcriptional initiation, but also in downstream transcriptional events that 
take place after GATA1 binding has been established113. The role of BET proteins 
in establish transcription factor occupancy may be key to the observation that 
“inducible” genes tend to be the most sensitive to BET inhibition96. This indicates 
that lineage- or state-dependent transcriptional programs – whether oncogenic, 
inflammatory, or stress-induced – may be more easily targeted by therapeutic BET 
inhibitors.  
Predicting genes that are vulnerable to BET inhibition remains a challenge. 
No single chromatin attribute, including proximity to enhancers or degree of BET 
enrichment, adequately predicts a gene’s primary responsiveness to BET 
inhibition112. Moreover, comparison of JQ1-sensitive and JQ1-insensitive AML cell 
lines have shown that a core set of genes – including oncogenic Myc – are 
hypersensitive to BET inhibition regardless of the resultant effect on cell growth, 
indicating that even if a gene’s sensitivity could be predicted, the ultimate effect on 
cell phenotype cannot be predicted112. This suggests that for some transcriptional 
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programs, the cellular response to BET inhibition does not depend on the primary 
transcriptional response but instead on secondary cell-specific attributes. Plasticity 
within these transcriptional pathways may also be at fault for the development of 
resistance to BET inhibitors over time86,114–116. Therefore, a better understanding 
of the exact role BET proteins play in transcription is needed to guide the 
development of more dependable anti-BET therapeutic strategies.  
In scenarios where BET inhibition has a favorable outcome, the therapeutic 
efficacy is often attributed to BRD4 inhibition. This is in part due to the proposed 
BRD4-PTEFb molecular mechanism considered to be important for transcriptional 
pause-release and elongation77. Though many studies do not investigate the 
independent roles of BRD2/3/4, in the case of AML, depletion of BRD2 or BRD3 
does not affect cell proliferation or POL2 phosphorylation whereas depletion of 
BRD4 does80,94,112. However, in other cases, BRD2 and BRD3 do in fact contribute, 
which will be discussed below. Thus, though BRD4 certainly contributes to 
transcription, it is important to remember that BET bromodomain inhibitors typically 
used in these studies do not discriminate between individual BET proteins. Their 
therapeutic effect is thus the aggregate result of inhibiting the entire BET family. 
Identifying the individual roles of BET proteins in transcription is critical to 
understanding the mechanism of action of BET inhibitors.  
Evidence for distinct BET protein functions 
BET proteins are epigenetic reader proteins – adaptor proteins with 
specialized domains that bind to acetylated chromatin and recruit multi-protein 
complexes. However, it remains unclear whether individual BET proteins function 
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distinctly or redundantly. Identifying distinct functions for individual BET proteins is 
complicated by their propensity to dimerize with one another35, to associate with 
similar multi-protein complexes30,31,64, and to co-localize on chromatin63,102,117,118. 
Given these findings, one can imagine models where BET proteins function 
interdependently within multi-unit complexes. The purpose of this section is to 
synthesize the evidence that individual BET proteins function non-redundantly and 
thus possess specialized functional niches on chromatin.  
Insights revealed by genetic studies 
The phenotypes of genetic knockout mice provide the strongest evidence 
that BET proteins function non-redundantly. For example, both BRD2 and BRD4 
are independently required for embryonic development, and the phenotypes of 
these mice are distinct. BRD4-defects manifest earlier during development 
resulting in early post-implantation defects, whereas BRD2-defects occur later 
during development resulting in impaired neural tube closure21–23. Interestingly, 
mice with hypomorphic Brd2 alleles (resulting in global reduction of BRD2 protein 
across tissues) are viable but display metabolic irregularities, indicating that even 
the levels of BRD2 are critical119. BRD3 knockout mice have not been reported.  
The requirement for individual BET proteins can also be identified through 
targeted depletion strategies. For example, depletion of BRD2, BRD3 or BRD4 
each reduces proliferation of castration-resistant prostate cancer cells and diffuse 
large B cell lymphoma cells63,98. Likewise, depletion of all three BET proteins 
effects cell growth in Ewing sarcoma cells101,120,121. Both BRD2 and BRD4 are 
individually required for the differentiation of CD4+ Th17 cells122, and all three BET 
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proteins contribute to LPS-induced stimulation of cytokine expression in 
macrophages123. These studies indicate that like BRD4, BRD2 and BRD3 are also 
required for many biological processes.  
Global transcriptional signatures and phenotypes are also different 
depending on whether BRD2, BRD3 or BRD4 are depleted. For example, in 
pancreatic beta cells, depletion of either BRD2 or BRD4 enhances transcription of 
insulin, whereas inhibition of BRD2 but not BRD4 enhances fatty acid oxidation104. 
A global analysis of gene expression changes in these cells revealed that depletion 
of BRD2, BRD3 and BRD4 each yielded different signatures, indicating that 
individual BET proteins are involved in both shared and discrete transcriptional 
pathways104. A similar gene expression analysis performed in breast cancer cells 
revealed distinct effects on a panel of epithelial-to-mesenchymal transition (EMT) 
genes upon depletion of BRD2, BRD3 or BRD4. Phenotypically, BRD2 appeared 
to promote EMT whereas BRD3 and BRD4 repressed EMT124. Likewise, in skeletal 
myogenesis, depletion of BRD3 and BRD4 have opposing effects on myogenic 
differentiation with BRD4 appearing to promote differentiation and BRD3 
appearing to inhibit it (BRD2 depletion was not achieved so was not examined 
further)125. In embryonic stem cell differentiation into myoblasts, Nodal gene 
expression is mediated first by BRD4 and then by BRD2 with a concomitant switch 
in the BET protein predominantly found at cis-regulatory elements near the Nodal 
gene126. This indicates that BRD2 and BRD4 promote Nodal gene expression 
independently. In blocking interferon-induced gene expression, targeted BRD4-
depletion was not as effective as pan-BET bromodomain inhibition, supporting 
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contributory or perhaps independent roles for BRD2 and BRD3 in transcription110. 
BRD2 and BRD4 also have unique roles in the DNA damage response with BRD2 
directly contributing to DNA repair at double-strand breaks127 and BRD4 
functioning as a more general insulator of acetylated chromatin128. Collectively, 
these studies strongly suggest that BRD2, BRD3 and BRD4 function within distinct 
niches during transcription and other nuclear processes.  
Insights revealed by chromatin occupancy studies 
The distribution of individual BET proteins on chromatin are largely similar 
but with some distinctions. A list of studies that perform chromatin 
immunoprecipitation coupled to high-throughput sequencing (ChIPseq) for two or 
more BET proteins in parallel is presented as Table 1.2.  
 
Table 1.2. Studies comparing chromatin distribution of two or more BET 
proteins. PubMed IDs (PMID) listed for reference. 
Study Cells/tissue PMID BET proteins Main findings
Nicodeme et al, Nature  (2010) 
Mouse bone marrow derived 
macrophages PMID: 21068722 BRD2/3/4 Gene tracks show similarities and distinctions.
LeRoy et al, Genome Biol 
(2012) Human 293T cells PMID: 22897906
BRD2/3/4 (Flag-
tagged) Similar metaprofiles across genes
Asangani et al, Nature  (2014) Human prostate cancer cells PMID: 24759320 BRD2/3/4
Colocalization at many regions as well as 
independent peaks.
Anders et al, Nature Biotech 
(2014)
Human MM1.S multiple 
myeloma cells PMID: 24336317 BRD2/3/4
Strong colocalization of BRD2/3/4 at promoters 
with BRD2/4 but little BRD3 at enhancers
Di Micco et al ,Cell Reports 
(2014) Human ESC PMID: 25263550 BRD2/3/4 No comparative analysis
Fong et al, Nature  (2015) Mouse MLL–AF9 AML cells PMID: 26367796 BRD2/3/4 No comparative analysis 
Ding et al, PNAS  (2015)
Human LX-2 cells (hepatic 
stellate cells) PMID: 26644586 BRD2/3/4 No comparative analysis
Keck et al, J Biol Chem  (2017)
Human MutuI cells ( EBV-
positive Burkitt lymphoma) PMID: 28588024 BRD2/3/4
Strong colocalization at the EBV lytic origins of 
replication
Stonestrom et al, Blood  (2015) 
& Hsu et al, Mol Cell  (2017)
Mouse G1E-ER4 erythroblast 
cells
PMID: 25696920 & 
PMID: 28388437 BRD2/3/4
Colocalization of BRD3/4 at GATA1 and 
BRD2/3 at CTCF
Cheung et al, Mol Cell  (2017)
Mouse CD4+ T cells (Th17 
cells) PMID: 28262505 BRD2/4 Colocalization with more BRD2 at CTCF
Piunti et al, Nat Med  (2017)
Human SF8628 cells (diffuse 
intrinsic pontine glioma) PMID: 28263307 BRD2/4 Colocalization of BRD2/4
Fontanals-Cirera et al, Mol Cell 
2018 Human melanoma cells PMID: 29149598 BRD2/4
Similar metagene profiles at promoters and 
enhancers, perhaps more BRD2 at promoters
Xu et al, PNAS  (2018) Human U87 gioblastoma cells PMID: 29764999 BRD2/3/4 Colocalization at E2F1 target genes
Chen et al, Nature Commun 
(2019) Human liposarcoma cell lines PMID: 30903020 BRD2/3/4
Colocalization with more BRD2/3 at promoters 
and more BRD4 at enhancers
Khoueiry et al, Epigenetics 
Chromatin  (2019) Human K562 cells PMID: 31266503 BRD2/3/4 Similar metagene profiles at promoters
Bevill et al, Mol Cancer Res 
(2019)
Human breast cancer cells 
(MDA-MB-231) PMID: 31000582 BRD2/4 Similar metagene profiles at promoters
Federation et al, Cell Reports 
(2020) Human K562 cells PMID: 32101728 BRD2/3/4 Similar gene track profiles
Gilan et al, Science  (2020) Human THP-1 cells PMID: 32193360 BRD2/3/4 Similar gene track profiles
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BET proteins tend be highly enriched at promoters and enhancers, 
consistent with their role in regulating transcription. There is some indication that 
BRD2 and BRD3 are slightly more enriched at promoters in comparison to 
enhancers, whereas BRD4 is more enriched at enhancers102,117,129. This is 
consistent with BRD2 and BRD3 binding more strongly to the promoter-associated 
histone variant H2A.Z57–59. Interestingly, whereas BD1-specific bromodomains 
inhibitors displace BRD2, BRD3, and BRD4 relatively equally from chromatin, 
BD2-specific inhibitors affect BRD2 and BRD3 while leaving BRD4 occupancy 
largely intact110. This indicates that BRD2 and BRD3 may bind chromatin using 
mechanisms inherently differently than BRD4. Nevertheless, all three BET proteins 
bind promoters where they exhibit similar binding profiles55,118. BET proteins may 
also bind within gene bodies potentially reflecting a role in transcriptional 
elongation40,41,55. However, in comparison to promoter-proximal binding, the 
degree BET protein binding over gene bodies is not as defined as that of POL2 or 
other components of the elongating POL2 complex130. This indicates that BET 
proteins may not travel as part of the elongating POL2 complex directly, but the 
exact details of BET protein function over gene bodies remains unclear. Consistent 
with the observation that the transcriptional elongation promoting activity is shared 
by all three BET proteins, no obvious differences in their distributions at promoters 
or within genes can be appreciated40,41,55. In addition to enrichment of BET proteins 
at promoters, enhancers and gene bodies, we and others have noted some degree 
of overlap between BRD2 (and BRD3) and the architectural protein CTCF122,129,131. 
This suggests a role for BRD2 and possibly BRD3 in higher order chromatin 
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organization via the maintenance of topologically associating domains (TADs) 
and/or transcriptional boundaries. However, the degree of colocalization and the 
specificity of overlap between CTCF and BRD2 versus BRD4 varies between study 
and technical replicate. In summary, BET proteins tend to bind similar regions of 
the genome. Though some distinctions have been identified, a thorough meta-
analysis of publicly available data is required to confidently state which differences 
are robust to experimental parameters and thus reflect true functional specificity.  
Insights revealed by protein interaction studies 
BET proteins may carry out distinct functions or bind unique regions of the 
genome by associating with different protein complexes. However, as with the 
chromatin occupancy profiles described above, the interactomes of BRD2, BRD3 
and BRD4 are also largely similar30,31. This may be due to the tendency of BET 
proteins to associate with one another through direct dimerization, their mutual 
association with active chromatin, or their shared possession of the highly 
conserved ET protein-protein interaction domain. Nevertheless, one clear 
difference that is observed is that BRD4 tends to associate more strongly with the 
PTEFb than does BRD2 or BRD330,31. BRDT also binds to PTEFb31, which is 
consistent with both BRD4 and BRDT containing the PTEFb-interacting CTM 
domain on their extended tail. This is in contrast to interactions with casein kinase 
II (CK2) which are predominated by BRD2, BRD3 and BRDT31 and to interactions 
with the RNA polymerase II associated factor (PAF) complex which occur to some 
degree between all BET proteins30. Immunoprecipitation of ectopically expressed 
BRD3 was shown to enrich PTEFb, PAF, and CK2 among many other chromatin-
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associated proteins71. Unlike for PTEFb, BET protein domains that interact with 
PAF and CK2 are not known, though CK2 has been shown to phosphorylate 
regions of BRD4 that are conserved with the other BET proteins85. Several 
additional interactions known to be mediated by the ET domain (JMJD6, ATAD5, 
WHSC1L1/NSD3) are also found in interactome datasets.  
In summary, BET proteins are highly enriched at active chromatin where they bind 
acetylated residues and interact with multiple chromatin regulators, but the mechanisms 
underlying BET-specific functions in transcription remain unresolved. It has been 
proposed that BET-specific functions are conveyed in part via selectivity of the 
bromodomains for distinct acetylated substrates44,55. Specificity may also be mediated in 
a bromodomain-independent manner by protein-interaction domains such as the ET 
domain that influence co-factor recruitment and perhaps chromatin binding30,31. 
Nevertheless, the chromatin distributions and protein interaction networks of BET 
proteins are largely similar though with some exceptions. Additional work is 
required to determine whether these exceptions reflect biologically significant 
differences in BET protein function.  
Functions of BET proteins in GATA1-mediated transcription 
Our laboratory has used GATA1-mediated erythroid cell differentiation as a 
model system to further dissect the functions of BET proteins in transcription132. 
Interestingly, anemia is one of the predominant side effects observed in patients 
treated with clinical BET inhibitors133–135. Thrombocytopenia (reduced platelet 
count) is another common toxicity. GATA1 drives the differentiation of both 
erythrocytes and megakaryocytes (the cells that give rise to platelets) from a 
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common precursor136. This clinical picture is highly indicative of deficient GATA1 
activity in patients treated with anti-BET therapy. GATA1-mediate transcription in 
erythroid cells is thus a physiological and clinically relevant model for the study of 
BET protein function.  
GATA1 is acetylated by the acetyltransferases EP300 and CBP137,138. The 
BET protein bromodomain BD1 binds to a di-acetylated peptide within GATA1 
using a mechanism reminiscent of acetylated histone peptide recognition50. 
Though this was demonstrated in structural detail for BRD3-BD1, acetylated 
GATA1 peptides also enrich BRD4139. Mutations of the acetylated GATA1 residues 
recognized by BD1 prevent erythroid maturation and reduce occupancy of GATA1 
on chromatin, indicating that GATA1 acetylation is critical for its function in vivo140. 
GATA1-induced gene expression is also drastically reduced by BET bromodomain 
inhibition, indicating that BET proteins are critical mediators of acetylated GATA1 
activity113,139. In support of this model, BET proteins colocalize with GATA1 
genome wide, are required for GATA1 recruitment, and mediate transcription 
downstream of GATA1 binding113. Using GATA1-mediated erythroid maturation, 
our laboratory has demonstrated that BRD2 and BRD4 are both uniquely required 
for GATA1 activity (Figure 1.6)113. BRD3 appears dispensable, potentially due to 
compensation by BRD2113. Thus, BRD2 and BRD3 may function independently of 




Figure 1.6. BET protein requirements in erythropoiesis. Adapted from 
Stonestrom et al132. BRD2 depletion partially inhibits erythroid maturation. BRD3 
depletion has no apparent effect itself, but when combined with BRD2-deficiency, 
completely blocks maturation. BRD4 depletion prevents maturation on its own.   
 
The distinct functions of BRD2 and BRD4 may be reflected by their unique 
distribution patterns on chromatin. Whereas BRD4 tightly colocalizes with GATA1 
and binds chromatin in a GATA1-dependent manner, BRD2 exhibits a more 
GATA1-independent occupancy pattern and is also enriched at CTCF-sites113,131. 
It remains unclear whether these differences in chromatin occupancy patterns 
reflect the distinct functions of BRD2 and BRD4. Moreover, the structural basis for 
these distinct patterns remain unknown. Identifying the BET protein structural 
domains that underlie the shared and distinct functions of BET proteins may offer 
a window of insight into the mechanisms by which individual BET proteins function 
distinctly or cooperatively in transcription. Moreover, identification of structural 
features that differ between BRD2 and BRD4 could be exploited to design BET 
inhibitors that target specific BET proteins. The goal of my dissertation is thus to 
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use GATA1-mediated differentiation to map the domains that distinguish BET 




CHAPTER 2: MATERIALS AND METHODS 
 
Cell lines, cell culture, and GATA1-ER activation 
G1E cells are erythroblasts derived from Gata1-null male mouse embryonic 
cells141. G1E-ER4 cells are subcloned from G1E cells after expressing a retrovirally 
inserted construct that encodes GATA1 fused to the ligand binding domain of the 
estrogen receptor (GATA1-ER), which allows for conditional activation of GATA1 
upon administration of estradiol142. Brd2-null G1E-ER4 cells (BRD2 KO1-KO4) 
cells were derived by single cell cloning after nucleofection with vectors expressing 
spCas9 and a gRNA targeting the first bromodomain of BRD2 as previously 
described113. Clones KO1 and KO2 were previously described131. G1E-ER4 based 
cells were grown in suspension flasks in a humidified incubator at 37C at 5% 
carbon dioxide in G1E media. G1E media consists of the following reagents: 
Iscove’s Modified Dulbecco’s Medium (Corning, 10-016-CV); 15% FBS (Gemini, 
100-106), 2% Pen Strep (Gibco, 15140-122), 140µM 1-Thioglycerol, (Sigma, 
M6145), 2U/mL Epoetin (Amgen) and conditioned medium (titered for optimal cell 
growth) from a kit ligand producing CHO cell line. Cells were maintained in culture 
at a cell density of 0.1-1.0e6 cells/mL. Erythroid maturation experiments were 
performed by plating G1E-ER4 based cells at a cell density of 0.4-0.5e6 cells/mL 
in fresh G1E media containing 100nM estradiol (Sigma, E2758) for 24 hours. For 
the visualization of hemoglobin production, 40e6 cells were plated as above and 
matured for 48 hours with estradiol. 293T cells used for retrovirus production were 
grown on 100mM plasma-treated polystyrene plates in 293T media: Dulbecco’s 
Modified Eagle Medium (Gibco, 11965084), 10% FBS (Gemini, 100-106), 2% Pen 
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Strep (Gibco, 15140-122), 1% L:-Glutamine 200mM (Gibco, 25030-081) and 1% 
100mM sterile-filtered sodium pyruvate. 293T cells were split every 2-3 days using 
0.05% Trypsin-EDTA (Gibco, 25300-054). 
RNA isolation and RTqPCR 
For gene expression analysis, up to 1 million cells were resuspended in 
1mL of TRIzol (Ambion, 15596018). 200µl of chloroform (Fisher, BP1145-1) was 
added to each sample. Samples were vigorously inverted for 15 seconds, rested 
for 3 minutes and spun at 10,000 rpm for 15 minutes at 4C in a microcentrifuge. 
The aqueous phase (top layer) was applied to purification spin columns from the 
RNeasy® Mini Kit (Qiagen, 74106). Subsequent purification steps, including an 
on-column DNase treatment step (Qiagen, 79256), were followed according to the 
manufacturer’s instructions. RNA was eluted from the column in 40µl RNAse-free 
water from the kit, and the RNA concentration and purity were quantified using a 
spectrophotometer (Thermo Scientific, Nanodrop 2000). Reverse transcription 
was performed on 1µg of RNA using the iScript Reverse Transcription Supermix 
for RTqPCR (Bio-Rad, 1708841). The cDNA samples were diluted 5x in sterile 
0.2µM filtered MiliQ water. RTqPCR was performed using 2µl diluted cDNA,1µl of 
9µM forward/reverse primers and 5µl Power SYBR™ Green PCR Master Mix 
(Thermo Fisher Scientific, 4367660) on an ABI Vii7 real-time PCR machine. qPCR 
primers were designed to target mature transcripts. RTqPCR primer sequences 




Table 2.1. RTqPCR primer sequences used in this study 
Relative mRNA levels were quantified using the delta cycle of threshold (Ct) 
method (Relative mRNA Level = 2^(Ctcontrol gene – Cttarget gene). All gene expression 
analyses included at least two of the following housekeeping genes as controls for 
normalization: Pabpc1, Actb and Gapdh. All RTqPCR experiments were 
performed at least in triplicate (three independent GATA1-ER induction replicates). 
Plots illustrating gene expression were generated in RStudio using ggplot2. 
RNA sequencing 
For the RNA sequencing experiment, parental G1E-ER4, BRD2 KO1 and 
BRD2 KO2 cells were matured for 24 hours with estradiol prior to harvesting RNA. 
The experiment was performed in three replicates yielding a total of 9 samples.  
Library preparation and sequencing 
RNA concentration was determined using the Agilent RNA 6000 Nano kit 
(Agilent, 5067-1511) and 4µg of total RNA was enriched for mRNA by polyA 
Name Forward Reverse Note
Brd2 5' TTAAACACCCCATGGACCTC ATCAGCAGCAAACTCCTGTG mouse RTqPCR
Brd2 3' GCTCAACTCCACCAAAAAGC AGAAGAGGAAGATGACGACGAG mouse RTqPCR
Brd3 GGAGATGCTGTCCAAGAAGC TGTGCATCTGGGTACTCTCG mouse RTqPCR
Brd4 5' TAAAGTGCTGCAGTGGCATC TGGAGAACATCAATCGGACA mouse RTqPCR
Gata1-ER TATGGCAAGACGGCACTCTAC TGTTGTTGCTCTTCCCTTCC mouse RTqPCR
GFP/YFP AAGGGCATCGACTTCAAGG ATGCCGTTCTTCTGCTTGTC mouse RTqPCR
Hbb-b1 AACGATGGCCTGAATCACTTG AGCCTGAAGTTCTCAGGATCC mouse RTqPCR
Hba-a1 GTGGATCCCGTCAACTTCAAG CAAGGTCACCAGCAGGCAGT mouse RTqPCR
Alas2 TATGTGCAGGCCATCAACTACCCATTTCCATCATCTGAGGGCTGTGGTmouse RTqPCR
Slc4a1 TGGAGGCCTGATCCGTGATA AGCGCATCGGTGATGTCA mouse RTqPCR
Spta1 AAAGAGTTCCGCTCTTGCCTGAGATTTCCTCCCTGGATCCACAGCATTmouse RTqPCR
Csf2rb AAGAGCCTGCAACTCACTGG AGGGCTTGTGATTCTTCCCT mouse RTqPCR
Csf2rb2 GAGCGAGTGGAGCAATGAGTA ATAAACACGGCCAAAGTGGA mouse RTqPCR
Kcnn4 TCTCTGGCTCACCACAGCTT GGAATGTGATCGGAATCAGC mouse RTqPCR
Rhag TTCTGGAAATTGCTGTATTTGCTCTCCAAAGGCATGGATTGTC mouse RTqPCR
Actb ACACCCGCCACCAGTTC TACAGCCCGGGGAGCAT mouse RTqPCR
Gapdh AGGTTGTCTCCTGCGACTTCA CCAGGAAATGAGCTTGACAAAG mouse RTqPCR
Pabpc1 CTACCAGCCAGCACCTCCTT TGCAGCACGGTTCTGAGTCT mouse RTqPCR
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selection with Dynabeads mRNA DIRECT Micro Kit (Life Technologies, 61021) 
using the mRNA Isolation from Purified Total RNA protocol. Concentration of 
mRNA enriched samples was measured using the Agilent RNA 6000 Pico kit 
(Agilent, 5067-1513) before proceeding to library preparation with the remaining 
sample volume using the Ion Total RNA-Seq Kit c2 and IonXpress RNA-Seq 
Barcode 1-16 kit (Life Technologies, 4475936, 4475485). Final libraries were 
assessed using the Agilent High Sensitivity DNA kit (Agilent, 5067-4626) before 
pooling on an equimolar basis as determined by Bioanalyzer (Agilent) molarity 
estimate of each library. The pool was subsequently sequenced three times on an 
Ion Torrent Proton sequencer using Ion PI Hi-Q OT2 200 Kit, Ion PI Hi-Q 
Sequencing 200 Kit and Ion PI Chip Kit v3 (Life Technologies, A26434, A26433, 
A26771).  
Computational analysis  
Primary analysis of sequence data was performed by Ion Torrent Torrent 
Suite software (v4.4.3) before being exported into FASTQ format. Mapping to the 
mm10 genome (GCF_000001635.24_GRCm38.p4_genomic.gff) was performed 
using the following STAR options: runThreadN 8, readFilesCommand zcat, 
outSAMtype SAM, 
chimSegmentMin 32, outFilterType BySJout, outFilterMultimapNmax 20, 
alignSJoverhangMin 8, alignSJDBoverhangMin 1, outFilterMismatchNmax 999, 
outFilterMismatchNoverLmax 0.04, alignIntronMin 20, alignIntronMax 1000000, 
alignMatesGapMax 1000000. The following analyses were performed using the 
indicated R packages/functions: PCA (stats/prcomp), differential gene expression 
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(DEGandMore/DeWrapper), heatmap visualization (stats/pheatmap). The top ten 
gene sets enriched in the list of differentially expressed genes were identified from 
the Molecular Signatures Database hallmark gene sets using the GSEA online tool 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) with FDR cutoff of 
0.05. Plots illustrating gene expression and gene set enrichment were generated 
with custom code in RStudio using ggplot2. For the comparison with the previous 
microarray data set assessing the impact of JQ1 treatment on GATA1-ER activity, 
we downloaded publicly available data from Gene Expression Omnibus 
(GSE62709: samples G1E GATA-ER +E2 and G1E GATA-ER +E2 +JQ1 
replicates 1-3). Genes were included in the merged data if they had an average 
microarray measurement of 6 or higher in at least one of the groups and had an 
average normalized RNA-seq read count of 6 or higher in at least one of the 
groups. A correlation between the two datasets was tested by calculating a 
Pearson correlation coefficient and a linear regression line was computed. 
Differentially expressed genes were identified from the microarray based on an 
average fold change > 2 and FDR < 0.01, which were then intersected with 
differentially expressed genes from the RNAseq experiment (using same criteria) 
as depicted by the Venn diagrams in Figure 3.2.G. Statistical significance for each 
overlap was calculated using a Fisher’s Exact Test. For differential isoform 
analysis, the Ensembl gene mode of mouse Brd4 that includes 7 known alternative 
transcripts was used. All reads aligning to Brd4 by STAR (run with a 2-pass gap 
alignment mode) were included. The Bioconductor package was used to tabulate 
the sequencing depth at each Brd4 exon and the frequency of reads mapping to 
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junction sites. The reads all three replicates in each group were summed and 
DEseq2 was used to calculate statistical significances between groups. 
Plasmids and cloning 
All cloning was performed using standard molecular cloning techniques. 
PCR was performed using Platinum® Pfx DNA Polymerase (Invitrogen, 11708). 
All constructs were cloned into the MigR1 murine retroviral vector (with an IRES-
GFP selection marker) or a PK1-based N-terminal YFP fusion vector. For 
constructs requiring assembly of multiple PCR fragments, Gibson Assembly® 
Master Mix was used (NEB, E2611L). The vectors and inserts for each construct 




Table 2.2. Mouse BET protein expression constructs used in this study.  
Cell growth assay 
Differences in cell growth upon transduction with retroviruses expressing 
BET protein constructs were performed using viral titers that yield 30-40% GFP+ 
cells. GFP% was measured by flow cytometry and tracked over time while 





HA-Brd2-4S MigR1 Fusion of Brd2(1-456)-Brd4S(463-723)
HA-Brd4-2 MigR1 Fusion of Brd4S(1-462)-Brd2(457-798)
HA-Brd2dET MigR1 Brd2 with Brd2(629-716) deleted




YFP-Brd2-4S PK1 Fusion of Brd2(1-456)-Brd4S(463-723)
YFP-Brd4-2 PK1 Fusion of Brd4S(1-462)-Brd2(457-798)
YFP-Brd2-4mid PK1 Fusion of Brd2(1-456)-Brd4S(463-599)-Brd2(629-798)
YFP-Brd2-4ET PK1 Fusion of Brd2(1-628)-Brd4S(600-687)-Brd2(717-798)
YFP-Brd2-4end PK1 Fusion of Brd2(1-716)-Brd4S(688-723)
YFP-Brd4S-2ET PK1 Fusion of Brd4S(1-599)-Brd2(629-716)-Brd4S(688-723)
YFP-Brd4S-2CC PK1 Fusion of Brd4S(1-687)-Brd2(717-762)-Brd4S(688-723)
YFP-Brd4S-2ETCC PK1 Fusion of Brd4S(1-599)-Brd2(629-762)-Brd4S(688-723)
YFP-Brd2dET PK1 Brd2 with Brd2(629-716) deleted




GST-BRD2-CCp pGEX-2T Brd2(717-762, E725P+R732P+D740P)








maintaining the cells at a cell density of 0.1-1.0e6 cells/mL. %GFP was normalized 
by subtracting the starting %GFP (either day 1 or day 2). All cell growth assays 
were performed in triplicate (three independent transduction experiments).  
Retrovirus production and transduction 
Retroviruses were produced using calcium phosphate co-transfection of 
15µg construct and 15µg of pCL-Eco packaging plasmid into 293T cells. 293T cell 
media was replaced with G1E media after 24 hours. Virus-containing G1E media 
was then harvested after an additional 24 hours and passed through a 0.2µm filter. 
Viral supernatants were diluted in G1E media to find titers that yield 30-40% 
GFP/YFP+ cells. Retroviral transduction was performed by adding 250µl of titered 
virus to one million G1E-ER4 (or BRD2 KO) cells in 1mL G1E media supplemented 
with 4µl/mL polybrene and 10µl/mL 1M HEPES (Gibco, 15630080) in 12-well 
plates and spinning at 2000rpm in an centrifuge for 90 minutes. The supernatant 
was removed, and cells were resuspended in 5mL fresh G1E media. Fluorescence 
was measured 24 hours later on a flow cytometer.  
TER119 staining, flow cytometry, and cell sorting 
Flow cytometry was performed using standard antibody staining protocols 
and cytometry settings. Briefly, 105 to 106 cells were harvested and washed with 
PBS. For TER119 expression experiments, cells were infected with low-titer YFP-
BET encoding (or empty vector control) virus to guarantee single copy gene 
integration. After 24 hours of rest, estradiol was added to the mixed population of 
infected/uninfected cells for an additional 24 hours. Cells were then resuspended 
in a 100µl of staining buffer (PBS, 2% FBS) with a 1:200 dilution of anti-TER119-
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APC (Biolegend, 116211) and incubated on ice for 30 minutes. Samples were 
washed three times with PBS and resuspended in 200µl staining buffer and 
analyzed by flow cytometry by gating on YFP- or YFP+ cells. Derivation of stable 
YFP-BET expressing cell lines was achieved by iterative fluorescence activated 
cell sorting with narrow sorting gates in order to achieve similar YFP mean 
fluorescent intensity between cell lines.  
Whole cell extracts 
Whole cell extracts were prepared using standard laboratory techniques. 
Briefly, 1-3e6 cells were harvested for each sample. After washing in ice-cold PBS, 
cells were resuspended in 50-100µl RIPA buffer (150mM NaCl, 0.5% Na 
Deoxycholate, 50mM Tris-HCl pH 8.0, 1% NP-40, 0.1% SDS and freshly added 
500x protease inhibitor cocktail [Sigma, P8340] and 100x 100mM 
phenylmethylsulfonyl fluoride [PMSF]) and incubated on ice for 30 minutes. Lysed 
cells were sonicated in a Qsonica sonicator (model Q800R) for 3x 30 second on/off 
cycles at maximum amplitude in a water bath chilled to 4C. Insoluble material was 
pelleted by centrifugation at 15000 rpm for 5 minutes at 4C in a microcentrifuge. 
The supernatant was transferred to fresh microcentrifuge tubes and used 
immediately or snap frozen in liquid nitrogen and stored at -80C. Protein 
concentration was determined using the BCA protein assay (Pierce, 23225) with 
absorbance measured at 562nM compared to a BSA protein standard curve.   
Western blotting 
Western blots were performed using standard laboratory techniques. 
Briefly, protein samples were resuspended in 4x sample buffer (500mM Tris-HCl 
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pH 6.8, 8% sodium dodecyl sulfate, 20% 2-mercaptoethanol, 0.3% bromophenol 
blue, 30% glycerol) and denatured at 95C for 10 minutes.  Equal protein amounts 
were loaded and separated on 4-15% or 4-20% gradient pre-cast gels (Bio-Rad, 
4561084 or 4561096) and transferred to nitrocellulose membranes (Bio-Rad, 
1620115). Primary antibodies include: Brd2 N-term (Cell Signaling, 5848S), Brd2 
C-term (Bethyl, A302-583A), Brd3 (Active Motif, 61489), Brd4L (Bethyl, A301-
985A), Brd4 N-term (Abcam, ab128874), HA (monoclonal 12CA5, purified in-
house) or HA (Cell Signaling, C29F4), GFP/YFP (Abcam, ab290), PCNA (Santa 
Cruz, sc-9857) and β-Actin−Peroxidase (Sigma, A3854). Secondary staining 
reagents include goat anti-rabbit IgG-HRP (Abcam, ab6721), donkey anti-goat 
IgG-HRP (Santa Cruz, sc-2020) and Protein A-HRP (Thermo Fisher Scientific, 
101023). Stained membranes were imaged using enhanced chemiluminescent 
substrate (Thermo Scientific, 34080 or 34095) and autoradiography film (Denville 
Scientific, E3012). For fluorescent Western blots, fluorescent secondary 
antibodies conjugated to IRDye-680 or IRDye-800 and the Odyssey imaging 
system and buffers were used (LI-COR).  
Coiled coil prediction 
Coiled coil prediction was performed by inputting the UniProtKB amino acid 
sequences for the following mouse BET proteins BRD2 (Q7JJ13-1), BRD3 
(Q8K2F0-1), BRD4S (Q9ESU6-2) and BRD4L (Q9ESU6-1) into a Hidden Markov 
Model coiled coil prediction algorithm 
(https://toolkit.tuebingen.mpg.de/#/tools/marcoil)143. To generate the plots in 
Figure 3.7.A, the output was graphed and scaled to the BET protein diagrams 
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using ggplot in R. The sequence alignments of the regions surrounding and 
containing the ET and CC domains in Figure 3.7.B was generated using Jalview 
software144 for the indicated UniRef entry names and fragments. Sequences were 
sorted by length and individual residues were labeled using Clustal X default 
coloring and thresholding.  
Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed using the following 
antibodies: GFP/YFP (Abcam, ab290), LEO1 (Bethyl, A300-175A), CSNK2A1 
(Bethyl, A300-198A). Antibody specificity was verified by comparing to isotype 
control IgG/sera as well as in the case of the GFP/YFP antibody to epitope-
negative samples (data not shown). 
For the LEO1_r1 sample, sonication-based ChIP was performed on G1E-
ER4 cells as described131. For the YFP-BET, CSNK2A1, and LEO1_r2 samples, 
the ChIP protocol was adapted for enzymatic fragmentation as follows. G1E-ER4 
cells (≥10 million per sample) were fixed in 1% formaldehyde in PBS at room 
temperature with agitation for 10 minutes, then quenched with 1M glycine for 5 
minutes. Fixed cells were resuspended in 1mL cell lysis buffer (10mM Tris-HCl pH 
8.0, 10mM NaCl, 0.2% NP-40/Igepal) prepared fresh with 500x protease inhibitors 
(Sigma, P8340) and 1mM PMSF and incubated on ice for 10 minutes. Nuclei were 
pelleted and digested with 10U/µl MNase in 400µl MNase buffer (NEB, M0247S) 
at 37C for exactly 5 minutes. MNase activity was quenched with 10µl of EGTA. 
Nuclei were pelleted and resuspended in 1mL nuclear lysis buffer (50mM Tris-HCl 
pH 8.0, 10mM EDTA, 1% SDS, prepared fresh with protease inhibitors and PMSF). 
49 
 
Samples were split into 500µl aliquots in 1.5mL polystyrene sonication tubes 
(Active Motif, 53071) and sonicated for three 10 second intervals at 4C. After 
sonication, samples were spun at 13000rpm in a microcentrifuge for 5 minutes at 
4C to remove debris. Aliquots were combined and diluted with 4mL of IP dilution 
buffer (20mM Tris-HCl pH 8.0, 2mM EDTA, 150mM NaCl, 1% Triton X-100, 0.01% 
SDS prepared fresh with protease inhibitors and PMSF). To preclear, 50µg of 
protein A/G agarose beads (agarose beads slurry was prepared by mixing Protein 
A [Invitrogen 15918014] and Protein G [Invitrogen 15920010] agarose beads at 
1:1 ratio) and 50µg of isotope-matched IgG were added. Samples were precleared 
for ≥2 hours. Prior to setting up immunoprecipitation (“IP”) reactions, 200µl of 
precleared chromatin was removed as “Input.” IP reactions were performed by 
adding 35µl of protein A/G beads pre-bound with antibody (35µl protein A/G bead 
slurry, 1mL PBS, 10µg antibody, incubated with rotation at 4C for ≥2 hours) and 
rotated overnight at 4C. 
Beads were washed once with IP wash buffer 1 (20mM Tris-HCl pH 8.0, 
2mM EDTA, 50 mM NaCl, 1% Triton X-100, 0.1% SDS), twice with high salt buffer 
(20 mM Tris-HCl pH 8.0, 2mM EDTA, 500 mM NaCl, 1% Triton X-100, 0.01% 
SDS), once with IP wash buffer 2 (10 mM Tris-HCl pH 8.0, 1mM EDTA, 0.25 M 
LiCl, 1% NP-40/Igepal, 1% Nadeoxycholate), and twice with TE (10mM Tris-HCl 
pH 8.0, 1mM EDTA pH 8). All washes were performed on ice. Following the final 
wash, beads were moved to room temperature and eluted twice with 100µl of 
elution buffer (100mM NaHCO3, 1%SDS, prepared fresh) for a final eluate volume 
of 200µl. The following were added to each IP and input sample: 12µl of 5M NaCl, 
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2µl RNaseA (10mg/ml, 10109169001 BMB) and samples were incubated at 65C 
for ≥1 hour. 3µl of Proteinase K (20mg/ml, 3115879 BMB) was added and samples 
were incubated at 65C overnight. Following overnight incubation, 10µl of 3M 
sodium acetate pH 5.0 was added to each sample and DNA was purified using the 
QIAquick PCR Purification kit (Qiagen 28106) per the manufacturer’s instructions. 
IP samples were eluted with 60µl water, and input samples with 133.3µl water. 
ChIP-qPCR was performed as described above. Standard curves were 
constructed for each input sample and used to calculate the IP quantities for each 
primer set.  
ChIP sequencing 
Library preparation and sequencing 
 Samples for ChIP sequencing (ChIP-seq) were prepared as above for ChIP-
qPCR. ChIP-seq libraries were processed using the TruSeq Sample Preparation 
Kit (Illumina, IP-202-1012/IP-202-1024) per manufacturer’s instructions. Following 
library preparation, SPRIselect beads (Beckman Coulter, B23318) were used at 
0.9X and 0.5X for left and right-side size selection, respectively, for the MNase-
fragmented samples. For sample LEO1_r1, which was fragmented using 
sonication, 0.6X right-side size selection was used yielding library sizes in the 300-
600 bp range with average sizes ~450 bp. Final library size and concentration was 
measured using BioAnalyzer (Agilent). Single-end sequencing (1 x 75 bp) was 
performed on the Illumina Nextseq 500 in high-output mode per manufacturer’s 
instructions. Reads were converted to fastq using bclfastq2 v2.15.04 (default 
51 
 
parameters). Fastq reads were aligned to the mm9 genome using bowtie (bowtie 
--best --strata --chunkmbs 512 -S -q -l 40 -n 1 --phred33-quals -p 3 -m 1).  
Computational analysis 
After alignment, peaks were called and bedgraph files were generated using 
MACS2 (callpeak -B -p 1e-5 --SPMR --nomodel --extsize 300 --local 100000 -g 
mm). The bedGraphToBigWig tool from UCSC was used to convert into bigwig. 
Enrichment scores in peak coordinates were calculated using 
multiBigwigSummary in deepTools. All enrichment scores and bigwig files are 
library size normalized using reads per million. Merging of bigwig files for technical 
replicates was performed using bigwigCompare in deepTools (bigwigCompare –
operation mean -bs 200). Pearson coefficients comparing correlations across 
samples were calculated using plotCorrelation in deepTools. Metaprofile plots 
across peaks were generated using computeMatrix (computeMatrix reference-
point –referencePoint center -b 1000 -a 1000) and plotProfile in deepTools. 
Consensus peak sites were calculated from ChIPseq replicates using bedtools 
intersect. Differential binding analysis was performed using DiffBind. Annotation of 
genomic regions was performed using annotatePeaks.pl mm9 in Homer. Genome 
browser views were generated using IGV. Transcription factor motif analysis was 
performed using findMotifsGenome.pl mm9 -size 200 in Homer. A peak file 
containing consensus peaks generated by DiffBind was used as background to 
calculate motif enrichment. Scatter plots and volcano plots were generated using 




Structural assessment of human BRD2/3-CC  
Protein purification 
The coiled coil domain of human BRD2 (715-757) and that of human BRD3 
(641-688) were cloned into pGEX6p and expressed with a GST tag. BL21 (DE3) 
colonies transformed with respective plasmids were inoculated into LB and after 
overnight incubation, were used to inoculate 1-2L of culture. The culture was 
induced at OD600 = 0.75 with 0.5mM isopropyl β- d-1-thiogalactopyranoside 
(IPTG), followed by overnight expression at 25C. 
The cell pellet was resuspended in 50 mM Tris pH 7.2, 500 mM NaCl, 0.1% 
Triton X-100, 1 mM dithiothreitol (DTT), 10µg/ml DNase I, 10 µg/mL RNase A and 
1× cOmplete EDTA-free protease inhibitor (Roche, 11873580001)  at ~10 mL/g of 
cells and then lysed via sonication. After clarification at 15,000× g for 30 min at 4C, 
the clear lysate was incubated with pre-equilibrated glutathione-Sepharose 4B 
beads (GE Healthcare, 17075601) for 1.5 hours at 4C with mixing. The beads were 
washed with 3× 5 CV of GST wash buffer containing 10mM Tris pH 7.2, 100 mM 
NaCl and 1 mM TCEP. The proteins were eluted with wash buffer containing 50 
mM reduced glutathione. The GST tag was cleaved using HRV-3C protease by 
incubating with the eluted protein overnight. On the next day, the cleavage protein 
sample was concentrated and then injected onto a pre-equilibrated (in the GST 
wash buffer) Superdex™ 75 16/600 column, and the gel-filtration chromatography 
was run at 1 mL/min for 1.25× CV with 1-mL fractions collected. Fractions 




Size exclusion chromatography 
Size exclusion chromatography with inline multi-angle light scattering (SEC-
MALLS) analysis runs were performed on either a Superdex™ 75 10/300 GL 
column or a Superdex™ peptide 10/30 GL column (GE Healthcare) with an in-line 
MiniDawn MALLS detector with a laser source at 690 nm (Wyatt Technology, 
Santa Barbara, CA, USA) and Wyatt refractometer. Proteins were eluted in 10 mM 
Tris pH 7.2, 100 mM NaCl, 1mM TCEP using a flow rate of 0.5 mL/min. The weight-
average molecular weight was calculated using the intensity of scattered light at 
90° in combination with the change in refractive index. Protein concentration at the 
detector was determined by the change in refractive index. Allexperiments were 
performed at room temperature (25C). Data collection and SEC-MALS analysis 
were performed with ASTRA 6.1 software (Wyatt Technology). 
Circular dichroism spectropolarimetry 
Circular dichroism spectropolarimetry spectra were recorded on a Jasco J-
720 spectropolarimeter using a 1-mm quartz cuvette. In each case, spectra 
comprised the sum of three successive spectra with a step size of 0.5 nm, a 1-s 
response time and a 1-nm bandwidth. Data were acquired at 4C. Secondary 
structure content was estimated using Raussens’ method 
(http://perry.freeshell.org/raussens.html). 
GST pulldown and proteomic analysis 
Protein purification 
The sequences from mouse BRD2, BRD3 and BRDT (BRD2-mB, BRD2-
ET, BRD2-CC, BRD2-CCp, BRD2-CCd, BRD2-ETCC, BRD3-ET, BRD3-ETCC, 
BRDT-ET, and BRDT-ETCC [Table 2.2]) were cloned into the pGEX-2T GST 
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fusion vector. The GST fusion proteins were expressed and purified from bacteria 
as above with the following changes: after BL21 transformation, a 5mL LB/Amp 
culture grown at 37C overnight was used to inoculate 200mL LB/Amp, which was 
then grown at 37C for 2.5 hours. Protein expression was induced with 0.25mM 
IPTG and the culture incubated at 30C for an additional 2.5 hours. Cell pellets were 
resuspended in 5mL BC500 (20mM Tris-HCl pH 8.0, 0.5mM EDTA, 50mM KCl, 
20% glycerol, 1% NP-40, 1mM DTT, 500x protease inhibitor cocktail [Sigma, 
P8340]). Prior to sonication, 50µl of 100mg/mL lysozyme and 0.5mL of 20% Triton 
X-100 was added. Bacterial suspensions were sonicated (Misonix, Sonicator 
3000) at 50% output with microtip limit for 1 second for three sets of 10 cycles, 
keeping samples on ice. The bacterial lysates were cleared with 10,000rpm 
centrifugation for 10 minutes at 4C. The cleared supernatant was harvested and 
250µl of glutathione agarose beads (Pierce, 16100) were added with gentle 
inversion overnight at 4C. After overnight incubation, the beads were centrifuged 
at 1500rpm at 4C for 3 minutes. The beads were washed 4x in 5mL BC500 and 
1x in a wash buffer (1x PBS, 20% glycerol, 1% NP-40, 1mM DTT, 500x protease 
inhibitor cocktail [Sigma, P8340]). GST proteins were eluted from the beads using 
3x washes in 0.833 mL reduced glutathione solution (50mM Tris-HCl pH 8.8, 
100mM NaCl, 20mM reduced glutathione [Sigma, G4251], final pH adjusted to 8.0) 
pooling each eluate yielding approximately 2.5mL of soluble protein. Protein 
samples were concentrated using Amicon Ultra-4 conicals (Millipore-Sigma) 
centrifuged at 4100rpm for 10-40 minutes per manufacturer’s instructions. The spin 
was repeated twice after refilling to maximum volume with BC100 (20mM Tris-HCl 
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pH 8.0, 100mM KCl, 0.5mM EDTA, 20% glycerol, 1mM, DTT, 500x protease 
inhibitor cocktail [Sigma, P8340]). Protein concentration was estimated using BSA 
standards on an SDS-PAGE gel and aliquots were stored at -80 °C. 
Nuclear extract preparation 
 Nuclear extracts were prepared from murine erythroleukemia (MEL) cells. 
Briefly, ~100e6 cells increments were washed in PBS and resuspended in 10x cell 
pellet volume of Buffer A (10mM HEPES-KOH pH 7.9, 1.5mM MgCl2, 10mM KCl, 
1mM DTT, 100mM PMSF, 500x protease inhibitor cocktail [Sigma, P8340]) and 
incubated on ice for 30 minutes with intermittent vortexing to lyse the cell 
membrane. Nuclear pellets were resuspended in 3x pellet volume of Buffer C 
(20mM HEPES-KOH pH 7.9, 25% glycerol, 420mM NaCl, 1.5mM MgCl2, 0.2mM 
EDTA, 1mM DTT, 100mM PMSF, 500x protease inhibitor cocktail [Sigma, P8340]) 
and incubated on ice for 30 minutes with intermittent vortexing. Nuclear extracts 
were cleared by spinning in tabletop microcentrifuge at 13000rpm for 5 minutes at 
4C. Concentrations for cleared extracts were determined using the A280 
absorbance measurement on a spectrophotometer (Thermo Scientific, Nanodrop 
2000). Samples were stored at -80C. 
GST pulldown assay 
 GST pulldown assays were performed by diluting 500µg of nuclear extract 
in dilution buffer (50mM Tris-HCl pH 7.5, 0.5% NP-40) to a final NaCl concentration 
of 150mM and bringing to a final volume of 1mL using binding/wash buffer (150mM 
NaCl, 50mM Tris-HCl pH 7.5, 0.5% NP-40). 2.5µg of respective GST fusion 
proteins and 20µl of glutathione agarose beads (Pierce, 16100) were added and 
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samples were incubated with rotation 4 hours to overnight at 4C. Beads were 
washed 5x in 1mL binding/wash buffer and eluted in 50µl 4x sample buffer. Eluted 
samples were run on SDS-PAGE gels and either submitted for mass spectrometry 
or analyzed by Western blot (see above).  
Mass spectrometry 
 Liquid chromatography coupled with tandem mass spectrometry (LC–
MS/MS) analysis was performed by the Proteomics and Metabolomics Facility at 
the Wistar Institute using a Q Exactive Plus mass spectrometer (Thermo Fisher) 
coupled with a Nano-ACQUITY UPLC system (Waters). Samples were digested 
in-gel with trypsin and injected onto a UPLC Symmetry trap column (180 μm i.d. × 
2 cm packed with 5 μm C18 resin; Waters). Tryptic peptides were separated by 
reversed-phase HPLC on a BEH C18 nanocapillary analytical column (75 μm i.d. 
× 25 cm, 1.7 μm particle size; Waters) using a 95 min gradient formed by solvent 
A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). A 30 
min blank gradient was run between sample injections to minimize carryover. 
Eluted peptides were analyzed by the mass spectrometer set to repetitively 
scan m/z from 400 to 2,000 in positive-ion mode. The full MS scan was collected 
at 70,000 resolution followed by data-dependent MS/MS scans at 17,500 
resolution on the 20 most abundant ions exceeding a minimum threshold of 
20,000. Peptide match was set as preferred, exclude isotopes option and charge-




Peptide sequences were identified using MaxQuant 1.5.2.8. MS/MS spectra 
were searched against a UniProt mouse protein database using full tryptic 
specificity with up to two missed cleavages, static carboxamidomethylation of Cys, 
and variable oxidation of Met and protein N-terminal acetylation. Protein 
quantification was performed using razor +unique peptides. Razor peptides are 
shared (non-unique) peptides assigned to the protein group with the most other 
peptides (Occam's razor principle). False discovery rates for protein and peptide 
identifications were set at 1%. Identified proteins required a minimum of 2 razor or 
unique peptides in at least one of the samples. The list of proteins was further 
filtered by dropping proteins not identified in 5/7 observed samples per replicate 
and by dropping proteins observed in only one of three replicates per sample. 
Intensity values were normalized to GST detected for each sample. Values for 
proteins absent in one replicate were imputed by averaging the intensity values of 
the flanking proteins in the other two replicates. If the flanking proteins are absent 
in one of the two remaining replicates, the protein was discarded, and if one of the 
flanking proteins was absent in both replicates, an average of the two remaining 
flanking proteins (one from each replicate) was used. Finally, ComBat145 was 
applied to reduce batch effect between replicates. Comparison between samples 
was performed by calculating the mean of the log2 of the ratio between two 
samples from each replicate and the log10 of the Q-value. STRING protein 
interaction network analysis (https://string-db.org/) was performed on proteins 
more strongly enriched in the ETCC sample than the ET sample (log2ratio > 1.2, 
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logQvalue > 4) using the highest confidence setting (0.900) labeled with 
experimentally validated interactions and interactions from curated databases.  
Data availability 
The FASTQ files for the RNA sequencing data have been deposited in the 
NCBI BioProject database with BioProject accession number PRJNA560407. 
ChIP sequencing data will be made publicly available through the Gene 
Expression Omnibus (GEO) pending publication.  
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CHAPTER 3: DOMAIN MAPPING REVEALS A COILED COIL THAT FUNCTIONALLY 




Research described in this chapter forms the basis of a pending manuscript 
currently in the review process title “Comparative structure-function analysis of 
bromodomain and extraterminal motif (BET) proteins using a gene-
complementation system”. Many people contributed to this work. The initial cell 
growth and hemoglobinization experiments were performed by Sarah Hsu and 
Kristen Jahn while they were in the Blobel lab. Sarah Hsu also conducted the RNA 
sequencing experiment in collaboration with Tapan Ganguly and Erik Toorens from 
the Perelman School of Medicine Penn Genomics Analysis Core. Computational 
analysis of the RNA sequencing data was performed by Zhe (Jim) Zhang from the 
Children’s Hospital of Philadelphia (CHOP) Department of Biomedical and Health 
Informatics. Analysis of proteomic data was carried out in collaboration with Perry 
Evans of the CHOP Department of Biomedical and Health Informatics. Other 
members of the Blobel lab contributed significantly to this work. Hongxin Wang 
provided a substantial amount of technical support as did Nicole Hamagami and 
Jennifer Yano. 
Introduction 
Bromodomain and extraterminal motif (BET) proteins mechanistically link 
chromatin acetylation to gene transcription15,20. The BET family consists of BRD2, 
BRD3 and BRD4, which are widely expressed across tissue types, and the testis-
specific BRDT20. BET proteins share a general domain structure consisting of 
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tandem N-terminal bromodomains and a C-terminal ET domain conserved across 
species18. The bromodomains bind to acetylated lysine residues on histones and 
transcription factors15. The ET domain is a protein-protein interaction motif that 
recruits additional co-activators31,64,66,68,71,72. BET proteins thereby function as 
molecular scaffolds for transcriptional regulators. Small molecules which target the 
bromodomains partially displace BET proteins along with associated co-factors 
from chromatin95,96. BET inhibitors are in clinical trials for the treatment of several 
cancers and may have additional use in inflammatory, metabolic and cardiac 
disorders20,45. Because the bromodomains are similar between BET proteins, 
molecules targeting them do not strongly discriminate between individual BET 
proteins95,96,117. The lack of specificity might underlie some of the unwanted side 
effects of BET inhibitors and constrain their use. Moreover, clinical exploitation of 
BET inhibition requires a better understanding of selective BET protein functions.  
Structurally, the long-isoform of BRD4 (BRD4L) is the most distinct BET 
protein in that it possesses a unique extended C-terminal tail that recruits factors 
required for the transition of RNA polymerase 2 from transcriptional initiation into 
productive elongation76,78,146. The short isoform of BRD4 (BRD4S) lacks this 
domain and is thus structurally more similar to BRD2 and BRD3, but its expression 
and function in most cell types remains poorly characterized70,82. Depletion of 
BRD2 or BRD3 results in transcriptional and phenotypic outcomes that in some 
settings are different from BRD4 depletion104,124, suggesting non-overlapping 
functions among them. In fact, BRD2 deficient mice exhibit a phenotype distinct 
from that of BRD4 deficient mice21–23,119. BRD3-null mice have not been reported. 
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It has been proposed that BET-specific functions are conveyed in part via 
selectivity of the bromodomains for acetylated substrates44,47,48,51–53. Specificity 
might also be mediated by additional domains that influence chromatin 
occupancy35,36 or by differences in protein interactions30,31. However, the ET 
protein interaction domain is highly conserved across BET proteins, making its 
contribution to BET-selective interactions unclear64,66,68,71,72. Thus, whereas all 
BET proteins are enriched at acetylated chromatin, the mechanisms underlying 
BET-specific functions remain unresolved.  
GATA1-mediated erythroid cell differentiation has provided a useful model 
for the dissection of BET protein biology132. GATA1 is a master erythroid 
transcription factor that drives the terminal maturation of erythroid precursor 
cells136. BRD3 and to a lesser extent BRD4 bind to GATA1 in an acetylation 
dependent manner and co-localize with GATA1 on chromatin113,139. Point 
mutations in the BET-binding motif of GATA1, or pan-BET inhibition, impair GATA1 
occupancy on chromatin113,139,140. GATA1 transcriptional activity has been 
extensively studied in G1E-ER4 cells, an erythroid progenitor line that stably 
expresses a conditional form of GATA1 fused to the ligand binding domain of the 
estrogen receptor (GATA1-ER)147. Using this system, GATA1-ER target genes can 
be activated upon treatment with estradiol, which faithfully recapitulates terminal 
erythroid maturation147. BRD2 and BRD4 are both necessary for GATA1-ER-
mediated gene expression113. In contrast, BRD3 appears to be dispensable, but 
BRD3 loss exacerbates defects associated with BRD2 deficiency, suggesting 
overlapping functions of these two proteins113. Accordingly, overexpression of 
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BRD3 can partially compensate for BRD2 loss113. BRD3 is expressed 
approximately four-fold less than BRD2 based on RNA-sequencing in G1E-ER4 
cells, potentially explaining its lack of compensatory activity when not 
overexpressed148. It is unclear whether BRD2 and BRD3 possess structural 
features that could facilitate functions that are distinct from BRD4. 
To better understand functional differences between BRD2, BRD3 and 
BRD4, we took advantage of Brd2-null G1E-ER4 erythroblasts. These cells are 
viable but fail to undergo GATA1-mediated terminal maturation. We asked whether 
reconstitution of these cells with exogenous BET proteins rescues their growth 
rate, maturation and gene expression. We found that the BRD4 isoforms are 
functionally different from BRD2 and BRD3. Moreover, the bromodomains 
contribute surprisingly little in terms of BET specific functions. We define a small 
region adjacent to the ET domain that contains a predicted coiled coil structure in 
BRD2 and BRD3 but not BRD4 that we show to contribute to BRD2 selective 
activity. 
BRD2 is essential for GATA1 dependent erythroid differentiation and gene 
expression 
A mechanistic explanation for specific functions of individual BET proteins remains 
unresolved. We therefore took advantage of a cellular system in which BET proteins can 
be directly compared. We generated four Brd2-null G1E-ER4 cell lines (KO clones, KO1 
- KO4) using CRISPR-Cas9 (see “Materials and Methods”). The absence of BRD2 was 
confirmed by Western blot with antibodies against BRD2 N- and C-terminal epitopes 
(Figure 3.1.A). We measured BRD3 and BRD4L protein levels and found them to be 
unchanged in the BRD2 KO cells (Figure 3.1.A), indicating that BRD2 is not necessary 
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for BRD3 and BRD4L expression, and that any defects in the BRD2 KO cells cannot be 
attributed to their loss. We were unable to detect endogenous BRD4S protein in 
whole cell lysates using commercially available antibodies (Figure 3.1.B) but reads 
mapping to the BRD4S-specific exon were detected by RNA sequencing. Exon-
exon junction analysis suggested that BRD4S is the minor isoform with 
approximately ~33% of BRD4 transcripts corresponded to it in parental G1E-ER4 
cells, ~24% in BRD2 KO1 cells and ~19% in KO2 cells, indicating that BRD2 does 
not influence which isoform predominates. Thus, changes in BRD4 mRNA 
alternative splicing likely do not account for any phenotypic differences observed 
in BRD2 KO cells. To test whether GATA1-driven erythroid maturation depends on 
BRD2, we exposed BRD2 KO clonal lines to estradiol for 24 hours147, a time point 
sufficient for the maximal accumulation of GATA1-ER target genes. Consistent with our 
previous studies113, all BRD2 KO clones failed to induce the expression of major erythroid 
GATA1 target genes, including Hbb-b1, Alas2, Slc4a1 and Spta1 (Figure 3.1.C). 
Importantly, BRD2 depletion did not appear to impact RNA levels of the Gata1-ER 
transgene or housekeeping genes Actb and Gapdh. Consistent with the Western blots, 
Brd3 and Brd4 RNA levels were unchanged in BRD2 KO cells. 
Identification of a BRD2-specific transcriptional signature 
To measure the global transcriptional changes associated with BRD2 loss, we 
performed RNA-sequencing on parental G1E-ER4 and two BRD2 KO clones (KO1 and 
KO2) after 24 hours of GATA1-ER induction. Pearson correlation coefficients 
demonstrated strong reproducibility between the three replicates for each cell line and 
higher similarity of KO1 and KO2 (Figure 3.2.A). The overall high correlations between 
each of the samples indicate that a majority of genes are similarly expressed. 
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Dimensionality reduction using principle component analysis showed separation of the 
two KO clones from the parental G1E-ER4 cells on PC1 (37.3% of variance), revealing 
the transcriptional impact of BRD2 depletion. Separation of the three cell lines on PC2 
(18.9% of variance) suggested clonal variation between the cell lines (Figure 3.2.B). We 
therefore classified differentially expressed genes as those that exhibit a ≥ 2-fold change 
(false discovery rate [FDR] < 0.01) in both KO clones compared to parental G1E-ER4 cells 
and that were unchanged between the two KO clones (Figure 3.2.C). This identified 158 
downregulated genes (Table 3.1) and 261 upregulated genes (Table 3.2). A less 
stringent cutoff of ≥ 1.5-fold change (FDR < 0.05) resulted in 433 and 626 genes that were 
downregulated and upregulated, respectively (Figure 3.2.C). Expression of several highly 
expressed maturation associated genes (Hbb-b1, Hbb-b2, Hba-a1, Hba-a2, Alas2, Slc4a1 
and Spta1) was decreased in the BRD2 KO cells in comparison to the parental cells, 
whereas many genes whose expression is high in immature cells and downregulated 
during erythroid maturation (Gata2, Myc, Myb, Kit, Il2rg, Lyl1 and Vim) were elevated in 
at least one of the BRD2 KO cell lines (Figure 3.2.D). This indicates a general failure of 
BRD2 KO cells to fully mature upon GATA1-ER activation. 
To determine what biological pathways could be affected by the observed 
transcriptional changes, we queried the differentially expressed genes for enrichment of 
hallmark gene sets in the Molecular Signatures Database. The gene sets most associated 
with the downregulated genes were HEME_METABOLISM, MTORC1_SIGNALING and 
CHOLESTEROL_HOMEOSTASIS (Figure 3.2.E, right). These pathways are consistent 
with known biological processes important for erythroid maturation149–151. The gene sets 
most associated with the upregulated genes include IL2_STAT5_SIGNALING, 
TNFA_SIGNALING_VIA_NFKB and P53_PATHWAY. The relevance of these pathways 
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is not immediately clear but could reflect a failure to downregulate genes important for cell 
proliferation. An analysis using the less stringent list of differentially expressed genes (fold 
change ≥ 1.5, FDR <0.05) yielded similar gene set enrichment results (not shown).  
The pharmacologic BET inhibitor JQ1 targets all BET proteins with comparable 
efficacy95. We assessed to what extent the cellular response to JQ1 can be attributed to 
BRD2 inhibition by comparing the transcriptome analyses of BRD2 KO cells to our prior 
data sets in which these cells were exposed to JQ1. Since the prior experiments employed 
a microarray platform113, we first intersected genes detected by both methods, resulting 
in 9132 genes (see “Materials and Methods”). Comparison of the gene expression 
changes in the two datasets revealed a positive correlation between genes impacted by 
BRD2 loss and JQ1 exposure (Pearson correlation coefficient of R=0.47 (p<2.2e-16)) 
(Figure 3.2.F). Of the 248 genes upregulated in BRD2 KO cells, 104 were also 
upregulated (FC>2, FDR<0.01) upon JQ1 treatment (p<2.2e-16), and of the 137 
downregulated genes, 54 were also downregulated upon JQ1 treatment (p<2.2e-16) 
(Figure 3.2.G). A limitation to this comparison is that alterations in gene expression upon 
chronic BRD2 loss are a composite of direct and indirect effects. In contrast, JQ1 treatment 
enables detection of an immediate response to BET inhibition. Moreover, JQ1 does not 
fully displace BET proteins from chromatin95,117, which might limit effect size. In spite of 
these limitations, these results suggest that impaired BRD2 function accounts for at least 
part of the effects of JQ1 treatment. In sum, BRD2 is critical for the regulation of a wide 
array of erythroid genes involved in multiple aspects of GATA1-mediated differentiation, 
and loss of BRD2 activity accounts for at least part of the JQ1 effects. 
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BET specific functions during erythroid cell growth and differentiation 
While BET proteins are structurally similar, few studies have directly examined 
whether conserved protein domains contribute to BET selective functions or whether they 
simply reflect functional overlap (Figure 1.4, Table 1.1)25,35,79,85,152. We previously 
reported that BRD2 and BRD3 can partially compensate for each other in G1E-ER4 
cells113. We next tested whether a similar functional overlap exists between BRD2 and 
either BRD4S or BRD4L in these cells. Although BRD4S was not detected in G1E-ER4 
cells, we included it in this functional comparison due to its structural resemblance to 
BRD2 and BRD3. We used a murine retroviral expression vector to transduce HA-tagged 
forms of BRD2, BRD3, BRD4S or BRD4L cDNA into parental G1E-ER4 cells or BRD2 
KO1 cells. We used three assays to study the relative activities of these proteins: 1) a 
reddening of the cells indicating activation of the hemoglobin synthesis pathways, 2) 
expression of erythroid maturation associated genes upon GATA1-ER activation, and 3) 
cell growth. To visualize hemoglobinization, we induced GATA1-ER activity for 48 hours 
at which time the cells normally have turned red. As expected, BRD2 was required for 
hemoglobin production (Figure 3.3.A). Expression of BRD2 restored the ability of BRD2 
KO1 cells to produce hemoglobin. BRD3 was also able to rescue hemoglobinization, but 
both BRD4S and BRD4L displayed much lower activity in this assay. We next measured 
the mRNA levels of Hbb-b1, which was one the most differentially regulated genes in the 
BRD2 KO cells based on the previous analysis. Activation of GATA1-ER failed to induce 
expression of Hbb-b1 in the BRD2 KO1 cells. However, expression of BRD2 and BRD3 
restored Hbb-b1 expression in BRD2 KO1 cells to similar levels while BRD4S and BRD4L 
showed little activity (Figure 3.3.B). Note that overexpression of BET proteins in parental 
cells did not overtly perturb Hbb-b1 expression or hemoglobin production, suggesting that 
excess levels of a given BET protein is compatible with cell maturation. 
67 
 
To further compare the activities of BET proteins, we assessed the impact of BET 
expression on cell growth. The retroviral vector encoding the BET cDNAs contained an 
IRES-GFP module to mark cells with stably integrated constructs. We designed a 
competitive growth assay which monitors the fraction of GFP+ cells in a mixture of infected 
and uninfected cells over time using flow cytometry.  Restoration of BRD2 expression in 
BRD2 KO1 cells increased the fraction of GFP+ cells by ~40% over the time course 
(Figure 3.3.C). BRD3 expression augmented growth almost to the same extent as BRD2. 
In contrast, BRD4S expression failed to rescue BRD2 KO1 cell growth and even lowered 
cell numbers. We also measured growth rates in cells expressing BRD4L and found 
BRD4L to be incapable of restoring BRD2 KO1 cell growth (Figure 3.3.D). In parental 
cells, BRD2 overexpression had no impact on cell growth, whereas BRD3 resulted in a 
~20% decrease, BRD4S in a ~40% decrease and BRD4L in a 10% decrease (Figure 
3.3.C,D), suggesting that excess levels of these molecules can impair proliferation or 
viability. In sum, both differentiation and growth assays point at overlapping functions 
between BRD2 and BRD3, while BRD4S, which is overall structurally similar, and BRD4L 
exert distinct functions in these cells. 
The abundance of BRD2 and BRD4S is strongly influenced by their N-terminal 
halves 
Even though the BET constructs were expressed by the same vector, the resulting 
protein amounts were markedly variable as determined by Western blot with anti-HA 
antibodies (Figure 3.3.E). Specifically, BRD3 and BRD4S were readily detected, whereas 
BRD2 was not detected unless a BRD2-specific antibody was used. Differences in 
exogenous BET expression potentially confound interpretation of the results. However, 
comparisons between the effects of BRD3 and BRD4S might still be instructive since 
these proteins are expressed at similar levels and their effect on BRD2 comparable. For 
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example, BRD3 and BRD4S exert opposite effects on BRD2 KO1 cell growth, with BRD3 
restoring their expansion and BRD4S lowering cell numbers (Figure 3.3.C). Similarly, 
whereas BRD3 rescued Hbb-b1 expression to levels comparable to that achieved by 
BRD2, BRD4S failed to do so (Figure 3.3.B). 
Variable production of BET proteins could be due to differences in mRNA stability, 
translation and/or protein turnover. To address this, we measured mRNA levels of the 
BRD2, BRD3, BRD4S and BRD4L transgenes in the above cells using primers common 
to all constructs (specific to the GFP coding portion of the mRNAs). We found that mRNA 
levels varied substantially less than protein levels. In fact, Brd2 transcripts were somewhat 
higher than the others (Figure 3.3.F), indicating that the decreased BRD2 protein was due 
to a post-transcriptional mechanism.  
To identify which features may be dictating the contrasting nature of BRD2 and 
BRD4S in terms of function and stability, we began to dissect their differences by 
designing chimeric BET constructs consisting of the N-terminal and C-terminal halves of 
BRD2 and BRD4S fused immediately downstream of the second bromodomain. These 
chimeric BET proteins were termed BRD2-4S and BRD4-2, respectively (Figure 3.4.A). 
This strategy preserved their overall modular domain structure, including the N- and C-
terminal nuclear localization signals153,154. These constructs were introduced into the 
same retroviral vector as described before. We infected parental and two BRD2 KO cell 
lines expressing the chimeric and intact BET proteins and isolated stably expressing cell 
lines. We measured mRNA levels produced by each construct and found them to be 
similar (Figure 3.4.B). Strikingly, the protein levels of BRD2 and the chimeric BRD2-4S 
were dramatically lower than those of BRD4S and chimeric BRD4-2 (Figure 3.4.C). To 
quantify these differences in protein expression, we repeated the infection of BRD2 
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KO1 cells with retroviruses encoding the intact BRD2, BRD3, BRD4S and BRD4L 
HA-tagged proteins, as well as the chimeric BRD2-4S and BRD4-2 constructs and 
performed a Western blot probing the HA epitope using fluorescently labeled 
antibodies. This strategy allowed the visualization and quantification of all six BET 
proteins (Figure 3.4.D). Consistent with our prior observations, BRD2 and BRD2-
4S were expressed at equally low levels in comparison to BRD3, BRD4S and 
BRD4-2. BRD4L was expressed at an intermediate level. This indicates that steady 
state protein levels are determined by the N-terminal halves of the BET proteins. 
Selective functions of BET proteins are determined by their C-terminal halves  
To determine whether there are BET-selective functions that are conveyed by 
domains that do not affect protein levels, we tested the ability of BRD2, BRD4S and the 
chimeric BRD2-4S and BRD4-2 proteins to restore BRD2 KO cell growth and 
differentiation-associated gene expression. BRD2-4S, which was expressed at similar 
levels as BRD2, was impaired in its ability to restore cell growth compared to BRD2 (Figure 
3.4.E), whereas BRD4-2, which was expressed similarly to BRD4S, had a positive effect 
on BRD2 KO cell growth (Figure 3.4.F). Given that BRD2 but not BRD4S rescued the 
expression of Hbb-b1 in BRD2 KO cells (Figure 3.3.B), we asked whether the C-terminal 
halves of BRD2 and BRD4S were responsible for this differential activity. BRD4-2 rescued 
Hbb-b1 expression comparably to wild type BRD2 whereas BRD2-4S had no measurable 
effect (Figure 3.4.G). The same trends held true for the expression of the other major 
globin chain gene Hba-a1, though compared to Hbb-b1, Hba-a1 expression was less 
affected by BRD2 depletion (Figure 3.4.H). Together, these observations suggest that the 
C-terminal half of BRD2 encodes its specific activity, which can be grafted onto the N-
terminal half of BRD4S to substantially convert it into a BRD2-like molecule. This further 
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suggests that the specific functions of BET proteins are not critically determined by 
differences in the bromodomains, but rather by differences in the C-terminal halves of the 
proteins. 
So far, comparisons among proteins were largely limited to those that were 
expressed at comparable levels, but the drastic differences in protein abundance 
conferred by the N-terminal halves of BRD2, BRD3 and BRD4S confounded direct 
functional comparison across all of the constructs. To overcome these limitations, all BET 
constructs were fused to YFP and stably introduced into BRD2 KO1 cells via retroviral 
transduction. Generation of cell lines with comparable expression of each construct 
required careful titering of viruses and multiple rounds of fluorescence-activated cell 
sorting using stringent gating on the YFP signal (Figure 3.5.A). In that manner we 
eventually succeeded in isolating subpopulations of cells in which all proteins were 
produced at nearly equal levels that in turn were similar to the amount of endogenous 
BRD2 in parental G1E-ER4 cells (Figure 3.5.B). YFP-BET transgene mRNAs were 
measured with qPCR primers that target the YFP sequence (YFP) and the 5’ and 3’ end 
of Brd2 (Figure 3.5.C). These measurements indicate that the RNA levels corresponding 
to the YFP-BRD2 and YFP-BRD2-4S proteins were slightly higher than the RNA levels for 
the YFP-BRD3, YFP-BRD4S and YFP-BRD4-2 proteins. This is consistent with the lower 
protein yields for BRD2 and BRD2-4S, requiring selection of cells with higher RNA 
expression. These relative mRNA differences, however, were not as drastic as the original 
protein differences. The YFP sequence may stabilize BRD2 mRNA or protein to some 
extent resulting in a better correlation between its RNA and protein levels. Of note, levels 
of Gata1-ER and Gapdh mRNA were similar in the cell lines (Figure 3.5.C).  
71 
 
We next assessed whether the reconstituted BRD2 KO1 cells could activate eight 
BRD2-dependent genes during erythroid maturation. As expected, expression of Hbb-b1, 
Alas2, Slc4a1, Spta1, Csf2rb, Csf2rb2, Kcnn4 and Rhag were all reduced in the un-
reconstituted BRD2 KO1 cells compared to the parental G1E-ER4 cells (Figure 3.5.D). 
Expression was rescued by YFP-BRD2 and to a lesser extent by YFP-BRD3, indicating 
that the increased bulk added by the YFP fusion onto the N-terminus of BET proteins did 
not impact their overall function. YFP-BRD4S had a marginal impact on the expression of 
these BRD2-dependent genes and was clearly less potent than YFP-BRD3. We next 
assessed the functions of the chimeric YFP-BRD2-4S and YFP-BRD4-2 BET proteins. 
YFP-BRD2-4S was unable to restore expression of 7 of the 8 genes. In contrast, YFP-
BRD4-2 was able to restore expression of all 8 genes to levels comparable to YFP-BRD2 
and parental G1E-ER4 cells.  
To test for the global rescue of GATA1-induced erythroid maturation by the various 
BET proteins, we examined the ability of the YFP-BRD2, YFP-BRD4S and the two 
chimeric YFP-BRD2-4S and YFP-BRD4-2 proteins to rescue hemoglobinization in BRD2 
KO1 and KO2 cells after sorting for equal YFP-BET levels, which was confirmed by post-
sorting flow cytometry revealing comparable YFP intensity for all of the YFP-BET proteins 
(Figure 3.6.A). As previously observed, parental G1E-ER4 cells fully hemoglobinized 
whereas the BRD2 KO1 and KO2 cells failed to turn red (Figure 3.6.B). YFP-BRD2 
expression in both BRD2 KO cell lines rescued hemoglobin production to levels 
comparable to the parental G1E-ER4 cells, whereas YFP-BRD4S expressing BRD2 KO 
cells failed to turn red. Chimeric YFP-BRD2-4S failed to rescue BRD2 KO cells whereas 
YFP-BRD4-2 restored hemoglobinization comparably to, if not better, than YFP-BRD2. To 
further confirm that these phenotypic changes reflect underlying gene expression changes 
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associated with rescued GATA1-ER activity, we measured mRNA levels of candidate 
BRD2-dependent GATA1-activated genes in these cells after 24 hours of GATA1-ER 
activation. These data indicate that the C-terminal but not the N-terminal half of BRD2 
conveys BRD2’s functional specificity in BRD2-dependent cell growth, differentiation and 
gene expression.  
BRD2 and BRD3 contain a putative coiled coil domain that contributes to BRD2 
activity 
The previous experiments reveal that BRD2-like activity shared by BRD2 and 
BRD3 maps to the C-terminal half of BRD2. We therefore examined the amino acid 
sequences of the C-terminal halves of both BRD2 and BRD3 for shared features that may 
distinguish them from BRD4S. Coil prediction of the mouse BET proteins using 
MARCOIL143 reveals multiple putative coiled coils (Figure 3.7.A). We identified a region 
immediately downstream of the ET domain that is predicted to harbor a coiled coil (that 
we refer to as the CC domain) in BRD2 and BRD3 but not in BRD4. The CC domain is 
conserved across the BRD2, BRD3 and BRDT paralogues in human, mouse and zebrafish 
(Figure 3.7.B). It is also conserved in the Drosophila BET paralog FSH as well as one of 
the yeast paralogs, BDF1 but not BDF2. We therefore asked whether this region could 
account for some of the observed differences between BRD2/BRD3 and BRD4S.  
To expedite analyses of several constructs testing the function of this region 
without having to generate multiple independent cell lines for each, we developed a flow 
cytometry-based version of the erythroid maturation gene complementation assay in G1E-
ER4 cells. This approach quantifies the fluorescent tag on each construct as a proxy for 
protein abundance and the erythroid-specific surface antigen TER119 as a measure of 
GATA1-mediated differentiation (Figure 3.8.A). As expected, TER119 was only 
expressed on G1E-ER4 cells upon GATA1-induced maturation (Figure 3.8.B)155. We 
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validated the use of the TER119-based erythroid maturation assay by demonstrating that 
YFP-BRD2, but not a YFP empty vector, restored GATA1-mediated TER119 expression 
in BRD2 KO cells to levels observed in the parental G1E-ER4 cells (Figure 3.8.B, 3.8.C). 
We also compared erythroid gene expression levels to TER119 surface staining after 24 
hours of GATA1-ER activation in parental G1E-ER4 cells or BRD2 KO1 cells expressing 
YFP-fused BRD2, BRD3, BRD4S, or chimeric BRD2-4S or BRD4-2 (Figure 3.8.D). There 
was a strong correlation between the amount of TER119 expression on the surface of 
these cells and the mRNA levels of the erythroid genes Alas2 (R=0.81, p=0.026), Hbb-b1 
(R=0.84, p=0.017), Slc4a1 (R=0.82, p=0.024) and Spta1 (R=0.88, p=0.009). For example, 
whereas the parental G1E-ER4 cells exhibited high levels of mRNA and TER119 staining, 
the BRD2 KO1 cells without YFP-BET contained low mRNA levels of these genes and 
exhibited minimal TER119 staining. However, the YFP-BRD2-rescued BRD2 KO1 cells 
expressed mRNA and TER119 levels comparable to the parental G1E-ER4 cells. YFP-
BRD3 and YFP-BRD4-2 likewise rescued the BRD2 KO1 cells, albeit to varying degrees, 
whereas YFP-BRD4S and YFP-BRD2-4S failed to rescue mRNA and TER119 expression. 
These data indicate that the gene encoding the TER119 antigen is BRD2-dependent and 
is representative of erythroid maturation.  
The ET region is a protein-protein interaction domain that recruits transcriptional 
co-activators to chromatin64. Given the proximity between the CC and ET domains, it is 
possible that the CC contributes to the ET-mediated interactions or functions 
independently. We therefore deleted both the ET (BRD2dET) and CC (BRD2dCC) regions 
individually to determine if either region contributes to BRD2 activity in G1E-ER4 cells 
using YFP-BET fusions (Figure 3.9.A, middle). YFP-BRD2dET and YFP-BRD2dCC were 
expressed at levels similar to full length YFP-BRD2 based on YFP fluorescence (Figure 
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3.9.A, left). Deletion of the ET domain completely abrogated TER119 expression in 
comparison to full length YFP-BRD2 (Figure 3.9.A, right). Deletion of the CC domain also 
reduced TER119 expression, albeit to a lesser extent. To measure the effect of the ET 
and CC deletions on BRD2 protein expression and BRD2-mediated gene expression and 
cell growth, we expressed HA-tagged versions of these proteins in BRD2 KO1 cell lines. 
RNA levels of the constructs were similar based on qPCR primers targeting the 5’ end of 
Brd2 and the GFP sequence (Figure 3.9.B). Levels of Gata1-ER, Brd3, and Brd4, as well 
as the control genes Actb and Gapdh were similar across the cell lines. The protein levels 
of the constructs were likewise similar, indicating that the ET and CC domains do not 
significantly contribute to BRD2 stability (Figure 3.9.B, inset). As seen previously, 
restoration of BRD2 rescued the expression of multiple BRD2-dependent genes (Hbb-b1, 
Alas2, Slc4a1, Spta1, Csf2rb2, Kcnn4, Rhag) (Figure 3.9.C). Deletion of the ET domain 
completely abrogated the ability of BRD2 to rescue these genes. Deletion of the CC 
domain had a more partial, but uniform, effect on the expression of these genes. These 
data indicate that whereas the ET domain is absolutely critical for proper BRD2 functioning 
during erythroid maturation, the CC region contributes more partially to BRD2 function. 
In addition to restoring erythroid gene expression, BRD2 also restores the cell 
growth rate of BRD2 KO cells. We therefore tested whether the ET and CC regions 
contributed to BRD2-mediated cell growth. As performed previously to measure the effect 
of BET protein expression on cell growth, we infected parental G1E-ER4 as well as BRD2 
KO1 and KO2 cells with viruses encoding HA-tagged BRD2, BRD2dET and BRD2dCC 
and tracked the effect of BET expression on cell growth by measuring the fraction of the 
GFP+ cells over time. Reconstitution of BRD2 in BRD2 KO1 and KO2 cells led to a ~45% 
increase over the time course (Figure 3.9.D). Deletion of the ET domain drastically 
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decreased BRD2 function in this assay. Interestingly, though the CC domain contributed 
only partially to erythroid gene expression as seen above, its deletion had a significant 
impact on BRD2 function in cell growth, indicating that the erythroid genes assayed may 
not completely reflect the overall gene expression changes associated with loss of the 
BRD2 CC region. In summary, whereas the ET domain is essential for BRD2 function, the 
CC region may play a more variable role in the expression BRD2-dependent genes.   
The combined ETCC region functionally distinguishes BRD2 and BRD4S 
Like the bromodomains, the ET region is highly conserved between BET proteins. 
The adjacent CC region, however, is present in BRD2 and BRD3 but not in BRD4. We 
therefore asked whether either the ET, the CC, or the combined ETCC region functionally 
specified BRD2 and BRD4S. To do this, we devised additional chimeric BET proteins 
using BRD2 and BRD4S as the backbones onto which the sequences surrounding or 
containing the ET and CC domains were interchanged (Figure 3.10.A). We can broadly 
classify these constructs based on the whether they are composed of the BRD2 or BRD4S 
N-terminal half. For the BRD2-based chimeric constructs, we tested which, if any, of the 
C-terminal segments (the middle region between BD2 and ET, the ET, or the end 
segment) resulted in a loss of BRD2 function when the corresponding region from BRD4S 
was substituted. For the BRD4S-based chimeric constructs, we tested whether the BRD2 
ET domain, the CC region or a segment containing both could impart BRD2 function to 
BRD4S. As controls, we compared these new chimeric constructs to the original N- and 
C-terminal-swapped chimeras BRD2-4S and BRD4-2. We also compare these constructs 
to BRD2 and BRD3, which possess the CC region, and to BRD4S, which lacks the CC 
region (Figure 3.10.B, center). We used a combination of TER119 marker expression 




We first examined TER119 expression by flow cytometry. Of note, we used low 
titer viruses that statistically guarantee single-copy gene integration into the cells. 
Therefore, any differences in protein expression detected by YFP fluorescence were not 
due to gene copy number. YFP fluorescence revealed that BRD3 and BRD4S were 
expressed approximately 2-3-fold higher than BRD2 (Figure 3.10.B, left). This difference 
is less than that observed without the use of YFP fusion (Figure 3.3.E), indicating that the 
YFP sequence stabilizes BRD2 mRNA or protein to some extent. Next, we examined 
erythroid maturation based on TER119 surface phenotyping. As expected, a YFP empty 
vector or no vector infection had no impact on TER119 expression in BRD2 KO cells 
whereas virus encoding BRD2 restored TER119 close to parental G1E-ER4 levels (Figure 
3.10.B, right). BRD3 also restored TER119 expression, although to a lesser extent than 
BRD2. BRD4S had minimal impact on TER119 expression.  
We next examined the relative abilities of the BRD2-based chimeric BET proteins 
to restore TER119 and erythroid gene expression. All of the BRD2-based constructs are 
expressed at levels similar to BRD2 based on YFP fluorescence (Figure 3.10.B, left). 
Replacing the middle region (BRD2-4mid) or the ET domain (BRD2-4ET) from BRD2 with 
the corresponding regions from BRD4S had no appreciable impact on TER119 expression 
(Figure 3.10.B, right. However, replacing the end segment of BRD2 (BRD2-4end), which 
contains the CC region, completely abrogated its activity to the same extent as replacing 
the entire C-terminal half (BRD2-4S). To examine gene expression, we established stable 
BRD2 KO1 cells expressing the above constructs at similar levels (Figure 3.11.A, left). 
Expression of the Brd2-based transgenes and control genes (Actb and Gapdh) was similar 
across the cell lines (Figure 3.11.A, right). Examination of erythroid gene expression 
revealed differences in the ability of these constructs to rescue expression of Hbb-b1, 
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Csf2rb, Csf2rb2 and Rhag and to a lesser extent Alas2, Spta1 and Kcnn4 that largely 
reflect the differences in TER119 expression (Figure 3.11.A, right). For some of these 
genes, all of the chimeric constructs exhibited reduced activity. However, BRD2-4end had 
the least activity and most resembled BRD2-4S for 7 of the 8 genes examined. In 
summary, the activity of the BRD2-based chimeras indicates that the region that 
functionally discriminates BRD2 and BRD4S is the C-terminal end segment containing the 
CC domain. The middle segment and the ET domain appear interchangeable with minimal 
disruption of BRD2 activity and therefore do not contain functionally specific elements.     
We next assessed the activities of the BRD4S-based chimeras. The BRD4S-based 
chimeric BET proteins were expressed at similar levels, about 2-fold higher than BRD2 
based on YFP fluorescence (Figure 3.10.B, left). Replacing the BRD4 ET domain with 
that of BRD2 (BRD4S-2ET) did not increase TER119 expression (Figure 3.10.B, right). 
Adding the BRD2 CC domain adjacent to the BRD4 ET domain (BRD4S-2CC) likewise 
did not impact TER119 expression. However, when both the ET and CC domains from 
BRD2 were inserted into BRD4S (BRD4S-2ETCC), TER119 expression was restored to 
BRD2-like levels. The BRD4-2 protein, containing the entire C-terminal half of BRD2, had 
an even greater impact on TER119 expression, indicating that additional C-terminal 
domains may contribute to BRD2 function. To examine gene expression, we established 
BRD2 KO1 cell lines stably expressing the above constructs. Protein levels of the BRD4S-
based constructs were about two-fold higher than BRD2 protein levels but were similar 
across the cell lines (Figure 3.11.B, left). Despite the lower protein level of YFP-BRD2, 
its mRNA was slightly higher than that of the YFP-BRD4S-based BET proteins as 
measured by qPCR primers targeting YFP or the 3’ end of Brd2, consistent with the 
decreased protein:RNA ratio previously observed for BRD2 (Figure 3.11.B, right). Levels 
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of mRNA for Gata1-ER, Actb and Gapdh were similar. As with TER119 staining, the ET 
and CC domains were insufficient to confer BRD2-like activity to BRD4S based on the 
inability of the BRD4S-2ET and BRD4S-2CC proteins to restore erythroid gene activation 
(Figure 3.11.B, right). However, the combined ETCC domain (BRD4S-2ETCC) clearly 
imparted BRD2-activity to BRD4S as Hbb-b1, Csf2rb, Csf2rb2 and Kcnn4 expression were 
at least partially increased above the levels achieved by BRD4S. As with TER119 staining, 
BRD4-2 construct had the most BRD2-activity at these genes.  
To test whether the various BRD4S-based constructs were able to rescue BRD2-
dependent hemoglobinization, we visualized cell pellet color after 48 hours of GATA1-ER 
activation. As seen previously, BRD2 KO1 cells failed to hemoglobinize in comparison to 
parental G1E-ER4 cells, a defect which is largely rescued by the restoration of BRD2 
expression in the BRD2 KO1 cells (Figure 3.11.C). Whereas BRD4S fails to rescue 
hemoglobinization, substituting the ET and CC regions into the BRD4S backbone partially 
converts BRD4S into a BRD2-like molecule, but the combined addition of the ETCC 
region, or the entire BRD2 C-terminal half more fully restores hemoglobinization.  
Lastly, we asked whether the ET, CC or combined ETCC domain from BRD2 could 
confer BRD4S with the ability to promote cell growth. Note that in both parental G1E-ER4 
cells and BRD2 KO cells, overexpression of BRD4S inhibits growth, but chimeric BRD4-
2, which contains the entire C-terminal half of BRD2, promotes growth when expressed in 
BRD2 KO cells. To test the role of the ETCC domains, we repeated the cell growth assay 
after expressing the HA-tagged BRD4S-based chimeric BET constructs in parental and 
BRD2 KO1 cells. Consistent with our previous experiments, expression of BRD2 promoted 
cell growth in BRD2 KO1 cells but had no effect in parental G1E-ER4 cells which possess 
endogenous BRD2 (Figure 3.11.D). BRD4S, on the other hand, repressed parental and 
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BRD2 KO1 cell growth. Substitution of the BRD2 ET domain into BRD4S (BRD4S-2ET) 
slightly reduced the growth inhibitory effect of BRD4S. Addition of the BRD2 CC domain 
adjacent to the BRD4S ET domain (BRD4S-2CC) resulted in a minimal growth promoting 
effect when expressed in BRD2 KO1 cells. Strikingly, addition of both the ET and CC 
domains from BRD2 (BRD4S-2ETCC) had the same growth promoting effect as replacing 
the entire C-terminus with that of BRD2, indicating that the combined ETCC region is the 
module that functionally distinguishes BRD2 and BRD4S. 
Overall, these gene expression, differentiation, and growth assays suggest that 
neither the bromodomains, the ET domain nor the CC region are alone sufficient to convert 
BRD4S into a BRD2-like molecule. Instead, the combined region containing the canonical 
ET domain and the adjacent CC is the critical region encoding BRD2-specific function.  
Discussion 
We used BET dependent G1E-ER4 cell growth, maturation and gene 
expression to define functional similarities and differences among BET proteins. 
We exploited the fact that BRD2 is required for G1E-ER4 growth and GATA1-ER 
activity. Overexpressed BRD3, but not BRD4S or BRD4L, could significantly 
overcome defects associated with BRD2 deficiency, pointing to functional similarity 
among BRD2 and BRD3. When comparing BRD2 and BRD4S, most of their 
specific activities were determined not by the bromodomains but by the C-terminal 
halves of the molecules. We identified a short sequence downstream of the ET 
domain that contains a putative coiled coil (CC region) in BRD2 and BRD3 but not 
in BRD4. Together with the ET domain, the CC region conferred BRD2-like activity 
to BRD4S and deletion of the ET or CC domains diminished BRD2 function.  
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G1E-ER4 cells are a powerful system for the study of BET proteins since 
they are sensitive to pharmacologic BET inhibition and genetic perturbations of 
BET proteins113,139. Acetylation of GATA1 promotes association with BET 
proteins139 which in turn are thought to contribute to GATA1 activity. In this context 
it is worth noting that the clinical side effects of BET inhibition include anemia and 
thrombocytopenia133,134. Since GATA1 is essential for erythrocyte and 
megakaryocyte lineage differentiation, it is likely that the detrimental effects of BET 
inhibition are linked to GATA1 function. 
Over the course of our study, we uncovered a discrepancy in the amount of 
BRD2 protein compared to that of BRD3 and BRD4S when expressed from the 
same retroviral vector. BRD2 protein was substantially lower even though 
transcript levels of BRD2 were in fact higher than that of BRD4S, indicating that 
the mechanism for the low BRD2 abundance is post-transcriptional. The N-
terminal half of BRD2 was responsible for the low protein amounts, as the protein 
levels of the chimeric construct BRD2-4S were similar to BRD2 whereas the 
protein levels of the chimeric construct BRD4-2 were similar to BRD4S. By fusing 
YFP to the N-terminus of BRD2, the discrepancy between BRD2 protein and 
mRNA was reduced, though YFP-BRD2 protein was still lower than that of YFP-
BRD3 and YFP-BRD4S. The YFP portion might thus affect BRD2 protein 
production or turnover. It is interesting to note that a similar discordance between 
overexpressed BRD2 and BRD3 protein was observed in U2OS cells but not 
HEK293T cells31. Cell-type specific mechanisms may exist to tightly regulate 
BRD2 protein levels. SPOP-mediated proteasomal targeting has been implicating in 
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regulating BET proteins in some models156–158. However, SPOP recognizes a degron 
motif shared equally by each BET protein. Thus, this mechanism is unlikely to account 
for the differences we observed between BRD2/3 and BRD4S in G1E-ER4 cells. 
Additional studies are therefore required to elucidate what accounts for this 
specificity. 
Our unexpected finding that the BRD2 bromodomains can be exchanged 
for those of BRD4 with no substantial loss of BRD2 function suggests that potential 
differences in their affinities or specificities for acetylated substrates44,47,48,51–53 do 
not seem to contribute much to their selective functions. Our results suggest that 
the distinct functions of BRD2 and BRD4 are instead exerted by their C-terminal 
halves, in which the extended ET region containing the CC in BRD2 but not BRD4 
appears to be the critical element. Gene rescue experiments showed that ET 
domain itself was essential for BRD2 function, which is consistent with previous 
studies demonstrating that the ET domain recruits multiple chromatin regulators 
including NSD3, CHD8, ATAD5 and JMJD631,64,66,68,71,72. However, in our study, 
though the ET domain was essential, exchanging the BRD2 and BRD4S ET 
domains did not change the activities of either protein. Instead, the BRD2 ET 
domain appears to function in conjunction with the adjacent CC. Thus, when the 
combined ETCC region was grafted into BRD4S, it imparted BRD2-like activity to 
BRD4S.  
Coiled coils are structural motifs present in a wide variety of proteins and 
perform a multitude of functions including directly mediating protein-protein 
interactions159. In this case, the ET proximal CC may be recruiting additional 
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factors that are ultimately altering the function of BRD2 in comparison to BRD4. 
Alternatively, the CC domain may be modulating the structure of the ET domain by 
influencing its folding to create novel interaction surfaces at the junction. Protein 
interaction and structural studies are therefore warranted to better understand how 
this region contributes to BRD2 functional specificity.  
The ETCC region may therefore allow individual BET proteins to incorporate 
into different transcriptional complexes involved in discrete aspects of the 
transcription cycle. This may at least in part reconcile how BET proteins can 
function distinctly on chromatin while having relatively similar genome-wide 
distribution patterns, as observed in many studies55,63,96,102,114,117,118,129,160. Protein 
interactions mediated by the ET or ETCC regions may also account for 
bromodomain-independent chromatin binding36. Thus, the complexes that each 
BET protein associate with could also account for some of the differences in 
chromatin occupancy exhibited by each BET protein, as is the case at enhancers 
where there is a relative enrichment BRD4 and at promoters where there is a 
relative enrichment of BRD2 and BRD3113,117,129. There is also evidence that the 
conserved mB domain, which facilitates homo- and hetero-dimerization of BET 
proteins, is required for chromatin binding35. Heterodimerization of BET proteins 
might further explain their overlapping chromatin occupancy and may suggest that 
BET proteins function coordinately to assemble multiple factors onto chromatin. 
Together these considerations lead to a model in which BET proteins function both 
independently and interdependently during transcription.  
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At low doses of BET inhibitors, the expression of only a subset of genes is 
affected in a manner that is not easily predictable based solely on local chromatin 
features or levels of BET protein occupancy112,113. Predicting whether a gene 
responds to pharmacologic BET inhibition remains a challenge in part because 
cells express multiple BET proteins exhibiting mostly overlapping but partially 
distinct chromatin occupancy patterns. Moreover, partial redundancy among BET 
proteins, as exemplified by BRD2 and BRD3, might be rooted in structural and 
functional similarities. Thus, overexpression of BRD3 at least partially 
compensates for loss of BRD2113. This example illustrates that different BET 
protein dependencies can also be a result of the expression levels of each protein. 
These factors need to be taken into consideration when assessing the effects of 
targeting BET proteins pharmacologically. 
Hence, identifying BET protein specific mechanisms and predicting what 
disease processes might be targeted by BET inhibitors remains an important goal. 
Achieving this level of mechanistic understanding requires consideration of BET 
protein expression levels, assessment of functional overlap among BET proteins, 
and the identification of functional domains that are required for BET protein 
activity in diverse contexts. Our work begins to address these criteria by identifying 
the ETCC module, which may mechanistically differentiate BRD2, and given the 
structural similarities also BRD3, from BRD4. In the next Chapter, we explore the 
mechanisms by which this domain may contribute to transcription. We speculate 
that targeting this region with a small-molecule inhibitor might provide a more 




Figure 3.1. Brd2-null G1E-ER4 cells fail to activate erythroid genes. A) Western blot 
of endogenous BET protein levels in whole cell lysates from parental G1E-ER4 cells or 
multiple Brd2-null clones (KO1-KO4). B) Western blot of endogenous and overexpressed 
BRD4 isoforms using an N-terminal antibody that is predicted to detect both BRD4S and 
BRD4L and a C-terminal antibody that only recognizes BRD4L. Whole cell lysates from 
parental G1E-ER4 cells expressing no construct or HA-tagged BRD4S or BRD4L. C) 
Gene expression levels normalized to Pabpc1 after 24 hours of GATA1-ER activity (+E2) 
Actb Gapdh
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in the indicated cell lines. Averages and standard deviation (error bars) are derived from 





Figure 3.2. BRD2-dependent gene expression. A) Heatmap depicting Pearson 
coefficients of pairwise gene expression correlations in three independent RNAseq 
replicates (r1-r3) after GATA1 activation. B) Principle component analysis (see text for 
details). C) Summary of differentially expressed genes (FC=fold-change, FDR=false 
discovery rate). Subsets used for subequent analysis shaded in red or gray. D) Normalized 
read counts (FPKM) for indicated genes activated or repressed upon GATA1-ER 
activation. Averages and standard deviation (error bars) are derived from three 
independent replicates. E) Enrichment scores (log10Qvalue, left) and gene names (right) 
in the top ten Hallmark gene sets from the Molecular Signatures Database enriched in the 
up- and down-regulated genes. F-G) Correlation of all detected genes (F) and intersection 
of most differentially expressed (FC>2, FDR<0.01) genes (G) after 24 hours of JQ1 
87 
 
treatment or BRD2 depletion in GATA1-ER activated cells. P value (p), 95% confidence 





Figure 3.3. Differential function and expression of BRD2, BRD3 and short and long 
isoforms of BRD4 in G1E-ER4 cells. A) Visualization of hemoglobin production 
(redness) with or without 48 hours of GATA1-ER activation (+E2) in parental (P) or Brd2-
null (KO1) G1E-ER4 cells stably expressing the indicated HA-tagged BET proteins after 
retroviral transduction. B) Hbb-b1 mRNA levels normalized to Pabpc1 after 24 hours of 
GATA1-ER activation. C-D) Competitive growth assay in which %GFP is tracked after 
retroviral transduction with bicistronic vector encoding indicated BET protein and GFP 
selection marker. Bars indicate consecutive days of GFP percentage measurement from 
left to right starting with day 2 (d2) and ending with d8. Starting %GFP has been subtracted 
to scale measurements to same axis. E) Western blots of HA-tagged BET protein 
expression in whole cell lysates from BRD2 KO cells, representative of similar expression 
patterns seen in lysates from parental G1E-ER4 cells. *NS = non-specific bands 
associated with HA antibody. F) GFP mRNA levels (indicative of transgene expression) 
normalized to Pabpc1. Averages and standard deviation (error bars) are derived from 
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Figure 3.4. Structure, expression and function of chimeric BET proteins composed 
of N- and C-terminal halves of BRD2 and BRD4S. A) Design of chimeric BET proteins 
Location of epitope recognized by BRD2 antibody used in (C) is indicated. B) GFP mRNA 
levels (indicative of transgene expression) normalized to Pabpc1 after 24 hours of GATA1-
ER activation (+E2). C) Western blot of HA-tagged BET protein expression in whole cell 
lysates from BRD2 KO cells, representative of patterns also observed in lysates from 
parental cells. NS = non-specific bands associated with HA antibody. D) Quantitative 
western blot comparing protein expression levels of chimeric BET proteins with intact BET 
proteins in BRD2 KO1 whole cell lysates, representative of expression patterns in parental 
and BRD2 KO2 lysates. ACTB normalized signal plotted below. E-F) Competitive growth 
assay in which %GFP is tracked after retroviral transduction with bicistronic vector 
encoding indicated BET protein and GFP selection marker. Bars indicate consecutive 
days of GFP percentage measurement from left to right starting with day 2 (d2) and ending 
with d8. Starting %GFP has been subtracted to scale measurements to same axis. G-H) 
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Hbb-b1 and Hba-a1 mRNA levels normalized to Pabpc1 after 24 hours of GATA1-ER 
activation. Constructs grouped by expression levels. Averages and standard deviation 






Figure 3.5. The C-terminal halves of BRD2 and BRD4S distinguish their function. A) 
Schematic of YFP-fusion constructs utilized in this experiment. B) Western blot detection 
of exogenous YFP-fused BET proteins in whole cell lysates after expression in BRD2 KO1 
cells with detection of endogenous BRD2 in parental G1E-ER4 cell for comparison. C) 
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Gene expression levels of BRD2-dependent and control genes normalized to Pabpc1 after 
24 hours of GATA1-ER activity (+E2). 5’ and 3’ indicate the respective halves of the 







Figure 3.6. Control gene expression and hemoglobin synthesis in BRD2 KO 
cells expressing YFP-BET proteins. A) YFP-BET protein levels after iterative cell 
sorting measured by flow cytometry. B) Visualization of hemoglobin production 






Figure 3.7. Identification of a conserved putative coiled coil (CC) domain 
adjacent to the ET domain. A) MARCOIL coiled coil prediction across the mouse 
BRD2, BRD3, BRD4S and BRD4L amino acid sequences. B) Conservation of the 
ET and predicted coiled coil region between BET proteins and across species. 
Color coding: blue (hydrophobic), red (positive charge), magenta (negative 
charge), green (polar), pink (cysteines), orange (glycines), yellow (prolines), cyan 





Figure 3.8. Validation of TER119 erythroid maturation assay. A) Schematic 
depicting TER119 detection after 24 hours of GATA1-ER activation (+E2). B) 
Representative flow cytometry data of parental G1E-ER4 cells or BRD2 KO1 cells 
expressing an empty YFP vector or YFP-BRD2 with or without 24 hours of GATA1-
ER activation (+E2). C) Summary data quantifying mean fluorescence intensity 
(mfi) of TER119 staining from three independent replicates. D) Scatter plots 
depicting relationship between the amount of TER119 surface expression for 
indicated cell lines and the amount of mRNA for the indicated erythroid genes upon 
24 hours of GATA1-ER activity. R = Pearson coefficient. Averages and standard 






Figure 3.9. The ET and CC domains each contribute to BRD2 function. A) 
Schematic of BRD2 constructs with the ET and CC domains deleted (middle) and 
their resultant protein expression levels (left) and effect on TER119 surface 
expression (right) when expressed in three independent BRD2 KO cell clones after 
24 hours of GATA1-ER activation. Values are normalized to YFP-BRD2.  B-C) 
Gene expression levels of control genes (B) and BRD2-dependent genes (C) 
normalized to Pabpc1 in cells stably expressing the indicated HA-tagged BET 
proteins after 24 hours of GATA1-ER activation. Inset. Western blot of HA-tagged 
BET protein levels. D) Competitive growth assay in which %GFP is tracked after 
retroviral transduction with bicistronic vector encoding indicated BET protein and 
GFP selection marker. Starting %GFP has been subtracted to scale 
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measurements to same axis. Averages and standard deviation (error bars) are 





Figure 3.10. THE ETCC region functionally distinguishes BRD2 and BRD4S. 
A) Schematic of the YFP-BET fusion constructs in which C-terminal regions have 
been interchanged. B) Protein expression levels (left) and TER119 surface levels 
(right) of YFP-BET constructs after 24 hours of GATA1-ER activation. Values are 
normalized to YFP-BRD2. C-D) Expression levels of mRNA normalized to Pabpc1 
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after 24 hours of GATA1-ER activity (+E2). Averages and standard deviation (error 




Figure 3.11. Protein levels, gene expression, hemoglobinization, and growth 
associated with chimeric BET proteins. A-B) Left: western blots of YFP-BET 
proteins in G1E-ER4 (P) or BRD2 KO1 lysates. Right: gene expression of BRD2-
dependent genes (top row) and control genes (bottom row) normalized to 
Pabpc1.C) Hemoglobinization of BRD2 KO1 cells with total color signal intensity 
averages across two replicates (error bars depict standard deviation). D) 
Competitive growth assay in which %GFP is tracked after retroviral transduction 
with bicistronic vector encoding indicated HA-tagged BET protein and GFP 
selection marker. HA-BRD2-expressing cells have been grouped separately based 
on lower protein expresson levels (data not shown). Bars indicate subsequent days 
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Table 3.1. Gene expression analysis of Brd2-null G1E-ER4 cells: down-
regulated genes. Differentially expressed genes in Brd2-null G1E-ER4 cells were 
identified based on >2-fold change in expression compared to parental cells after 
24 hours of GATA1-ER activation. Genes were only included if identified in both 
BRD2 KO1 and KO2 cell lines.  
  
Alas2 Hbb-b1 Slc4a1 Ctsz Morc2a Fdps Sdsl
Aldoc Hr Tgfbr3 Mrpl54 Fam46c Slc25a38 Arhgef40
Bnip3 Il9r Tgm1 Cystm1 Fads1 Syne3 Shc4
Btk Itga7 Trap1a Smim5 Srxn1 Mylk3 Hist1h2af
C3 Itgb2 Tuba4a Grtp1 Nxpe2 Slc25a21 C5ar2
Anxa2 Kcnb1 Vegfa Cntd1 Ifitm2 Plekhb2 Tcp11l1
Cetn3 Kcnn4 Slc23a3 Wfdc15a Trim2 Fam132b Treml2
Socs3 Fabp5 Kel Agpat4 Sec16b Pdk1 Il1bos
Coq7 Lrp8 Gcat Pmvk Igsf9 Ctso Rph3al
Csf2rb Lss Hs6st1 Cd177 Hemgn Phf24 Tmem29
Csf2rb2 Rdh11 Slc25a13 Zg16 Hecw1 Oscp1 Fam205a1
Esd Mif St3gal6 Pdia2 Igflr1 Pla2g4c Ccdc8
Foxh1 Ncf4 Higd1a Slc52a3 Ttc41 Zfp939 Hbq1b
Fdft1 Nfe2 Ctsf Ptrhd1 Tcrg-C1 Zfp599 Kalrn
Fkbp1b Pctp Mocs1 Tspo2 Scml2 Ttc12 Tubb1
Slc6a13 Pgk1 Dnajb2 Dlg5 Shmt2 Pcyt1b Myh7b
Gch1 Rit1 Sult5a1 Gypc Ston2 Zfp870 Hbb-bs
Arhgdig Scd2 Slc43a3 Esco2 Ank2 Plekhm3
Galk1 Spi1 Arhgap23 Cyp2c55 Hyal3 Ypel4
Hba-x Six4 Syne1 Uba7 Arrb1 C2cd4a
Genes down-regulated in Brd2 -null G1E-ER4 compared to parental cells after 24 




Table 3.2. Gene expression analysis of Brd2-null G1E-ER4 cells: up-
regulated genes. Differentially expressed genes in Brd2-null G1E-ER4 cells were 
identified based on >2-fold change in expression compared to parental cells after 
24 hours of GATA1-ER activation. Genes were only included if identified in both 
BRD2 KO1 and KO2 cell lines.  
  
Abca2 Ier2 Rom1 Map3k14 Ydjc Pag1 Znrf1 Snx33 Nckap5l
Agrn Ier3 Pmel Sept9 Bst2 Cnnm4 Il17rc Gk5 Pdp1
Akap1 Itgb7 Slc19a1 Cdkl2 Mfsd3 Sfxn3 Fut10 Nbeal2 Zfp69
Akr1b3 Itpr1 Sms Rfx5 Fastkd3 Fam102a Galnt10 Irf2bpl Nxpe3
Alox5 Itpr2 Sntb2 Trim3 Cpne3 Tiparp Mical1 Ccnb1ip1 Gnptab
Slc25a4 Itpr3 Serpinb9 Espn Slc29a3 Tdrd7 Hexim1 Exd1 Acsl5
Anxa4 Jun Sptan1 Sept6 Cotl1 Pafah2 Pla2g15 Usp35 Parp14
Aprt Kcnu1 Srm Rec8 Zfp661 Acacb Grhl1 Peak1 Stard9
Rnd2 Khk Srpk2 Bcam Lrrc8e Slc6a8 Gramd1c Fam199x Fam129c
Cbfb Kifc2 Stk10 Kcne3 Fgfbp3 Etv5 Ccdc62 Acsf3
Ccnd2 Arhgef2 Stx1a Extl2 Mblac2 Sbk1 Thnsl1 Pkn3
Entpd6 Lcat Tac2 Dip2a Top1mt Srl Zfp710 Bahcc1
Plk3 Lgals9 Tep1 Dip2a Tmem192 Ppcs Tmem164 Xxylt1
Ctsl Limk1 Tgif1 Ifi30 Ccdc103 Trip10 Suox Znf512b
Dlx1 Man2b1 Klf10 Asph Itpripl1 Tnfaip8 Fam46a Irf2bp2
Dnmt3b Mfge8 Tle2 Lyrm9 Tubb2b Osr2 Slc35e3 Maml2
Lefty1 Map4 Tnnc1 Ahnak Iqce Frs3 Ccdc92 Mbtps2
Nr2f6 Gadd45b Tnni3 Rnf128 Ppapdc2 Baiap2 Pdxk Tango6
Fmo5 Myo5a Tuft1 Bzw2 Pomk Nabp1 Kctd11 Tmcc3
Fyn Ncoa3 Ugdh Pqlc1 Cklf Fam212b Plekhh3 Ccdc171
Fzd7 Nnt Xpc Ptgr1 Exoc6b Ssc4d Cdca7l Bcorl1
Gamt Nnt Ikzf2 Fam132a Lhpp Pygb Tmem184b Itpkb
Gata2 Oprl1 Zyx Adck3 Ppp1r18 Ggct Rnd1 Gchfr
Gata3 P2rx4 Mgll Retsat Klhl2 Amhr2 Camk1d Soga1
Gip Pdcd4 Spry4 Ppfibp1 Prss36 Nr3c2 Tnks1bp1 Nol4l
Hhex Pik3r3 Homer2 Prpsap1 Eml4 Kiss1r Cyb5rl Adgrl1
Hk2 Prkce Dlc1 Dynll2 Zfp623 Dok4 Zfp382 Piwil4
Hoxc8 Ppap2a Galns Mpzl1 Srd5a1 Tle6 Zfp764 Acad12
Icam1 Pros1 Hgsnat Gpr155 Nfkbiz Man2a2 Fhod1 Muc6
Id1 Psen2 Nucb2 Zfp707 Kremen1 Igf2bp1 Klhl36 Nefh









Research described in this chapter is a combination of experiments that will 
be included in a pending publication “Comparative structure-function analysis of 
bromodomain and extraterminal motif (BET) proteins using a gene-
complementation system” and unpublished work. This chapter will include 
unpublished chromatin immunoprecipitation (ChIP) sequencing data that was 
generated in collaboration with Cheryl Keller and Belinda Giardine in Ross 
Hardison’s laboratory at Pennsylvania State University. The analysis of this data 
includes comparisons to previously published data generated by Aaron 
Stonestrom and additionally analyzed by Sarah Hsu while they were in the Blobel 
lab113,131. This chapter also includes proteomic data that will be published in the 
above manuscript. Hongxin Wang was critical to the generation of the proteomic 
data and subsequent validation experiments. The mass spectrometry data was 
conducted in collaboration with Hsin-Yao Tang and Thomas Beer in the 
Proteomics and Metabolomics Facility at the Wistar Institute. Perry Evans of the 
CHOP Department of Biomedical and Health Informatics assisted with analysis of 
this data. Structural characterization of the coiled coil region of BRD2 and BRD3 
was performed by Yichen Zhong and Joel Mackay at the University of Sydney.  
Experiments examining the interaction between BRD2 and PAF/CK2 in 
more detail remain unpublished and will be the basis of future work to determine 




 BET proteins are being investigated as therapeutic targets in a number of 
solid and hematological cancers. However, treating these diseases with anti-BET 
therapy will require an intimate knowledge of how BET proteins regulate 
transcription. A simplistic model for BET protein function begins with the 
observation that BET bromodomains form contacts with acetylated lysine residues 
on active chromatin. Various chromatin regulators that influence POL2 activity are 
then recruited through protein-protein interactions. Because BET inhibitors 
typically disrupt the contact between the bromodomains and their acetylated 
substrates, the mechanism of action of these drugs is thought to be the 
displacement of POL2 regulators from chromatin. 
The exact details of this model are more difficult to discern. For example, 
though it is appreciated that some BET proteins (particularly BRD2 and BRD4) can 
function distinctly in their roles as transcriptional regulators, it remains unclear how 
this is achieved mechanistically. One hypothesis is that individual BET proteins 
participate in distinct protein interactions. This is supported by immunoprecipitation 
experiments demonstrating differential enrichment of protein complexes by each 
BET protein. For example, interactions with the negative elongation factor (NELF) 
and PTEFb are dominated by BRD4, whereas interactions with casein kinase II 
(CK2) and TFIID, a subunit of the POL2 complex, are preferred by BRD2 and 
BRD331. With the exception of the contacts made between BRD4 and PTEFb76, a 
mechanistic basis for these preferential interactions remains unclear. For example, 
CK2 is known to phosphorylate BET proteins at sequences that are well conserved 
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across BET proteins85, which would suggest equivalent interaction frequencies, 
not protein-specific ones. It is possible that BET proteins possess additional 
interaction domains that specify some of these binding events. One potentially 
significant domain is the ET domain. This domain has been well established as 
protein-protein interaction region. Its crystal structure has been solved and a 
consensus binding motif has been identified in many of its validated 
substrates66,68,72. These substrates include many known chromatin regulators 
such as ATAD5, JMJD6, GLTSCR1, WHSC1L1/NSD3, and NIPBL. Because the 
ET domain is approximately 80% conserved across BET proteins, it remains to be 
determined whether the remaining variation may confer some of the BET protein-
specific interactions that have been observed. 
The interaction between BRD4 and PTEFb (composed of the CDK9 and 
CCNT1) is perhaps one of the best studied molecular mechanisms involving BET 
proteins. The specificity of PTEFb for BRD4 (and for BRDT in the testis) is 
attributed to the CTM domain76. It is thought that BRD4 recruits PTEFb which 
phosphorylates POL2 and releases it from its paused state. However, several 
observations call into question the specificity and functional significance of this 
mechanism. First, though this interaction is strongest for BRD4, BRD2122 and 
BRD330 have also been shown to immunoprecipitate with CDK9. This may be 
driven in part by the ability of the ET domain76 and the second bromodomain161 to 
contribute to the PTEFb interaction. Second, regardless of which BET proteins 
recruit PTEFb, rapid depletion of BET proteins inhibits POL2 elongation without 
altering PTEFb levels on chromatin111, indicating an elongation role independent 
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from PTEFb activity. Accordingly, BET inhibitors and CDK9 inhibitors impact 
different subsets of genes112. In fact, in vitro transcriptional assays that do not 
include PTEFb components reveal that all BET proteins exhibit histone chaperone-
like activity (defined as the ability to facilitate passage of POL2 through 
nucleosome templates)40,41. In the case of BRD4, this activity is independent of its 
CTM domain. Whether this aspect of BET protein function accounts for all 
transcriptional defects associated with BET inhibition remains unclear. It is also 
unclear if BET proteins use similar or distinct mechanisms to carry out this activity.    
Another hypothesis regarding distinct BET protein functions stems from the 
observation that BET proteins can bind to unique regions of the genome. For 
example, though there is a large degree of overlap, BRD2 and BRD3 bind more 
predominately to gene promoters, whereas BRD4 favors enhancers. The basis for 
these patterns is not known, but it is possible that the preference exhibited by 
BRD2 and BRD3 for promoters is related to their interactions with the histone 
variant H2A.Z57–59. We and others have reported additional BRD2 and BRD3 
binding at CTCF sites, where they are thought to cooperate with CTCF to maintain 
TAD boundaries131 and regulate enhancer-promoter looping122. Notably, BRD4 
occupancy at these sites is minimal. This finding is consistent with previous work 
from our laboratory demonstrating that BRD2 and BRD3 exhibit overlapping 
functionality that is distinct from BRD4113. It is possible that these critical 
differences in genomic occupancy also underpin the unique transcription 
signatures apparent upon BRD2 and BRD4 depletion observed in other studies 
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and perhaps even the different developmental phenotypes associated with Brd2- 
and Brd4-null mice.  
In Chapter 3, we sought to identify the domain that biologically distinguishes 
BRD2 and BRD3 from BRD4. We found this domain to encompass the canonical 
ET sequence shared by BRD2/3/4 and an adjacent coiled coil found in BRD2/3 but 
not BRD4. We termed this BRD2/3-specific region the ETCC domain. In this 
chapter, we examine the genomic distributions of YFP-tagged BRD2/3/4S and test 
whether the C-terminal halves, either containing or missing the newly defined 
ETCC region, control differential BET protein occupancy. Given the proximity to 
the ET protein interaction domain, we then examine whether the ETCC mediates 
different protein-protein interactions.  
YFP-BET proteins share similar genome-wide binding profiles  
 BET proteins bind to similar regions of the genome – particularly promoters 
and enhancers – and largely colocalize genome-wide. However, some exceptions 
have been identified. For example, we and others observed BRD2/3-specific 
binding at CTCF sites. To determine whether the distinct functions of YFP-tagged 
BRD2, BRD3, BRD4S, and the chimeric BRD2/4S constructs are related to these 
different binding profiles, we performed chromatin immunoprecipitation followed by 
deep sequencing (ChIP sequencing) in the BRD2 KO1 cells expressing the YFP-
tagged BET proteins. Western blots detecting the levels of YFP-BET fusion 
proteins in these cells are in Figure 2.5. Note that the levels of ectopic YFP-BET 
protein are roughly similar to the level of endogenous BRD2 found in parental cells, 
minimizing the risk of overexpression artifact. We use the YFP moiety shared by 
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all of the ectopic BET proteins as the epitope for immunoprecipitation, allowing the 
use of the same antibody to enrich chromatin associated with each BET isoform. 
These technical considerations minimize biases related to protein expression and 
antibody affinity/specificity.  
We find strong reproducibility between replicates when assessing ChIP 
sequencing signal at gene transcription start sites (TSS) and previously annotated 
enhancer elements162 with Pearson correlation coefficients for each pair of 
replicates ranging from 0.9036 to 0.9725 at TSSs and from 0.8572 to 0.9349  at 
enhancers (Figure 4.1.A, Table 4.1). We therefore used the average of the binned 
read counts for each technical replicate in subsequent analyses. We next asked 
whether the YFP-tagged BET proteins were differentially bound at GATA1 and 
CTCF sites using previously published GATA1 and CTCF peaks in activated 
GATA1-ER4 cells113,131. All five YFP-BET proteins were enriched at GATA1 sites, 
though the average levels of YFP-BRD4S and BRD2-4S were slightly lower than 
those of YFP-BRD2, BRD3, and BRD4-2 (Figure 4.1B). Surprisingly, none of the 
YFP-BET proteins were enriched at CTCF sites (Figure 4.1B). Because we had 
previously observed colocalization of BRD2 and CTCF131, we repeated 
endogenous BRD2 ChIP sequencing in G1E-ER4 cells. We observed strong BRD2 
signal overall but found no BRD2 occupancy at CTCF sites (Marit Vermunt, 
personal communication [data not shown]). This discrepancy could be due to 
technical differences between the studies. For example, the previous BRD2 
antibody manufacturer lot number was unavailable for the second study. To rule 
out off-target binding for the new BRD2 antibody lot, antibody specificity was 
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confirmed by ChIP sequencing in BRD2 knockout controls (Marit Vermunt, 
personal communication [data not shown]). These data indicate that global 
differences in BET protein binding at GATA1 or CTCF do not likely mediate the 
differential activities of the YFP-tagged BET proteins.  
 To focus on differentiation-associated binding events, we next performed 
our chromatin occupancy analysis on peaks that are gained or lost peaks upon 
GATA1-ER activation. We hypothesized that changes in YFP-BRD2 binding would 
be mimicked by YFP-tagged BRD3 and BRD4-2, which have BRD2-like activity, 
but not by BRD4S or BRD2-4S. We thus centered our analysis on YFP-BRD2 
peaks. We identified 4,218 YFP-BRD2 binding sites that are lost and 3,080 that 
are gained upon GATA1-ER activation and measured the average levels of the 
YFP-BET proteins across these sites. Before GATA1-ER activation, YFP-tagged 
BRD3 and BRD2-4S levels are similar to those of BRD2 at both lost and gained 
sites, whereas levels of BRD4S and BRD4-2 are slightly lower, indicating that 
BRD3 largely mimics BRD2 and that differences in BRD2 and BRD4S levels are 
determined by the bromodomain-containing halves of these proteins (Figure 
4.1.C). Though these differences are maintained upon GATA1-ER activation, all 
of the YFP-BET proteins follow the same pattern as YFP-BRD2 at sites that are 
gained and lost. Together, these binding profiles suggest that though there may 
be subtle binding differences determined by the bromodomain-containing halves 
of these proteins, extrinsic factors that affect BET protein recruitment – likely 
histone acetylation – appear to be affecting all of the YFP-BET proteins equally. 
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However, careful interpretation requires additional testing to determine if histone 
acetylation patterns differ across the cell lines.  
To better understand the changes in occupancy that occur upon GATA1 
induction, we identified gained and lost sites for each YFP-BET protein and 
classified each region by genomic position (intronic, transcription start/termination 
site [TSS/TTS], etc). This revealed that GATA1-ER activation results in an overall 
redistribution of each YFP-BET protein towards TSS regions (Figure 4.1.D). For 
example, TSS regions comprise only ~6% of sites lost by YFP-BRD2 but make up 
over 30% of the gained sites, whereas the intergenic regions comprise ~50% of 
lost sites and only ~16% of the gained sites indicating a general shift of YFP-BRD2 
away from intergenic regions toward TSS regions. This dynamic is true for the 
other YFP-BET proteins, though the enrichment at TSS upon GATA1-ER 
activation is less apparent for YFP-BRD2-4S. To highlight the overall similarity of 
the chromatin occupancy profiles of each YFP-BET protein, a genome browser 
view of the Csf2rb locus is presented as Figure 4.1.E. The adjacent Csf2rb and 
Csf2rb2 genes were chosen as BRD2-dependent genes in the mRNA expression 
studies from Chapter 3. The genome browser view shows enrichment of all five 
YFP-BET protein at the intergenic Csf2rb region upon GATA1-ER activation, with 
levels of YFP-BET fairly similar and constant at the adjacent loci. In summary, our 
global analysis of the genomic distributions of the YFP-BET proteins reveals 
markedly similar binding at both stable and differentiation-associated loci. 
111 
 
Identification of genomic sites differentially bound by YFP-BET proteins 
Because our previous analyses did not identify clear differences in YFP-
BET binding patterns, we next looked specifically for regions that were occupied 
by the BRD2-like BET proteins YFP-BRD2/3/4-2 but not by YFP-BRD4S/2-4S. Out 
of 23,717 consensus regions prior to GATA1-ER activation, there were only 641 
sites that were preferentially bound by YFP-BRD2/3/4-2 (FDR<0.05) and 194 sites 
that were preferentially bound by YFP-BRD4S/2-4S (FDR<0.05) (Figure 4.2.A, 
left). Likewise, out of 19,921 consensus regions after GATA1-ER activation, 1,207 
were preferentially bound by YFP-BRD2/3/4-2 and only 6 were preferentially 
bound by YFP-BRD4S/2-4S (Figure 4.2.A, right). These numbers indicate that the 
vast majority of YFP-BET binding sites are shared by all five YFP-BET proteins, 
which is consistent with our previous analyses. Differentially bound loci 
exemplifying each condition, respectively, include the Dock2, Csmd3 and Txlnb 
loci (Figure 4.2.B). The specificity of the differentially binding of YFP-BET proteins 
at these sites in contrast to most other regions is highlighted by the relatively similar 
levels of YFP-BET at the Spdl1 TSS adjacent to the differentially bound Dock2 
TSS. Given that BET proteins are known to facilitate transcription factor 
recruitment, we hypothesized that the differential binding of YFP-BET proteins to 
this small percentage of regions may be due to the presence of transcription 
factors unique to each subset of sites. We therefore assessed these regions for 
transcription factor binding motifs. Interestingly, prior to GATA1-ER activation the 
YFP-BRD2/3/4-2-specific peaks are enriched most predominantly for the ETS 
factor motif whereas the YFP-BRD4S/2-4S-specific peaks are enriched only for 
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the GATA factor motif (Figure 4.2.C, left and middle). These findings are consistent 
with the role of ETS factors Fli1 and GABPa and GATA factors GATA1 and GATA2 
in erythroid cell development and function163. Thus, individual BET proteins may 
associate with these factors separately at some regulatory regions and these 
interactions may be driven at least in part by the C-terminal halves of BET proteins. 
After GATA1-ER activation, YFP-BRD2/3/4-2-specific peaks are enriched for 
several GC-rich motifs (Figure 4.2.C, right). Of note, only the top five of these 
motifs are shown, though 25 of these GC-rich sequences meet statistical 
significance (not shown). Each of these GC-rich motifs comprises only a small 
number of sites but collectively account for a more substantial proportion of the 
YFP-BRD2/3/4-2-specific peaks. No consensus motifs were enriched in the YFP-
BRD4S/2-4S-specific peaks after GATA1-ER activation, perhaps due to the small 
number of peaks detected. In summary, only a small number of YFP-BET peaks 
are bound preferentially by either the BRD2-like YFP-BRD2/3/4-2 proteins or the 
YFP-BRD4S/2-4S proteins. Of this small fraction, the BRD2-like proteins may be 
binding preferentially at ETS-factor binding sites whereas the YFP-BET proteins 
lacking BRD2-like activity may be binding at GATA1/2 binding sites prior to 
differentiation. 
The BRD2 and BRD3 CC domains are helical modules that do not dimerize 
 Our comparative YFP-BET chromatin occupancy data is consistent with 
many other studies that demonstrate strongly overlapping binding profiles of 
endogenous BET proteins55,63,96,102,114,117,118,129,160. We therefore hypothesized that 
the ETCC domain, which we previously showed to control BRD2/3-like activity, 
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may instead facilitate novel protein-protein interactions. We first characterized the 
structural features of the CC domain to determine whether it possesses helical 
structure or facilitates homo- or heterodimerization properties as seen with other 
coiled coils, including motif B35. To assess the structure of human BRD2-CC (715-
757) and human BRD3-CC (641-688), we expressed and purified these regions 
and recorded far-UV circular dichroism (CD) spectra of each protein (Figure 4.3.A). 
The spectra show minima at 222 nm, indicative of the presence of some helical 
structure. Raussens’ method estimates that each of the two peptides contains 
~33% helical structure (http://perry.freeshell.org/raussens.html). Because coiled 
coils often form dimers159, we assessed whether either the BRD2-CC or BRD3-CC 
domains can form a homomeric coiled coil using size-exclusion chromatography 
coupled to multiangle laser light scattering (MALLS). As shown in Figure 4.3.A, 
both peptides run with molecular weights that are close to the monomeric weights 
(5.3 kDa and 7.3 kDa, respectively), indicating that they do not significantly self-
associate in solution at a concentration of ~100 µM (accounting for dilution on the 
column). We also assessed the ability of the peptides to associate with each other 
using the same approach, but again no significant self-association was observed. 
We conclude that if these sequences form coiled coils, then they must do this by 
partnering with other proteins.  
The ETCC region binds to the PAF and CK2 complexes 
 To identify partner proteins, we generated GST-fusion proteins and 
exposed them to nuclear extracts from MEL cells (see Chapter 2: Materials and 
Methods; Figure 4.4.A). We included the mB region, which is also a putative coiled 
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coil. We also included two different sets of mutations in the CC predicted to 
abrogate coiled structure (CCp and CCd). Given that the ET domain is a known 
protein interaction domain and that the adjacent CC domain functions 
cooperatively with the ET domain in the domain-mapping studies, we included 
GST fusion proteins comprised of the ET domain alone or attached to the adjacent 
CC (its native context) for comparison. Each sample was compared to a GST-only 
control to determine signal above background. Mass spectrometry (see “Chapter 
2: Materials and Methods”) revealed enrichment of a total of 392 proteins (log2ratio 
> 1 over GST alone at FDR < 0.0001, Table 4.1). Several known BET binding 
partners were among these, validating our approach. For example, ATAD5, CHD8, 
SMARCA4/BRG1, WHSC1/NSD2, WHSC1L1/NSD3, and CDK9)64–66,71,76 were 
enriched significantly by both the ET and ETCC domains (Figure 4.4.B). Likewise, 
NIPBL, which has recently been shown to interact with the ET domain of BRD473,74, 
was also enriched in these samples. Two other previously reported ET-mediated 
interactions, CHD464,71 and CCNT176, did not meet the thresholds set in our 
analysis but were nonetheless enriched in the ET and ETCC samples. Likewise, 
mB interaction partner LYAR83,84 was elevated specifically in the mB sample. The 
392 enriched proteins were distributed in the samples as follows: ET (165), ETCC 
(179), mB (232), CC (0), CCp (2), and CCd (8). These data suggest that the CC 
does not engage in protein interactions on its own (Table 4.1, Figure 4.4.B). 
To identify the proteins that associate most strongly with the GST-fusion 
proteins, we increased the threshold to log2ratio > 1.5. This identified interactions 
that had not been previously reported. For example, the ET domain associated 
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most strongly with AHNAK, AHNAK2, CBX4, ZMYND8 and ZNF592. Interestingly, 
when combined with the CC domain, ETCC associated with several additional 
proteins, including all five members of the RNA polymerase II-associated factor 
(PAF) complex (PAF1, LEO1, CTR9, CDC73, WDR61) as well as the PAF-
associated protein IWS1 (Figure 4.4.C, 4.4.D), which are involved in transcriptional 
elongation130,164,165. The ETCC domain also enriched all three members 
(CSNK2A1, CSNK2A2 and CSNK2B) of casein kinase II (CK2), which like PAF, 
has been shown to occupy active chromatin166, associate with elongation 
factors167, and contribute to POL2 regulation168. The CK2 complex also interacted 
with mB (Figure 4.4.B). Of note, CK2 has been shown to phosphorylate BRD4 at 
conserved region that partially overlaps with the mB sequence85, potentially 
accounting for its association with BRD2 mB in this assay.  
Western blots with antibodies against components of the PAF and CK2 
complexes confirmed association with GST-ETCC but less so or not at all with 
GST-ET or GST-CC (Figure 4.4.E). The ETCC-mediated interactions with PAF and 
CK2 were also observed when using the ETCC regions from BRD3 and BRDT, but 
not their ET domains alone (Figure 4.4.F). These results suggest that the BRD2 
and BRD3 CC domains augment the ability of the ET domains to engage in specific 
protein contacts.  
Binding patterns of PAF and CK2 on chromatin 
 The ETCC domain does not appear to alter BET protein binding but may 
facilitate PAF and CK2 recruitment to chromatin. To assess the feasibility of this 
mechanism, we measured the genome-wide distributions of the PAF complex 
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member LEO1 and the CK2 member CSNK2A1 in parental G1E-ER4 cells using 
ChIP sequencing and compared them to the distributions of YFP-BRD2. We limited 
our comparison of PAF and CK2 occupancy to that of YFP-BRD2 as the other 
YFP-BET proteins strongly resemble YFP-BRD2. Technical replicates for 
CSNK2A1 were highly correlated (Figure 4.5.A). The replicates for LEO1 were also 
correlated but to a lesser degree, likely due to the use of different chromatin 
fragmentation methods (see “Chapter 2: Materials and Methods” for details). Thus, 
in the following analysis, the CSNK2A1 signal from each replicate was merged, 
whereas for LEO1 each replicate was analyzed separately.  
We first assessed the overall binding of CSNK2A1 and LEO1 to various 
genomic positions to see if either resembled the overall distribution of YFP-BRD2. 
The distribution of CSNK2A1 more closely resembled that of YFP-BRD2 with 
>20% of peaks mapping to TSS regions, whereas both LEO1 samples had lower 
enrichment at TSS regions and greater enrichment at TTS and 3’ UTR regions 
(Figure 4.5.B). The distribution of LEO1 is consistent with the chromatin 
distributions of other PAF members130 and with PAF involvement in the elongating 
POL2 complex as it travels through genes164. To visualize these differences in 
more detail, we generated heatmaps and meta-profiles for each factor across 
genes. This reveals an accumulation of YFP-BRD2 and CSNK2A1 proximal to the 
TSS with some extension into the gene bodies (Figure 4.5.C). This distribution of 
CSNK2A1 is consistent with that of a previous study implicating CK2 directly in 
transcriptional elongation168. In contrast, LEO1 is most notably found in gene 
bodies toward the end of genes and in the 3’ UTR region downstream of the TTS. 
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Of note, the different profiles of LEO1_r1 and LEO1_r2, particular near the TSS, 
are consistent with previous reports of LEO1 occupancy using the different 
fragmentation methods used to prepare these samples. Sonication-based 
methods (as used for LEO1_r1) yield stronger LEO1 signal near the TSS130,169, 
whereas enzyme-based methods (using endo/exo-nucleases, as used for 
LEO1_r2) yield a relative absence of LEO1 at the TSS170. This may be due to 
digestion of nucleosome-depleted chromatin at the TSS using enzymatic 
fragmentation. Though the distributions may differ, the cumulative intensity of each 
factor (both LEO1 replicates, CSNK2A1, and YFP-BRD2) over these regions is 
positively correlated suggesting co-involvement in gene transcription. The similar 
distributions of CSNK2A1 and YFP-BRD2 on chromatin support the notion of a 
stable interaction in vivo, though it can’t be ruled out that these factors are recruited 
independently to genes. The different patterns of YFP-BRD2 and LEO1 suggest 
that any bona fide interaction may occur transiently or perhaps before both factors 
assemble on chromatin.  
 Because CK2 colocalizes with BET proteins on chromatin and has also 
been shown to phosphorylate PAF, we hypothesized that phosphorylation may at 
least partially regulate the stability of the ETCC domain bound to PAF. We 
therefore repeated GST-ETCC pulldown assays using nuclear extracts generated 
from parental G1E-ER4 cells in the presence of phosphatase inhibitors, which 
preserve the overall phosphorylated state of the protein lysate. Strikingly, addition 
of phosphatase inhibitors dramatically hindered the interaction between the ETCC 
domain and all five members of the PAF complex (Figure 4.5.D). This finding 
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suggests that CK2, or perhaps one of the other promoter-proximal kinase, may 
regulate the affinity of the BRD2/3-PAF interaction on chromatin via 
phosphorylation. This mechanism may account for the reduced TSS-proximal 
localization of LEO1 on chromatin. Based on our findings, we propose a model by 
which BRD2/3 contributes to transcriptional regulation distinctly from BRD4 (Figure 
4.5.E). We speculate that BRD2/3 functions to recruit PAF to the TSS and that 
subsequent phosphorylation of the PAF complex by CK2 causes its disassociation 
from BRD2/3 into the elongating POL2 complex, allowing transcription to proceed.  
Discussion 
BET proteins are transcriptional regulators that share a conserved domain 
structure. In the previous chapter, we found that despite this shared structure, 
BRD2 and BRD3 contribute to transcription independently of BRD4. We traced this 
unique BRD2/3 function to the ETCC region, which BRD4 lacks. In this chapter, 
we explored whether the ETCC region may affect BRD2/3 function by influencing 
where BRD2 and BRD3 bind the genome in comparison to BRD4S. Surprisingly, 
we found this not to be the case. All three BET proteins bind the genome at GATA1 
sites but not CTCF sites and undergo similar changes in occupancy upon erythroid 
differentiation. Though BRD4S signal is lower at these sites, exchanging the 
bromodomain-containing segment with that of BRD2, but not the ET/ETCC-
containing segment, restores binding to BRD2 levels during erythroid maturation. 
Together, these data indicate that distinct BET protein functions are not related to 
differences in genomic localization. Instead, we found that the ETCC domain forms 
contacts with the PAF and CK2 complexes, both of which have been implicated in 
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transcription. Though PAF and CK2 colocalize with BET proteins at promoters, the 
majority of PAF is found over gene bodies and its interaction with the ETCC domain 
is phosphorylation-dependent, suggesting that it may transiently engage with 
BRD2/3 in a regulated manner. In summary, we conclude that the ETCC region 
functionally distinguishes BRD2/3 from BRD4 via the recruitment of distinct partner 
proteins that regulate transcription. 
The lack of colocalization between BRD2 and CTCF in this study is not 
consistent with our previous observation131. Technical differences may have 
contributed to the discrepancy. For example, our current study used MNase 
digestion rather than sonication to fragment DNA and used an antibody targeting 
ectopically expressed YFP-BRD2 instead of endogenous BRD2. These 
parameters were chosen after several rounds of optimization to yield strong and 
reproducible ChIP signal. It is conceivable that MNase preferentially degrades 
CTCF-associated DNA (though unlikely based on preliminary experiments). 
Likewise, it is possible that the YFP epitope blocks BRD2 binding at CTCF sites. 
However, more elusive technical differences are likely to blame, as we were unable 
to re-demonstrate endogenous BRD2 binding at CTCF sites using sonication-
based fragmentation and a newer lot number of the initial BRD2 antibody. It is 
important to note that several other studies have observed some degree of BRD2-
CTCF colocalization122,129. However, these experiments were performed using the 
same BRD2 antibody and were published in the same time frame as our previous 
study, suggesting that this finding may be specific to a particular batch of the BRD2 
antibody. Several BRD2 ChIP sequencing studies have been published in the 
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meantime using various antibodies and experimental approaches56,102,110,118,171. 
Future studies should perform CTCF ChIP sequencing in these models to 
thoroughly address the robustness of the overlap between BRD2 and CTCF 
across experimental systems and approaches.  
Several studies have reported the distributions of BRD2, BRD3, and BRD4 
on chromatin63,96,102,110,114,117,118,129,160,171. These studies use antibodies targeting 
the endogenous BET proteins. Therefore, the signal intensity is dependent on the 
amount of protein expression and the affinity of the antibody. These biological and 
technical differences may account for the partially different binding patterns when 
comparing BRD2, BRD3, and BRD4. Our study overcomes these limitations by 
using a tightly controlled ectopic system in which each BET protein is expressed 
at levels comparable to endogenous BRD2 and shares the same epitope tag for 
immunoprecipitation. Using this approach, we report strikingly similar genomic 
binding profiles of BRD2, BRD3, and BRD4S. This indicates that when BET 
proteins are expressed at equal levels and immunoprecipitated with the same 
antibody, they yield nearly identical chromatin binding patterns. This finding has 
several implications. First, differences in the affinities of the BET protein 
bromodomains for various acetylated substrates are unlikely to drive global 
differences in BET protein localization. Second, differences in BET protein function 
observed by us and others are not likely due to differential binding. Instead, BET 
proteins appear to co-congregate at highly acetylated chromatin near promoters 
and enhancers after which they then exert their unique influences on transcription.  
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Our study used BRD4S rather than BRD4L for our comparisons to BRD2 
and BRD3 because BRD4S structurally resembles these proteins in size. 
Therefore, our YFP-BRD4S ChIP sequencing data may not be representative of 
BRD4L, which is the dominant isoform expressed in G1E-ER4 cells and the 
isoform assayed in virtually all previously published BRD4 ChIP sequencing 
studies. Because previous studies suggest that BRD2 prefers promoters and 
BRD4L prefer enhancers, future studies should test whether this holds true when 
BRD2 and BRD4L are expressed at equal levels and precipitated with the same 
antibody. If so, our data would suggest that these predilections for genomic regions 
are driven not by bromodomain interactions but by protein-protein associations 
mediated by the C-terminal domains. In particular, BRD2 may associate more 
tightly with PAF and/or CK2 at promoters, whereas BRD4L may associate 
preferentially with PTEFb at more distal elements67,172. Future studies should also 
address how the ratio of BRD4S to BRD4L is regulated, as BRD4S appears to be 
the dominant isoform in some cell types70, and whether this stoichiometry has an 
effect on transcription.  
To investigate how the ETCC domain contributes to BRD2/3-selective 
function, we identified partner proteins using a proteomic approach. This revealed 
PAF and CK2 as the dominate ETCC-specific interactions. Because BRD4 does 
not possess the ET-proximal CC, BRD4 is not predicted to interact with PAF and 
CK2 by this mechanism. However, CK2 is known to phosphorylate BET proteinsat 
a conserved serine-rich region that partially overlaps with the mB segment used in 
this study85. Thus, mB-mediated enrichment of CK2 (Figure 4.4.B) likely relates to 
122 
 
this enzyme-substrate binding event and applies to BRD2, BRD3, and BRD4 
equally. It is plausible that CK2 phosphorylates serine-rich regions in the ETCC 
domain of BRD2 and BRD3 in a similar manner, but this is unlikely given that 
neither the ET nor CC domains alone enrich CK2 and no predicted CK2 substrates 
span the ET-CC junction (NetPhos 3.1). Thus, whereas CK2 may engage BRD2 
and BRD3 via multiple contacts, it likely only binds BRD4 via phosphorylation near 
the mB region. This is supported by immunoprecipitation data which revealed CK2 
is more highly enriched with the CC-containing BRD2/3/T proteins compared to 
BRD4, and that these interactions are enhanced upon bromodomain inhibition, 
indicating that they are mediated by C-terminal protein-interaction domains such 
the ETCC rather than by the bromodomains31. Future studies should address 
which subunit of CK2 directly contacts the ETCC and whether it does so in a 
manner similar to PAF.  
Like CK2, PAF has been found in previous BET protein interaction 
studies30,71, but it is notably absent in others31. These differences may be due to 
biological and technical variability between studies and the relatively weak nature 
of the interaction. For example, immunoprecipitation-based studies are limited by 
protein abundance, antibody quality, and protein extraction conditions. Even under 
ideal conditions, such as our GST pulldown assay in which large amounts of bait 
protein encompassing the interaction surface are used, we find the PAF 
association to be subject to the presence or absence of phosphatase inhibitors in 
solution. We also find that in vivo crosslinking (ChIP sequencing) only captures a 
minority of PAF co-localized with BET proteins on chromatin. Together, these 
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observations suggest that the BRD2-PAF interaction is transient and highly 
regulated by phosphorylation and/or other post-translational modifications.  
Future studies should confirm that full-length BRD2 and BRD3, but not 
BRD4, use the ETCC domain to associate with PAF and CK2. Based on the 
limitations of immunoprecipitation described above, approaches that use highly 
expressed or purified proteins, such as baculovirus-insect cell expression or in vitro 
transcription/translation, should be leveraged for this line of investigation. Once the 
individual partner proteins are identified from these multi-unit complexes, structural 
studies will be required to fully elucidate the details by which the ETCC binds to 
PAF and CK2. The role of phosphorylation in regulating the strength of these 
interaction must be considered through the use of phosphatase inhibitors and 
exogenous phosphatase. Ultimately, the exact residues that are phosphorylated 
and the kinases and phosphatases implicated in this regulatory mechanism should 
be identified and their role in transcription described.  
In addition to identifying PAF and CK2 as ETCC-specific interactions, we 
also identified ZMYND8 as the strongest ET-only interaction. ZMYND8 has been 
shown to form a highly abundant trimeric complex with ZNF592 and ZNF687 (Z3 
complex)173,174, both of which were also present in our proteomic data (though not 
as highly enriched). Previous studies have shown ZMYND8 to associate with BET 
proteins, including the BRD4-NUT fusion protein30,31,92. As in our study, this 
interaction appears to occur via the ET domain31.  Interestingly, ZMYND8 can function 
both as a transcriptional activator and as repressor, depending on whether it is in its 
monomeric or dimeric state175. In its dimeric state, ZMYND8 interacts with PTEFb 
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whereas as a monomer ZMYND8 interacts with the CHD4 component of the nucleosome 
remodeling and deacetylase (NuRD) complex175,176, both of which also associate with 
the ET domain. Further investigation into the role of the ET domain in mediating the 
various conformations of ZMYND8 and the impact of this on transcription is required. A 
direct fusion between BRD4 and ZNF592 (a component of the Z3 complex with 
ZMYND8) mimics BRD4-NUT in the molecular pathogenesis of NUT midline 
carcinoma177 indicating that the Z3 complex may be a major mediator of BET 
protein function. In addition to transcription, ZMYND8 may also coordinate with 
BET proteins and NuRD to facilitate double-strand break (DSB) repair127,178,179. 
These data support a multifunctional role for BET proteins via the recruitment of 
diverse chromatin regulators.  
The presence or absence of the CC domain may influence the strength of 
ET-mediated interactions with other protein complexes. For example, 
ZMYND8/ZNF592, TBLX1, and AHNAK/AHNAK2 are strong ET-only interactions, 
but their signal is reduced when the CC is included in the ETCC sample. In 
contrast, PAF and CK2 proteins are more enriched in the ETCC sample compared 
to the ET-only sample (Figure 4.4.B/C). As mentioned above, ZMYND8 and 
ZNF592 are components of the Z3 complex. TBL1X is a component of the nuclear 
receptor co-repressor (NCoR) complex180. Several other NCoR members 
(TBL1X1R1, NCOR1, NCOR2, HDAC2, and HDAC3) are enriched in the ET 
sample (Table 4.1). Together, these data suggest that whereas PAF and CK2 
preferentially associate with BRD2 and BRD3, Z3 and NCoR may preferentially 
bind to BRD4 which lacks the CC. This differential recruitment of transcriptional 
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regulators may have functional consequences. For example, preferential 
recruitment of NCoR, a repressive complex, may explain the growth restriction and 
reduced gene expression observed when BRD4S is over-expressed in G1E-ER4 
cells. The ETCC module may therefore control the major transcriptional 




Figure 4.1. YFP-BET proteins bind to similar regions of the genome. A) Left: 
Representative scatter plot comparing chromatin binding signal at transcription 
start sites (500 bp windows) between two technical replicates with the Pearson 
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correlation coefficient indicated. Right: Summary table of all of the Pearson 
correlation coefficients at transcription start sites and annotated enhancers 
between technical replicates. B) Average YFP-BET chromatin binding signal 
across 2kb regions spanning all CTCF and GATA1 binding sites113,131. C) YFP-
BET binding at 2kb regions spanning YFP-BRD2 binding sites that are gained or 
lost upon GATA1-ER activation. D) Percent/frequency of gained or lost binding 
sites upon GATA1-ER activation for each YFP-BET protein categorized based on 
proximity to known genes. E) Genome browser view of the Csf2rb locus, 
representing a region all YFP-BET proteins are recruited upon GATA1-ER 
activation despite some (YFP-BRD2/3/4-2) having more activity than others in the 
expression of the Csf2rb and Csf2rb2 genes.  
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Figure 4.2. Identification of differential YFP-BET binding sites. A) Volcano plots 
depicting the mean YFP-BET binding signal for YFP-BRD2/3/4-2 in comparison to 
YFP-BRD4S/2-4S before or after 24 hours of GATA1-ER activation (+/- E2). Each 
dot represents a differentially bound peak. Red dots are differentially bound peaks 
at an FDR ≤ 0.05. The number of such peaks is indicated. B) Genome browser 
views of representative differentially bound peaks. The peaks of interest are in a 
dashed box. C) Top 5 de novo motif analysis results with motif logos, best matched 
transcription factors and P-values indicated of the indicated sets of differentially 




Figure 4.3. The CC has helical structure but does not homo- or hetero-dimerize in solution. 
A) Far-UV circular dichroism spectra of hBRD2-CC (20 µM) and hBRD3 (45 µM). Spectra were 
obtained in 10 mM Tris pH 7.2, 100 mM NaCl and 1 mM TCEP at 4 ºC. B) SEC-MALLS data 
showing that hBRD2 and hBRD3 CC regions are monomers in solution. hBRD2 CC, hBRD3 CC or 
an equimolar mixture of the two proteins (total protein concentration = 700 µM in each case) was 
injected onto a Superdex 75 10/300 GL (for hBRD2 CC and h BRD3 CC) or Superdex peptide 
10/300 GL (for the hBRD2+hBRD3 CC mixture). The calculated molecular weight is shown together 
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Figure 4.4. The combined ETCC module binds to the RNA polymerase II-
associated factor (PAF) and casein kinase 2 (CK2) complexes. A) 
Experimental schematic of GST pulldown assay. B) Volcano plots depicting 
enrichment of bait proteins in each sample in comparison to GST alone controls. 
Prey proteins that exceed a log2ratio of 1.5 and -log10Qvalue of 4 (dashed lines) 
are labeled in red. Blue and green dots represent proteins known to interact with 
the ET domain (blue) or mB domain (green) as described in the text. C) Volcano 
plot comparing prey proteins enriched by the ET domain alone or the combined 
ETCC. Prey proteins exceeding log2ratio of 1.2 and -log10Qvalue of 4 are labeled 
in blue if higher in the ET sample and red if higher in the ETCC sample. Members 
of the PAF complex are colored green and members of CK2 are colored purple. 
D) Protein interactions (from STRING) of ETCC-high proteins. Purple lines indicate 
experimental determined protein interactions. Blue lines indicate interactions from 
curated databases. E) Western blot validation of PAF and CK2 complex members. 
F) Western blot validation of PAF and CK2 interactions with the ETCC domains 





Figure 4.5. Comparison of YFP-BRD2, CK2 and PAF localization across the 
genome. A) Scatter plot comparing technical replicates of CSNK2A1 and LEO1 
chromatin occupancy consensus peaks for each factor labeled with Pearson 
coefficients and p values for the correlation. See text for technical differences 
between replicates LEO1_r1 and LEO1_r2. B) Percent/frequency of binding sites 
for YFP-BRD2, CSNK2A1 and each LEO1 replicate categorized based on 
proximity to known genes. C) Meta-profiles and heatmap matrix illustrating 
average and individual chromatin binding distributions of YFP-BRD2, CSNK2A1 
and LEO1 across all known genes including the flanking 3kb regions. Gene lengths 
are normalized to 100 bins. D) Western blot detection of PAF members pulled 
down by GST-ETCC with or without the presence of phosphatase inhibitors. ACTB 
and GST are included as a negative and positive pulldown controls. E) A 





Prey proteins detected by each GST-fusion bait protein 
ET ETCC 
Myb Rpl35a Phf8 Tceb1 Rpl6 Grwd1 
Prrc2c Cbx4 Ppp1r10 Xrn1 Rplp1 Mphosph10 
Ints3 Hdac3 Med23 Lims1 Rpl5 Smndc1 
Lims1 Rpl7 Cwf19l2 Rpl23a Rpl13 Cggbp1 
Hdac2 Srp54 Tbl1xr1 Wdr61 Rpl26 Gltscr2 
Polr2a Rpl13a Znf592 Rpl19 Rpl27 Rcc2 
Smarca4 Hspa5 Mtbp Zmym4 Rpl37a Rpl24 
Med25 Tln1 Rcc2 Mllt3 Rps7 Rsl1d1 
Wdr61 Pik3r1 Ticrr Mrto4 Rps8 Iws1 
Gpatch8 Pura Lrch3 Tpx2 Rps14 Rbm14 
Cdc27 Cct8 Chd9 Ythdc2 Rps23 Utp15 
Med14 Hist1h1e Anapc2 Actb Rps11 Tceb3 
Mllt3 Rpl6 Med19 Rbm34 Rps13 Rbm28 
Tpx2 Rplp1 Tbl3 Llph Rps4x Gnl3 
Raly Rfx1 Bcor Aff3 Rpl18a Kdm1b 
Mga Cit Ago1 Whsc1 Rps6 Cdc73 
Actb Anapc1 Cdc73 Bre Tceb2 N4bp2l2 
Twistnb Wdr5 Bclaf1 Mki67 Rpl31 Polr1e 
Kif7 Ybx1 Taf10 Rplp0 Rpl32 Pop1 
Cep57 Rps27a Pop1 Nolc1 Rpl8 Pacs1 
Mbd3 Ywhah Paf1 Kif23 Ybx1 Paf1 
Anapc7 Erh Mepce Rnf169 Actg1 Mepce 
Aff3 Smarcc1 Tada3 Ankrd17 Rps17 Ccdc137 
Thoc6 Hnrnpul2 Luzp1 Ddx55 Csnk2b Nop14 
Whsc1 Prpf4 Nol6 Rpl15 Erh Luzp1 
Urb1 Larp7 Taf9 Inf2 Bop1 Nol6 
Mki67 Tfdp1 Traip Nop2 Rplp2 Imp4 
Gm8730 Chd8 Med28 Rpl29 Sap30bp Traip 
Kif14 Vrk3 Smc6 Rps18 Larp7 Ddx1 
Ankrd11 Rfc3 Med1 Taf5 Eif5b Znf622 
Kif23 Gtf3c3 Cdk9 Ddx24 Ect2 Taf5l 
Ahnak Zmynd8 Med24 Zc3h18 Chd8 Arrb2 
Ercc2 Mta3 Yaf2 Rpf2 Gpatch4 Ppan 
Rnf169 Rfc4 Med30 Tcof1 Mybbp1a Ddx27 
Ddx55 Lsg1 Rnf2 Rpl10 Utp18 Prpf3 
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Hjurp Eef1g Med31 Dnmt1 Rrp12 Cdk9 
Gatad2a Atad5 Mau2 Rpl21 Sf3b2 Gnl2 
Med16 Actl6a Haus5 Dhx15 Lsg1 Mmtag2 
Rpl29 Orc2 Ccdc101 Csnk2a2 Rpl4 Gtpbp4 
Ahnak2 Thrap3 Ftsj3 Eif6 Nufip2 Npm3 
Pcnt Ttf2 Ipo7 Rpl35a Npm1 Nop16 
Taf5 Kat7 Mllt1 Cbx4 Leo1 Rpl14 
Ncor2 Leo1 Aff4 Ncl Rpl10a Hnrnpa0 
Ddx24 Setd5 Hic2 Rpl7a Csnk2a1 Med31 
Ppp2r1b Pml Tbl1x Dnmt1 Khdrbs1 Rpl11 
Brf1 Rbbp4 Exo1 Rpl27a Kpna1 Rpl34 
Rnf219 Rbbp7 Med20 Rpl7 Ctr9 Mau2 
Rpf2 Hcfc1 Prpf40a Rplp0 Top2b Ebna1bp2 
Tcof1 Smarcd1 Racgap1 Hist1h1c Zcchc2 Pelp1 
Opa1 Taf6 Nup160 Rpl13a FAM120A Ftsj3 
Dnmt1 Zcchc2 Adnp Rps2 Nop58 Brix1 
Hdac1 Arhgap21 Ik Tln1 Ddx31 Mllt1 
Rpl21 Nipbl Orc1 Rpl3 Bms1 Aff4 
Pold2 Whsc1l1 Mbd3 Pabpc1 Rps9 Tmod3 
Slk Tubb2a Mbd2 Rpl12 Rpl36 Utp3 
      Chd1 Rpl17 Rcl1 
      Rpl28 Cd3eap Exo1 
      Pura Ppp1r10 Racgap1 




Prey proteins detected by each GST-fusion bait protein 
(continued) 
mB CCd CCp 
Msh3 Pnn Rps10 Rbm28 Gpatch8 Mov10 
Dhx30 Bysl Ppp2ca Sltm Hnrnpl Abcf1 
Rbpj Csnk2a2 Csnk2b Gnl3 Actg1   
Rpl23a Smarce1 Polr1b N4bp2l2 Ywhah   
Wdr61 Eif6 Rpl36a Polr1e Khdrbs1   
Rpl19 Rpl35a Erh Pop1 Cyfip1   
Gemin5 Gtf2h4 Polr1d Nat10 Rbm14   
Mrto4 Ncl Rps3a1 Paf1 Ipo7   
Tpx2 Rpl7a Smn1 Wdr33     
Ubtf Dnmt1 Rplp2 Sf3b4     
Casc5 Rpl27a Hnrnpul2 Ccdc137     
Rps16 Rpl7 Cdk7 Pspc1     
Slfn8 Rpsa Top1 Nop14     
Lrrc47 Hist1h1c Akap8 Nol6     
Ythdc2 Srp14 Larp7 Znf385a     
Actb Rpl13a Eif5b Hnrnpr     
Twistnb Rps2 Gpatch4 Traip     
Ddx18 Rpl3 Srsf10 Rbmxl1     
Rbm34 Rpl12 Fam98a Ddx1     
Gfi1b Chd1 Mybbp1a Znf622     
Cbfa2t3 Rpl28 Dazap1 Arrb2     
Cep57 Hist1h1e Rrp12 Gtf2h2     
Ylpm1 Hist1h1a Eif2s2 Sf3b3     
Llph Rpl6 Lsg1 Ddx27     
Rps5 Rplp1 Serbp1 Smc6     
Sf1 Rpl5 Polr2e Eif3m     
Urb1 Rpl13 Nmnat1 Gnl2     
Msto1 Cit Ddx47 Mmtag2     
Ankhd1 Ercc3 Rpl4 Gtpbp4     
Farsa Polr1c Nufip2 Npm3     
Gm8730 Snrpa1 Npm1 Nop16     
Nolc1 Fam207a Leo1 Nop10     
Kif23 Rpl26 Rpl10a Rpl14     
Ercc2 Rpl27 Csnk2a1 Nhp2     
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Rnf169 Rpl37a Fxr1 Rpl11     
Ankrd17 Rps8 Srsf2 Ilf2     
Ddx55 Rps15a Snrnp70 Skiv2l2     
Fmr1 Rps14 FAM120A Rps19     
Rpl15 Rps23 Ncapg2 Ndc80     
Gtf2h1 Rps29 Nop58 Rpl34     
Nop2 Rps11 Pdcd11 Nop56     
Dhx9 Rps13 Ddx31 Ebna1bp2     
Rpl29 Rps4x Rps9 Ftsj3     
Rps18 Rpl18a Rpl35 Brix1     
Srbd1 Rps6 Rpl36 Aff4     
Cdc45 Rps15 Rps12 Utp3     
Ddx24 Rps24 Rpl17 Ddx21     
Zc3h18 Rps25 Cd3eap Rcl1     
Rpf2 Tceb2 Znrd1 Ddx20     
Trip12 Rpl30 Safb2 Hic2     
Tcof1 Rpl39 Smndc1 Plec     
Knop1 Rpl31 Noc4l Uchl5     
Rpl10 Rps3 Gltscr2 Racgap1     
Dnmt1 Rpl32 Rcc2 Ik     
Rpl21 Rpl8 Rpl24 Orc1     
Polr1a Rps27a Naa25 Ilf3     
Srsf5 Actg1 Utp15       
Kpna6 Rps17 Smc5       
Table 4.1. GST protein pulldown assay results. Target/bait proteins from 
nuclear extracts pulled down by each GST-fused prey proteins (GST-ET, GST-
ETCC, GST-mB, GST-CCd, GST-CCp are listed. No proteins were detected in the 
GST-CC sample. Protein enrichment was measured using standard mass 
spectrometry label-free quantification (See “Chapter 2: Materials and Methods”). 
Only proteins with enrichments exceeding a log2ratio>1 over GST-alone controls 









BET proteins are transcriptional regulators implicated in multiple 
developmental and pathological pathways. As such, they have emerged as 
attractive therapeutic targets for many diseases, but their pharmacological 
inhibition can impair normal processes. Because the current inhibitors typically 
target the highly conserved BET bromodomains, many of these drugs cannot 
discriminate between individual BET proteins. Fundamentally, it remains unclear 
how individual BET proteins contribute distinctly to transcription and whether 
targeting single BET protein family members would be of therapeutic value. In this 
study, we set out to better understand the extent to which BET proteins BRD2, 
BRD3, and BRD4 differ functionally and to discover the domains and mechanisms 
by which they do so. We used the G1E-ER4 erythroid cell line, a model system 
where BET proteins are critical to cell growth and GATA1-mediated differentiation 
and found a key functional domain that may mechanistically distinguish BRD2 and 
BRD3 from BRD4. We posit that targeting this region, termed the ETCC, may 
provide a BRD2/3-specific drug that prevents the recruitment of certain 
transcriptional regulators. In this chapter, we expound upon this concept, discuss 
limitations of this work, and propose future studies to examine the mechanistic 
detail and broader applicability of these findings.   
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Distinct BET protein functions revealed by gene rescue and domain mapping 
Previous studies have shown that depletion of individual BET proteins 
results in distinct phenotypes (see “Chapter 1, Evidence for distinct BET protein 
functions”). In support of BET protein family members functioning distinctly, our 
work in G1E-ER4 cells suggests that BRD2 and BRD4 have independent roles in 
GATA1-mediated erythroid maturation. BRD3 behaves more similar to BRD2 in 
this context. We draw this conclusion based on gene rescue studies performed by 
ectopically expressing BET proteins in BRD2 knockout cells. An important 
limitation to this work is the lack of reciprocal experiments performed in BRD4-
depleted cells. We have been unable to generate BRD4 knockout G1E-ER4 cells, 
perhaps because BRD4 is required for cell survival. However, decreased BRD4 
expression and reduce erythroid maturation using RNA interference (RNAi) can be 
achieved113. Future experiments should be designed to test whether ectopic BRD2 
and BRD3 expression can protect cells against defects associated with BRD4 
depletion using this method. Based on our hypothesis, we would expect that 
neither BRD2 nor BRD3 can compensate for BRD4 function.  
It will be interesting to note whether ectopic BRD4S or BRD4L in isolation 
will protect against RNAi-related defects. To the best of our knowledge, BRD4L is 
the dominantly expressed isoform in this cell type, but BRD4S transcripts are 
expressed and BRD4S has been implicated in transcription in other cell types. For 
example, in CD4+ T cells, BRD4S is abundantly expressed and recruits SWI/SNF 
remodelers70. In cancer cells, BRD4S levels vary but correlate with nuclear puncta 
formation and exert BRD4L-independent effects on gene expression181. In some 
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cancers, BRD4S may oppose BRD4L or function independently to promote tumor 
growth and metastasis81,182. Thus, it is conceivable that both isoforms are 
necessary for erythroid maturation, which can be teased apart using a combination 
of isoform-targeted RNAi and ectopic BRD4S/L expression. 
Identifying the structural basis for overlapping BRD2 and BRD3 function  
In the absence of a distinct structural domain, it remained unclear prior to 
our study how BRD2 and BRD3 could function separately from BRD4, especially 
given that the bromodomains and ET domains are well-conserved across the 
family. Our domain mapping approach revealed that the extended ET domain, 
containing a coiled coil (ETCC) in BRD2 and BRD3 but not in BRD4S, is the critical 
region distinguishing these proteins. This finding contributes to a mechanistic 
model of how BRD2 and BRD3 can function distinctly from BRD4. For example, 
BRD4-specific activity is generally attributed to the CTM on the extended C-
terminal tail of BRD4L. Based on our domain mapping, we can now attribute 
BRD2/3-specific activity to the ETCC domain. Whereas it is thought that the CTM 
enables BRD4 to strongly associate with PTEFb, we propose that the ETCC 
domain enables BRD2 and BRD3 to more strongly associate with PAF and CK2. 
These distinct functions are likely in addition to shared functions, such as binding 
acetylated chromatin via the conserved bromodomains and recruiting NSD365 and 
JMJD667 by the conserved ET domains. We therefore suggest a model in which 
individual BET proteins function distinctly but interdependently to coordinate the 
recruitment of multiple transcriptional regulators to chromatin.  
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Several additional gene rescue studies are needed to bolster this model. 
First, additional chimeric BET proteins should be designed to test the ETCC 
domains from BRD3 and BRDT. Based on their ability to bind PAF and CK2, we 
hypothesize that the ETCC from these proteins should function similarly to the 
BRD2 ETCC in their ability to impart activity to BRD4S in gene rescue assays. 
Chimeric BET proteins possessing the BRD4L tail containing the CTM should also 
be constructed. We might expect that addition of the BRD4L tail to BRD2 would 
impart BRD4L-like activity to BRD2. In effect, this construct would resemble BRDT, 
which has the key structural features of both BRD2 (the ETCC) and BRD4 (the 
CTM). We did not include BRDT in our gene rescue assays, but it’s potential pan-
BET functionality in G1E-ER4 cells based on possession of both the ETCC and 
CTM domains may be a useful comparison in future experiments. BRDT is not 
expressed in G1E-ER4 cells, but we hypothesize that its ectopic expression might 
compensate for both BRD2 and BRD4 loss.  
Structure-function considerations related to BRDT  
As noted above, BRDT possesses both the ETCC domain shared by BRD2 
and BRD3 and the CTM domain of BRD4. The function of BRDT in comparison to 
the other BET proteins warrants further exploration. In the testis, where it is 
exclusively expressed19, BRDT is required for proper spermiogenesis24 likely due 
to an ATP-independent structural role it plays in large scale chromatin re-
organization involving histone compaction and protamine replacement183–186. 
Though the pronounced nuclear reorganization that occurs during spermatid 
formation highlights the role of BRDT in chromatin structure, other BET proteins 
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have been also been implicated in chromatin organization. For example, the yeast 
homologue BDF1 maintains euchromatin by preventing heterochromatin spread at 
transcriptional boundaries187, and mammalian BRD4 regulates nucleosome 
density79,188. Moreover, BRD2, BRD3, and BRD4 all exhibit in vitro histone 
chaperone activity that is independent of the CTM (in the case of BRD4) and 
specific for acetylated histones40,41. Thus, though it is tempting to ascribe a unique 
role for BRDT in this process, the other BET proteins may contribute to structural 
changes during spermiogenesis and may mediate similar acetylation-dependent 
nucleosomal dynamics in other cell types.  
In addition to its structural function, BRDT also mediates testis-specific gene 
activation via CTM-recruitment of PTEFb to gene promoters, akin to canonical 
BRD4-related transcriptional regulation186. Thus, BRDT likely contributes to 
spermiogenesis in two fundamental ways: 1) activation of genes required for 
meiosis and 2) nuclear compaction and histone removal. Interestingly, other BET 
proteins are expressed in the testis and contribute to spermiogenesis. In fact, Brd4 
heterozygous null mice have reduced spermiogenesis23, and BRD4 was shown to 
co-bind BRDT-bound promoter of active genes in spermatids189. Not unexpectedly, 
BET bromodomain inhibition using small molecule JQ1 results in meiotic arrest 
and reduced fertility in male mice190. The fact that BRDT and BRD4 are both 
required in the testis suggests that they have undergone some level of functional 
specification. For example, comparison of BRD4 and BRDT genome occupancy in 
post-meiotic spermatids revealed that only a small percentage of BRDT was found 
at gene promoters in comparison to BRD4189. And whereas BRD2 and BRDT 
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localize diffusely throughout the nucleus in the late stages of spermatid 
development, BRD4 forms a distinct ring-like structure adjacent to the cytoskeletal 
acrosome in a confined band around the nuclear periphery189. Of note, it is unclear 
if these structures involve full length BRD4 or a smaller noncanonical, possibly 
testes-specific isoform. This technical caveat may be meaningful given that the 
canonical BRD4S isoform associates preferentially with the nuclear envelope 
whereas BRD4L concentrates in the salt-extractable nuclear matrix82. Thus, 
differences in BET protein localization, genome occupancy, and function due to 
testes-specific regulation of endogenous proteins is unlikely. Instead, such 
dramatic differences likely reflect intrinsic protein attributes such as the gain/loss 
of entire domains. For example, the intranuclear compartmentalization of BRD2 
and BRDT versus the acrosomal localization of BRD4 might be explained the 
shared possession of the ETCC by BRD2 and BRDT but not BRD4. Thus, future 
studies should compare these proteins head-to-head in G1E-ER4 cells using 
equally expressed and epitope tagged constructs. This may lead to new insights 
about how the CTD-containing proteins BRD4L and BRDT function distinctly from 
one another in comparison to BRD2, BRD3, and BRD4S.  
In the absence of a robust cell culture system for modeling spermiogenesis, 
it may be difficult to tease apart the unique or overlapping roles of each BET protein 
– and map these similarities/differences to certain domains – as we have in the 
G1E-ER4 system which allows for gene rescue experiments. Nevertheless, 
spermiogenesis provides a unique biological setting to track differences in 
endogenous BRD2, BRD3, BRD4, and BRDT genomic distributions and protein 
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interaction networks through each stage of sperm development. The importance 
of BET protein function in sperm development is showcased in Drosophila, which 
lack a testis-specific paralog. In this setting, two proteins critical for spermatocyte 
development, tBRD-1 which lacks an ET domain and tBRD-2 which lacks a second 
bromodomain, can dimerize to reconstitute a BRDT-like BET isoform191. Future 
studies examining their individual and combined function can help isolate the 
critical domains necessary for BRDT’s role and may provide a window of insight 
into general BET protein function. 
Mechanisms of PAF recruitment by BET proteins 
Validation and further characterization of ETCC-mediated interactions with PAF  
We found that the GST-ETCC fusion proteins from BRD2, BRD3, and BRDT 
were able to precipitate the PAF complex from solution. This reproducibility across 
conserved but not identical ETCC sequences reassures us that is not a spurious 
finding. However, several experiments are required to fully validate the functional 
significance of this interaction. First, point mutations in conserved residues 
comprising the CC should be explored for their ability to reduce PAF binding 
without interrupting ET only-interactions. We have preliminary identified a set of 
proline insertions predicted to abrogate the coil (mutations depicted in Figure 4.4.A 
as CCp but data not shown) that when placed into ETCC reduce PAF signal 
without altering CDK9, an ET-only interaction. Interestingly, the leucine to aspartic 
acid mutations (depicted in Figure 4.4.A as CCd but data not shown) are also 
predicted to disrupt the coil but do not reduce PAF enrichment. Thus, the effect of 
these mutations on the structure of the ETCC domain should be verified using 
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circular dichroism to determine the role of the helical component on these 
interactions. Second, after isolating point mutations that abrogate the PAF 
interaction without compromising the ET domain, BRD2 constructs harboring 
these mutations should be expressed in Brd2-null G1E-ER4 cells so that their 
function in cell growth and GATA1-mediated differentiation can be assessed. Last, 
PAF occupancy should be measured in these BRD2 ETCC mutant-reconstituted 
cells to determine the impact of the ETCC mutations on PAF recruitment to BRD2-
bound genes. 
The GST pulldown experiments used large, micromolar amounts of GST-fused 
bait proteins to identify partners, in essence flooding the reaction with the interaction 
surface of interest. One advantage of this strategy is that the domain of interest 
has already been defined functionally and thus large amounts of it can be used to 
uncover weaker but still meaningful protein interactions that are perhaps 
overlooked when full-length BET proteins are used. A disadvantage, however, is 
that the ETCC domain in this case has been taken out of the context of the properly 
folded full-length protein, and thus interaction surfaces on the ETCC may be 
exposed that do not normally occur. Further complicating the matter is that 
transient interactions may be tightly regulated through post-translational 
modifications that alter protein conformation to open and close an interaction 
surface. For example, a phosphorylation-induced intramolecular switch was 
proposed to toggle BET proteins between two different conformations, one of 
which exposes the second bromodomain to form contacts with acetylated 
chromatin85. These factors must be considered when interpreting the following 
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observations: 1) despite robust interaction with the ETCC in our GST pulldown 
assays, PAF members are inconsistently co-immunoprecipitated with BET 
proteins30,31,71, 2) only a fraction of PAF co-localizes with BET proteins on 
chromatin, and 3) the ETCC-PAF interaction is sensitive to phosphorylation. Future 
studies using orthogonal approaches and not limited to a single modality192 are 
required to identify the exact conditions under which these proteins associate and 
the implication of these interaction on transcription.  
Toward this goal, we recommend against co-immunoprecipitation as the 
method of choice for further biochemical characterization. In our hands, these 
assays have failed to yield consistent results despite multiple attempts optimizing 
the antibody/epitope and buffer conditions. Moreover, immunoprecipitation 
enriches all three BET proteins regardless of the target BET protein. This is likely 
due to the tendency of BET proteins to agglomerate with shared protein 
complexes30 or to polymerize directly via the motif B35 rendering it difficult to tease 
apart which protein interactions are directly mediated by a given BET protein. 
Immunoprecipitation is also limited by endogenous protein level and specificity of 
available antibodies. Use of epitope-tagged protein could overcome both 
limitations but may lead to overexpression artifact.  
Instead, we propose using a baculovirus vector and insect cell expression 
system to purify high yields of individual BET proteins and PAF members (including 
IWS1). By selectively adding individual components to the reaction mixture, this 
system can be leveraged to 1) validate that interactions with PAF are strongest 
with full length BRD2/3/T in comparison to BRD4, 2) confirm that the ETCC domain 
146 
 
is the critical BET protein interaction surface, 3) determine which PAF member 
directly mediates this interaction, and 4) identify the reciprocal interaction surfaces 
on PAF. Though the PAF complex can be reconstituted using proteins derived from 
both bacterial and insect cell expression systems164,165,193, insect cells retain most 
post-translational modification processes that may be critical for the interaction 
with BET proteins.  
In vitro transcription/translation-coupled reactions may provide an 
alternative to the baculovirus system described above. These systems are 
generally conducted in reticulocyte lysates and may mimic, at least to some extent, 
the conditions of erythropoiesis. Moreover, these lysates should be devoid of 
nuclear components and lack endogenous PAF proteins, an advantage over insect 
cells where the insect PAF homologs may participate in the interactions. This 
system was used to successfully reconstitute the NuRD complex194.  
Given that coiled coil domains have a tendency to form dimers35,175, we 
might target our search for the ETCC-interacting component of PAF to those 
protein segments that possess putative coiled coil regions. Alternatively, it is also 
conceivable that all of the ETCC interactions with PAF are in fact indirectly 
mediated by mutual associations with CK2, though this is unlikely given that PAF 
and CK2 associate via FACT167,195, whose components (SUPT16H and SSRP1) 
are not found in our list of ETCC-enriched proteins.   
Functional significance of the BET-PAF interaction 
The PAF complex is a well-studied transcriptional regulator shown to affect 
POL2 pause-release and elongation. During the transition from transcriptional 
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pausing to elongation, PAF replaces NELF at a mutually exclusive region of POL2, 
and thus PAF is a core component of the elongating but not paused POL2 
structure164,196. Within the structure of elongating POL2, PAF induces a 
conformational change that unwinds upstream DNA, permitting POL2 forward 
passage164. Consistent with its role in elongation, PAF facilitates transcriptional 
elongation through chromatin templates in vitro165 and is found enriched over gene 
bodies on chromatin130,169. PAF1 depletion results in decreased elongation130,197, 
though some studies show the opposite effect (depletion of PAF increases 
elongation)198–200 so the exact role of PAF in transcription remains controversial. 
PAF has also been implicated in post-transcriptional RNA processing169,201,202, 
though studies in yeast show that almost all the effects of PAF depletion on 
transcripts levels are related to primary transcription suggesting that this is the 
ancestral function of PAF203.  
Mechanistically, the intrinsic elongation activity of PAF in vitro depends on 
histone acetylation165, indicating that PAF may cooperate with factors that possess 
acetylation-dependent histone chaperone activity. Intriguingly, this type of activity 
has been observed for BET proteins40,41. As the elongating POL2 complex 
approaches a nucleosome comprised of acetylated histones, BET proteins may be 
influenced by PAF via the ETCC on BRD2 and BRD3 to help disassemble and 
reassemble the nucleosome as POL2 passes through. Future studies will need to 
test whether addition of both PAF and BET proteins to these in vitro transcriptional 
assays yields synergistic effects. It is important to note that unlike serine-2-
phosphorylated POL2 (which demarks the elongating fraction of POL2) and the 
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associated PAF proteins130, BET proteins are not found highly enriched in gene 
bodies on chromatin, indicating that they likely do not travel with POL2 through 
genes as part of this complex. Instead, only a small fraction of the total BET 
proteins, which are mostly found near the TSS in promoters or at distal regulatory 
enhancer elements55,129, may be bound to nucleosomes within gene bodies. 
Nevertheless, the density of BRD4 in the gene bodies correlates better with gene 
expression than does the density of BRD4 at the promoter, indicating that this pool 
of BRD4 in the gene bodies, albeit the minority of BRD4, may be more directly 
involved in transcription41. A comprehensive correlation of BRD2, BRD3, and 
BRD4 levels in various genomic regions with gene expression in additional cell 
types is needed to better establish this paradigm.  
In addition to cooperating with the PAF complex to facilitate POL2 
processivity through nucleosomes, BET proteins may also recruit PAF to gene 
promoters. This is where the majority of BET proteins reside on chromatin. A 
similar mechanism has been proposed for PTEFb recruitment by BRD4 via its 
CTM-containing tail. But unlike PTEFb, which contributes to elongation but does 
not incorporate into the elongating POL2 complex, PAF binds to the elongating 
POL2 complex and leaves the promoter as it travels with POL2. In fact, 
phosphorylation of POL2 by PTEFb in the promoter dismisses NELF from the 
paused POL2 complex which allows PAF to takes its place in the elongating POL2 
complex164,196. These differences in PTEFb and PAF functions are reflected in their 
genomic distributions. PTEFb sits at the promoters colocalized with 
unphosphorylated POL2 (marking the paused fraction of POL2), whereas PAF is 
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split between a population colocalized with PTEFb and paused POL2 at the 
promoter, a fraction traveling with serine-2-phosphorylated POL2 over gene 
bodies (marking the elongating fraction of POL2), and a third pool enriched over 
the TES130,169. Given that PTEFb is required for the proper loading of PAF onto 
POL2, it may be difficult to disentangle the functions of BRD4 (which presumably 
recruits PTEFb) and BRD2/3 (which we propose to recruit PAF) based on gene 
expression signatures after depletion of a target BET protein. Instead, changes in 
the PTEFb and PAF chromatin occupancy patterns described above may be more 
informative. For example, we would expect that depletion of BRD2 may reduce 
PAF signal over gene bodies without altering PTEFb, whereas depletion of BRD4 
may reduce both PTEFb signal at the promoter and PAF signal throughout gene 
bodies.  
It has also been reported that PTEFb exists in multiple discrete 
complexes204, some of which are recruited by BRD4 and others of which are 
directly recruited by PAF via a mutual interaction with the elongation factor ENL205. 
Thus, rather than BRD2/3 and BRD4 functioning coordinately to promote POL2 
pause-release, it is also possible that BRD2/3 is responsible for PAF-dependent 
PTEFb recruitment whereas BRD4 is responsible for PAF-independent PTEFb 
recruitment. We would therefore predict BRD2/3-dependent genes to have 
stronger levels of ENL at promoters whereas BRD4-dependent genes may not, but 
this remains to be tested. Ultimately, these pathways may be more intertwined 
then these models suggest. In fact, mutations in either ENL206 or CTR9207 (a PAF 
component) predispose patients to Wilms tumors of the kidney. Given the rarity of 
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this cancer, this coincidence suggests very similar molecular pathways involving 
both proteins.  
Phenotypic studies exploring the functions of PAF and PTEFb argue in favor 
of more distinct functions. For example, PTEFb- or PAF-targeted depletion reveals 
their antagonistic roles in maintaining multipotent neural crest progenitors208 as 
well as the pluripotent state of embryonic stem cells209,210. Similar opposition 
between PAF and PTEFb has also been reported in zebrafish for genes controlling 
oligodendrocyte differentiation211 and perhaps most relevant to our study, for 
erythropoiesis198. These studies suggest a model in which PAF represses PTEFb-
mediated pause-release (preventing expressing of differentiation-related genes) 
as proposed by Chen et al199,200. PAF may therefore have two distinct and 
seemingly paradoxical functions in transcription. It may poise POL2 in its paused 
state, and then upon PTEFb phosphorylation of paused POL2, incorporate into the 
elongating POL2 complex to help facilitate POL2 progression through chromatin. 
This then allows another paused PAF/POL2 unit to take its place. These 
dichotomous functions, further complicated by potential auto-feedback loops 
regulating PAF and PTEFb recruitment and POL2 processivity, may explain the 
discrepant effects of PAF-depletion on elongation observed by different groups. In 
summary, the molecular mechanisms underpinning PAF and PTEFb coordination 
versus opposition are not clear but BET proteins may contribute to these regulatory 
pathways via BRD2/3 recruitment of PAF and BRD4 recruitment of PTEFb. This 
may explain why targeted depletion of single BET proteins can elicit unique gene 
expression changes and cellular phenotypes. Further biochemical characterization 
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of the BRD2/3-PAF interaction may allow for the development of molecular tools 
to purposefully and specifically disrupt this pathway to better identify their unique 
role in transcription. 
In addition to its roles regulating POL2 pause-release and elongation, PAF 
has also been strongly implicated in various histone modifications, particularly 
ubiquitylation of H2B (H2Bub) and subsequent H2Bub-dependent methylation of 
H3K4 and H3K79202. Mechanistically, H2Bub deposition may occur directly via 
PAF-mediated recruitment of ubiquitin ligases or indirectly through transcription-
mediated recruitment of the ubiquitylation machinery202.  Regardless, PAF-
regulated ubiquitylation H2B presents an intriguing parallel with BRD2 function. 
Ubiquitylation of H2A.Z is reported to directly antagonize BRD2 binding to 
acetylated H2A.Z at gene promoters59. Given that acetylated H2BK34 and 
H2BK120, the same residues targeted by H2B ubiquitylation, can bind some of the 
BET bromodomains44, it is possible that a similar antagonism between acetylation 
and ubiquitylation on BRD2 recruitment occurs on H2B, though further studies are 
required to clarify this. H2Bub may also directly regulate PTEFb recruitment212, 
further intertwining the functions of PAF, PTEFb, and individual BET proteins.  
Mechanisms of CK2 recruitment by BET proteins 
Validation and further characterization of ETCC-mediated interactions with CK2  
Interactions between BET proteins and CK2 are well supported by other 
studies. Dawson et al. found that CK2 (included as part of the NOLC1 complex 
with UBTF, NOLC and NHP2) co-immunoprecipitated with BRD2, BRD3, and 
BRD430. Wai et al. likewise identified CK2 among many other transcription-related 
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complexes associated with BRD3 (BRD2 and BRD4 were not included in the 
study)71. Intriguingly, Lambert et al. identified CK2 as a major interaction partner 
of BRD2, BRD3, and BRDT but not BRD431. This is consistent with BRD2/3/T but 
not BRD4 containing the ETCC segment which we propose to at least in part 
mediate the CK2 interaction. Moreover, inhibition of the BET bromodomains 
actually enhanced the CK2 interactions with BRD2/3/T, supporting our hypothesis 
that these interactions are bromodomain-independent. Importantly, CK2 is a 
serine-threonine kinase and CK2 has been previously shown to phosphorylate 
mammalian BET proteins as well as the yeast paralogs BDF1/2 at two conserved 
serine-rich regions85,213,214. BRD2 is also one of about 60 candidate CK2-target 
proteins identified in a large-scale meta-analysis of interlaboratory data215. 
Conservation of the residues phosphorylated by CK2 in BET proteins strongly 
suggests that these post-translational modifications are of functional significance. 
One of the conserved CK2 substrates overlaps partly with the motif B (mB) domain 
used in our GST-pulldown assay. This enzyme-substrate binding event appears to 
have been captured by the GST-mB sample in our GST pulldown experiment 
(Figure 4.4.B). The other conserved CK2 substrate occurs immediately 3’ to the 
ET domain in BRD4 and the ETCC domain in BRD2/3/T and in the last 26 residues 
of yeast BDF1, beyond the coiled coil region. Deletion of either the mB-proximal or 
ET/ETCC-proximal phosphorylated region impairs the ability of BDF1 to rescue the 
viability of bdf1/bdf2-null strains but does not impair its ability to rescue 
temperature sensitivity of bdf1-null strains, indicating that though both regions are 
required for full BDF1 activity, some redundancy exists between BDF1 and BDF2 
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in regard to phosphorylation-specific function214. In BRD4, the mB-proximal CK2-
substrate functions as phospho-switch regulating bromodomain-dependent 
chromatin contacts. The purpose of the ET-proximal substrate remains untested 
in mammalian BET proteins85,213.  
Though putative CK2 phosphorylation sites also occur in the ETCC, we do 
not believe the ETCC domain itself to be a true CK2 substrate. For example, 
neither the ET nor the CC domains alone precipitate CK2, indicating that the 
mechanism of CK2 interaction with the adjoined ETCC is likely to be more related 
to structural characteristics of the surface created by the ETCC than to enzyme-
substrate binding. However, in vitro phosphorylation and in vivo mutagenesis 
assays are required to verify this. Enzyme-substrate interactions may be transient 
and thus difficult to capture in proteomic analyses that are biased toward stable 
interactions, such as co-immunoprecipitation assays. The ability of the ETCC 
domain to form a more stable interaction with CK2 than otherwise allowed by the 
CK2 substrate regions may explain the BRD2/3/T-predominant CK2 associations 
described in the Lambert et al study31. However, as with PAF, the preference of 
CK2 for BRD2/3/T and the exact interacting fragments needs to be confirmed using 
purified proteins.  
Potential roles for CK2 in regulating BET and PAF transcriptional pathways 
CK2 is a ubiquitously expressed kinase complex with a vast array of targets, 
implicating it in numerous cellular functions and biological processes216. Given that 
it associates with many chromatin-bound proteins in yeast167,217,218, it is not 
surprising that deletions of CK2 subunits result in global gene expression 
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changes219. In mammals, CK2 is preferentially bound to transcriptionally active 
nucleosomes220, where it is thought to phosphorylate other nucleosome-bound 
proteins221. Candidate screens of potential CK2 phosphorylation targets have 
routinely yielded several chromatin-associated proteins, including members of the 
PAF complex and BRD2215,222. A screen for proteins bound to various chromatin 
fractions revealed that CK2 was associated with H3K9me3-marked chromatin166, 
which may play a role in gene expression and chromatin organization223. In fact, 
the chromatin-bound fraction of CK2 is distributed maximally at gene promoters 
with extensions into gene bodies, particular at highly expressed genes, and with 
accumulation at enhancers, all of which suggest a role in transcription168. In yeast, 
CK2 was found to be associated with several transcription elongation factors 
including the PAF complex and IWS1167. In mammals, multiple CK2 target 
substrates were identified within PAF including 13 phosphorylation sites on the 
LEO1 component alone222. Interestingly, the physical association between CK2 
and PAF is bridged by mutual interactions with the FACT complex167,195, which is 
a histone chaperone that facilitates removal and replacement of the H2A/H2B 
dimer upon POL2 passage through the nucleosome224. Given that both FACT and 
PAF are required for optimal POL2 elongation, it is thought they may function in a 
coordinated and interdependent fashion225. Mechanistically, by recruiting CK2 to 
PAF, FACT promotes the phosphorylation of PAF, which is required for PAF-
mediated H2B ubiquitylation195. Mutagenesis and structural studies are required to 
better understand how phosphorylation moderates PAF’s function in transcription. 
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It will be particularly interesting to note how phosphorylation of PAF by CK2 affects 
PAF’s ability to complex with elongating POL2.  
The exact role of BRD2 (and potentially BRD3 and BRDT) in this picture 
remains elusive. Given that the biochemical studies identifying PAF, CK2, and 
FACT interactions were performed in yeast, it is possible that in mammals BRD2 
replaces FACT as the mediator of PAF-CK2 contacts. Like FACT, BRD2 also 
possesses histone chaperone activity, though unlike FACT this activity is specific 
for hyperacetylated nucleosomes40. The shared functionality of BRD2 and FACT 
in these assays suggests common downstream mechanisms which may involve 
PAF and CK2. To clarify whether BRD2 recruits PAF and CK2 into close proximity, 
in vitro protein interactions studies should be performed using purified 
components. To assess in vivo, each factor should be targeted for depletion 
individually to reveal their roles on the others’ ability to bind chromatin. For 
example, if BRD2 is playing a central role that governs CK2 phosphorylation of 
PAF and subsequent PAF-mediated POL2 elongation, depletion of BRD2 should 
result in reduced CK2 occupancy at the promoter and reduced levels of PAF and 
serine-2-phosphorylated POL2 throughout gene bodies. Development of phospho-
PAF-specific antibodies would further help characterize distribution of the 
phosphorylated PAF in relation to total PAF on chromatin and the role of BRD2 
and CK2 in this modification.  
It is also possible that BRD2 interacts with PAF and CK2 separately, 
perhaps recruiting PAF to promoters (or facilitating its progression through 
nucleosomes) independently from any involvement in CK2-specific processes. For 
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example, CK2 has been implicated directly in transcriptional elongation via its 
ability to phosphorylate histone H2A at a conserved residue, which prevents 
H2B deubiquitylation by the SAGA complex168. It is therefore thought that CK2 
regulates the opposing actions of PAF (H2B ubiquitylation) and SAGA (H2B 
deubiquitylation) to ultimately promote elongation via H2Bub. In this setting, BRD2 
may separately recruit PAF and CK2 to active chromatin such that some BRD2 
molecules help load PAF onto chromatin and into the elongating POL2 while others 
simultaneously give CK2 access to H2A substrates on acetylated nucleosomes. In 
this way, BRD2 may be functioning as a docking site for various elongation factors 
involved in different (or perhaps interdependent) aspects of transcriptional 
elongation. Additional structural characterization of the ETCC interactions will 
elucidate whether BRD2, PAF, and CK2 form a single complex or separate entities. 
Identification of a common binding motif recognized by the ETCC domain in 
subunits of both PAF and CK2 would support the notion of independent 
interactions. 
In vivo, a large fraction of the chromatin bound CK2 is located at the 
promoter, and depending on the level of gene expression, CK2 signal is also 
detected throughout the gene body. PAF on the other hand has some signal at the 
promoter with stronger signal throughout the gene body and maximal signal at the 
termination site, largely paralleling that of elongating POL2 fraction marked by 
serine-2-phophorylation. BRD2 and the other BET proteins are mostly found at 
promoters. All three can be found distally at enhancers. The different distribution 
patterns of these three factors suggests that they do not form a single stable 
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complex on chromatin. Instead, the interactions we detect between the BRD2 
ETCC domain and PAF and CK2 likely reflect momentary contacts that take place 
in vivo during transcription. For example, the bulk of BRD2 may be engaged with CK2 
at the site of paused POL2. A smaller fraction of BRD2 may be present along the gene 
body and associate with PAF as it comes into contact with acetylated nucleosomes. 
Given that CK2 can phosphorylate BET proteins and various PAF subunits, we 
asked whether phosphorylation may be regulating the strength of the ETCC-PAF 
interaction. We found that in our pulldown assay the ETCC-PAF interaction was 
destabilized when phosphorylation was preserved through the use of phosphatase 
inhibitors. We therefore hypothesize that CK2 kinase activity regulates POL2 
pause-release by releasing PAF from promoter-proximal BRD2 allowing it to 
incorporate into elongating POL2 (Figure 4.5.E).  
However, much more work is needed to elaborate the details of this 
mechanism. First, as described in the prior section, the interface between the 
ETCC and the interacting PAF subunits needs to be identified. This structural 
characterization can then inform the search for the relevant residues that are 
phosphorylated by CK2. We expect that these amino acids will occur at an 
interface with the ETCC, but they could occur elsewhere and still exert 
intramolecular effects that modulate the ETCC interaction, akin to the phospho-
switch mechanism that occurs at the motif-B proximal CK2 phosphorylation site in 
BET proteins85. It is also possible that the structurally relevant phosphorylated 
residues are not in fact CK2 substrates. CK2 is a strong candidate based on its 
physical association with PAF and the identification of CK2 targets therein, but 
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other promoter-proximal kinases may contribute. These candidates can be 
screened using kinase-specific small molecule inhibitors. The druggable kinases 
which are known to phosphorylate various transcription cofactors include CDK7226–
228, CDK9 (component of PTEFb, as described in previous sections)229, 
CDK8/19230, and CDK12/13231. Drugs targeting these kinases can be tested in 
parallel with CK2 inhibitors to identify the relevant factor that phosphorylates PAF 
and reduces its ability to bind the ETCC domain. In addition to confirming the 
correct kinase, we must also consider the opposing function of phosphatases. For 
example, the phosphatase PP2A has been shown to counter CK2-mediated 
phosphorylation of BRD4 such that the balance of CK2 and PP2A activity on BRD4 
phosphorylation controls transcription and cell proliferation86. Chemical inhibition or 
activation of PP2A or other phosphatases can be tested to determine their role in 
controlling the ETCC-PAF interaction. Together, these studies will shed light on the 
molecular regulation of ETCC interactions.  
Chemical or genetic perturbation of promoter-proximal kinases, CK2, and 
phosphatases may also be useful for studying the in vivo function of these factors 
in BET-mediated transcription. For example, it is well known that PTEFb inhibition 
(targeting CDK9 kinase catalytic activity) blocks POL2 pause-release resulting in 
reduced POL2 elongation and transcription229. Inhibition of BET proteins has 
largely the same effect as PTEFb blockade. Though this similarity is often 
attributed to BRD4’s ability to recruit PTEFb67,232, BET proteins can promote 
elongation independently from PTEFb40,41,111,112. Therefore, definitive molecular 
mechanisms implicating BET proteins in elongation remain to be identified. We 
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propose that BRD2/3 recruitment of PAF and CK2 may be one such mechanism. 
In support of this, the effect of CK2 inhibition on elongation largely reflects that of 
BET or PTEFb inhibition168. However, more detailed studies are required to 
examine how CK2 inhibition effects BET protein recruitment.  For example, we can 
test whether CK2 activity is prerequisite for BET protein binding and more 
specifically whether BRD2/3 occupancy is more sensitive than BRD4 occupancy. 
It will also be interesting to note if CK2 activity is required for PAF recruitment to 
promoters or its release into gene bodies. In the latter case, CK2 inhibition may 
cause a pileup of PAF at the promoter. If so, we can then test if this promoter-
proximal PAF is BRD2-dependent using BRD2 KO cells.  This may reveal a role 
for BRD2 in recruiting PAF to chromatin before PAF is incorporated into elongating 
POL2 and relocated into gene bodies.  
Unlike CK2 and PTEFb, the exact effect of PAF on POL2 pause-release 
and elongation remains controversial. However, it is possible that the contributions 
of BET proteins and CK2 could help reconcile these differences and reveal 
mechanistic insight into transcriptional regulation. For example, some studies 
show that PAF depletion mimics BET or CK2 perturbation by causing reduced 
elongation130,197. Other studies instead show an increase in elongation, suggesting 
that PAF actually promotes pausing by somehow tethering POL2 to the promoter 
perhaps in an enhancer-dependent fashion198–200. Interestingly, PAF and CK2 
associate with FACT, which also has been found to exhibit dichotomous functions 
in transcription. FACT maintains POL2 in a promoter-proximal paused state on 
chromatin233, even repressing the expression of genes where it sits at the 
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promoter234,235, yet it also clearly functions as an elongation factor in transcription 
assays224,236. The distribution of FACT on chromatin resembles a blend of CK2 
and PAF occupancy with a significant portion of FACT found at promoters as well 
as within gene bodies233–235. This enrichment over gene bodies is consistent with 
FACT’s interactions with PAF as part of the elongating POL2 complex164. PAF and 
FACT may each have dual roles in pause-release and in elongation. Though BET 
proteins do not likely interact directly with FACT, they resemble FACT in 
transcription elongation assays and may associate together via PAF and CK2. 
Therefore, it is possible that BET proteins, alone or in conjunction with CK2, help 
to regulate or toggle between the various functions of PAF, potentially explaining 
some of the paradoxical effects when these factors are depleted.  
The overlap between BET proteins, CK2, and PAF in various functional 
studies, protein interaction networks, and chromatin distribution profiles suggests 
a common transcriptional pathway that may be independent from or in conjunction 
with PTEFb-related elongation mechanisms. However, whereas PTEFb has a 
relatively straightforward role in pause-release, the BET-PAF-CK2 pathway may 
involve both pause-release and elongation. To test the role BRD2 in these 
pathways, the chromatin distributions of PAF and CK2 can be measured in BRD2 
KO cells. To avoid the confounding effects of altered gene expression in the BRD2 
KO cells, a rapid depletion system targeting BRD2 can be developed to better define the 
causal relationship between loss of BRD2 and the direct impact on the recruitment and 
distribution of the other factors. We have preliminary data that the auxin-inducible 
system can be used to promptly and reversibly degrade BRD2 (data not shown), 
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as has been done for BRD4112. Similar systems have been used to target PAF for 
depletion200 and could be used in conjunction with CK2 kinase inhibition to 
elucidate the mechanics of this transcriptional pathway. Analysis of PAF and CK2 
occupancy in BRD2 KO cells expressing BRD2 proteins with mutations in the ETCC 
regions will help determine the extent to which this domain is directly involved in PAF 
and CK2 recruitment.  
 In summary, we propose that BRD2 and BRD3 function independently from 
BRD4 through protein contacts with PAF and CK2. Though the mechanistic details 
remain unresolved, our data indicate that different elongation factors associate 
preferentially with individual BET proteins. These pathways are unique enough that 
BRD2 and BRD4 cannot genetically compensate for each other and thus operate 
within distinct functional niches on chromatin.  
Implications for BET inhibitor studies and therapies 
In this study we identified a transcriptional mechanism that may involve 
BRD2 and BRD3 but not BRD4. Classic BET inhibitors like the small molecules 
JQ1 or I-BET targeting the bromodomains typically lack specificity for individual 
BET proteins. Their impact on transcription is thus an aggregate effect. Based on 
our findings we expect that at least part of their effect can be attributed to impeding 
BRD2/3-dependent PAF and CK2 recruitment. Mechanistically, recruitment of 
PTEFb and subsequent POL2 pause-release is often considered the downstream 
effector of BET protein function. This activity is generally attributed to BRD4. Yet 
when BET proteins are perturbed pharmaceutically, POL2 elongation is impacted 
without disrupting PTEFb occupancy111. A BRD2/3-dependent elongation 
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mechanism involving CK2 and PAF may thus partly explain this PTEFb-
independent elongation defect. It may also account for the different transcriptional 
signatures observed when comparing pan-BET and CDK9 (PTEFb) inhibitor 
treatment112. Furthermore, defective PAF and CK2 activity could account for the 
discrepancy between the effect of BRD4-specific depletion versus pan-BET 
bromodomain inhibition on gene expression110. In the future, careful comparison 
of genes affected by CK2 inhibition can help establish CK2 as a downstream 
mediator of BET proteins. Depletion studies can be performed to likewise identify 
common or distinct pathways involving PAF.  
Though BD2-specific inhibitors target all of the BET proteins, they seem to 
affect BRD2 and BRD3 chromatin occupancy more so than BRD4 occupancy. 
Thus, BD2 inhibitors are functionally more specific for BRD2 and BRD3. In this 
setting, it was found that BD2 inhibition has greater specificity for inflammation-
induced gene expression while leaving baseline gene expression alone110. This 
finding suggests that an intentionally targeted BRD2/3-based therapeutic may be 
better tolerated in patients. Toward this goal, our study proposes that the ETCC 
domain may offer a drug target that hits BRD2 and BRD3 while leaving BRD4 
intact. 
Concluding remarks 
The results presented here provide a mechanistic rationale for distinct BET 
protein functions. Our study highlights the value of combining a powerful gene 
function assay with simple domain mapping experiments to drive discovery. Using 
this strategy, we demonstrate a framework for the development of BET-specific 
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inhibitors. And by identifying cofactors implicated in BET function, our study points 
toward new avenues of investigation to better understand how chromatin 
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